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ABSTRACT
The Chorioallantoie Membrane (CAM) assay can be used to assess a 
treatment’s anti-angiogenie potential; but also, it can function as a tumour model in its 
own right. Tumourigenie cells are implanted in the embryo early in development, with 
these cells present before the development of the immune system, they are determined 
to be ‘self. From here, the tumour cells divide, usurp a blood supply for nutrients and 
oxygen and begin to form a tumour mass. This mass can then be subjected to 
treatments and can determine a treatment’s anti-angiogenie or anti-tumour efficacy. 
The recruitment of a blood supply, the process of angiogenesis, without which tumour 
cells cannot replicate beyond a defined volume as they are confined by the laws of 
diffusion.
Zoledronate (ZA) has previously been shown to possess some anti-angiogenie 
properties. ZA is used clinically to treat cancer associated bone disease and, as a 
fourth generation bisphosphonate, is very effective at preventing skeletal remodelling. 
The target of nitrogen containing bisphosphonates, such as ZA, is the mevalonate 
pathway; this pathway is responsible for the generation of lipids used to anchor 
proteins to the plasma membrane. With fewer proteins anchored in the plasma 
membrane, pro-survival signalling pathways are adversely affected.
The CAM assay was established and refined; multiple cancer cell lines and 
some human tumour tissue were engrafted, so displaying intriguing histological 
architecture. Real time biomarkers of tumour growth were also investigated. 
Examination of the molecular changes required for adaption from in vitro to tumour 
models revealed several interesting avenues of research, which are currently being 
pursued. The use of the CAM model in the evaluation of oncolytic viruses was also 
investigated, with results suggesting a model worthy of further investigation. ZA was 
shown to be cytotoxic to endothelial cells and induced apoptosis with little effect on 
the cell cycle. Treatment of endothelial cells with Vascular Endothelium Growth 
Factor (VEGF) increased their resistance to ZA-indueed cytotoxicity. The 
concentration of ZA required to inhibit the growth, or induce cytotoxicity, in a panel 
of renal cancer cell lines were much greater than that of endothelial cells. Apoptosis 
and Caspase assays, as well as cell cycle analysis, varied in result between renal
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cancer cell lines. VEGF had no effect on the proliferation rate of these cancer cell 
lines and an appropriate in vivo dose of a vascular disrupter was proposed. Neither ZA 
nor VEGF had any effect on the rate of tumour growth, either in the CAM or murine 
flank models. Only the vascular disrupter managed to impede tumour growth, but 
only for a time.
Overall, the CAM assay is a useful technique and further investigations will 
elucidate some of the molecular mechanisms behind it. ZA has a modest anti- 
angiogenie capability, but, its inability to hamper tumour growth, compared to that of 
an established drug, indicates further experimentation and analysis is required.
IV
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Chapter 1 
Introduction
1. INTRODUCTION
1.1 The enabling characteristics and hallmarks of cancer
For a cell to begin behaving in a cancerous manner, numerous genetic changes 
are required, and often our understanding of the way these changes interact is lacking. 
The effects of these changes are divided into two categories by Hanahan and 
Weinberg; enabling eharaeteristies (processes which improve the odds for a cancer to 
develop) and hallmarks (capabilities a cell must develop if it is to behave aberrantly).
Hanahan and Weinberg define two enabling characteristics for cancer:
• Tumour promoting inflammation
• Genome instability with mutation
These enabling characteristics allow the development of a neoplasia and are 
wholly different to hallmarks of cancer, which are processes that a cancer acquires as 
it evolves. With tumour promoting inflammation, there have been many reviews 
showing that immune cell infiltration of tumours is common (Sautes-Fridman, 
Cherfils-Vieini et al. 2011), with these immune cells supplying some of the growth 
factors/cytokines/proteases required for cancer development (Qualls and Murray 
2011). This suggests that those people suffering fiom chronic inflammatory disorders 
will have an increased risk of cancer development (Franks and Slansky 2012). 
Genetic mutation and genomic instability comes from a combination of environmental 
and genetic susceptibility. Most of the time, mutation occurs in the epithelia (fiilly 
differentiated non-stem cells) as these are the most exposed to the insults of existence, 
and are sloughed off or replaced with little effort by the system. If a mutation does 
occur, it may be in a non-coding region (i.e. in an intron of a gene, which will 
hopefully have little effect on the overall proteome) or produce a null mutation (e.g. 
Serine is encoded at the mRNA level by UCN, a transition or transversion at the third 
nucleotide will have no net effect on the amino acid added to the peptide chain). On 
top of this there are safeguards at the genetic (repair mechanisms of DNA), protein
(checks as to correct protein folding), system (tissue inhibitors of matrix 
metalloproteases [TIMPs] and endogenous, matrix derived inhibitors of angiogenesis, 
released when a tumour starts to degrade the tissue compartment it initiates from) and 
organism levels (antibody response to elevated self-proteins and natural killer cells).
The eight hallmarks (defining characteristics) of cancer are:
1. Insensitivity to anti-growth factors
2. Independence in proliferation signalling
3. Indefinite replication
4. Evasion of apoptosis
5. Angiogenesis
6. Invasion and metastasis
7. Deregulated cellular energetics
8. Evasion of destruction by the immune system
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Figure 1.1.1 The hallmarks of cancer. Figures taken from (Hanahan and Weinberg 2000) and (Hanahan 
and Weinberg 2011) showing enabling characteristics and hallmarks, as well as some suggestions as to 
the order in which capabilities are acquired.
Unfortunately some genes that are vitally important in maintaining a non­
cancer phenotype, aet in more than one hallmark e.g. TP53, one of the most 
frequently mutated genes in cancer - it is a control node, termed “the guardian of the 
genome” and its loss can act as both a pathway for apoptosis evasion and signals for
sustained neo-angiogenesis (Soussi 2007). The first four hallmarks are required to 
reach the state we began this introduction to neo-angiogenesis; a (possibly 
heterogeneous, in terms of levels of genomic mutation) population of approximately 
1x10^ cancer cells, not more than 1mm in diameter (Folkman 1971).
The level and type of invasion divides aberrant cellular masses into benign and 
malignant (metastatic), which also divides the mortalities associated with them. 
However, angiogenesis is critical to the growth of a tumour; there must be a signal to 
start this process. It is possible that a hypoxic region is generated in the centre of this 
mass of cells, possibly the occlusion of a supplying blood vessel by the uncontrolled 
replication of the cells on the periphery, which drives further genetic instability 
(Reynolds, Rockwell et al. 1996), which in turn allows the release of pro-angiogenic 
factors. This is the point where the activation of the ‘angiogenic switch’ is considered 
to be playing a vital role in the development of a tumour. In a normal situation the pro 
and anti-angiogenic signals (reviewed in (Nyberg, Xie et al. 2005; Ribatti 2009)) are 
balanced, at the end of wound healing the spectrum and intensity of anti-angiogenic 
signals ‘outweigh’ the pro-angiogenic signals, in a angiogenesis capable neoplasia, 
the pro-angiogenic signals are stronger than those inhibiting angiogenesis (you can 
consider a cancer like this to be an open wound that is never healed).
1.2 Angiogenesis
The evolution of a vascular network is pivotal to the development of multi­
system organisms. Without it, oxygen, nutrients and signalling molecules could only 
be exchanged by diffusion, limiting the size of the organism. In mammals, blood is 
oxygenated in the lungs (which have a huge surface area: volume), the oxygen is 
bound to the iron molecule of haemoglobin in red blood cells and will only be 
released where the level of oxygen is significantly lower than that of the bloodstream. 
Angiogenesis is the sprouting of new blood vessels from the existing vascular bed and 
starts at the capillary level to perfuse tissues. In healthy individuals, angiogenesis is 
only active in wound healing and the menstrual cycle. This process must be tightly 
controlled because this is a critical step in an organisms attempt to limit the growth of 
abnormal cells. Without a blood supply, a collection of abnormal, genetically
unstable, cells cannot exceed 1mm in diameter (or approximately 1,000,000 cells) 
(Folkman 1971). For example, in wound healing, the process of angiogenesis begins 
as soon as the fibrin clot has formed. The tissue that has been damaged and has 
reduced blood supply (therefore oxygen and nutrients) is termed hypoxic. Oxygen is 
vital for the maximal liberation of energy from glucose (aerobic respiration); as such 
cells will produce a massive response in order to correct this deficiency. This hypoxia 
is initially sensed by the electron transport chain of aerobic respiration, without 
oxygen. Adenosine TriPhosphate (ATP) levels drop as the cell now relies on 
glycolysis and anaerobic respiration; this causes the build-up of Kreb cycle substrates. 
Hypoxia Inducible Factors (HIFs) are heterodimers (a and (3 subunits) that are used to 
restore normoxia by the synthesis of proteins that will modulate cellular function 
towards this end. Under normoxia, HIFs are post-translationally hydroxylated at 
conserved prolines of the a subunit, which is recognised by the von Hippel Lindau 
(VHL) ubiquitin E3 ligase, which oligo-ubiquitinates HIFs, leading to their 
proteosomal destruction. Under hypoxic conditions, oxygen is no longer available as a 
cofactor for the HIF prolyhydroylases, HIF is no longer targeted for proteosomal 
destruction, which allows it to perform its function. HIFs migrate to the nucleus and 
as powerful transcription factors, stimulate the production of proteins that are capable 
of inducing the restoration of homeostasis (Carroll and Ashcroft 2005). These genes 
have a Hypoxia Response Element (HRE -  PurCGTG, where Pur is a purine) in their 
promoter sequence, upstream of the transcriptional start point, which the a subunit 
binds to, recruiting the transcription machinery (Kaluz, Kaluzova et al. 2008).
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Figure 1.2.1 The fate of HIF proteins in varying oxygen concentrations, taken from (Carroll and 
Ashcroft 2005). A graphic representation o f the effect oxygen concentration plays in the fate of  
Hypoxia Inducible Factors and the subsequent gene expression. Hypoxia Inducible factor (HIF)-la, 
proline hydroxylases (PHDl, 2 and 3), 2-oxoglutarate (2-OG), pVHL (the product o f the von Hippel- 
Lindau tumour suppressor gene), acetylated HIF-la (OAc), hypoxia-response elements (HREs), 
CREB-binding protein (GBP) and ubiquitin (Ub)
These mRNAs also sometimes have Internal Ribosomal Entry Sequences 
(IRESs) which give the 5’ UnTranslated Region (UTR) secondary structure that 
mimics an active ternary complex (Holcik and Sonenberg 2005) (with or without 
adapter proteins, known as 1RES Trans-Activating Factors, ITAFs (Bushell, Stoneley 
et al. 2006)), allowing the translation machinery to be active even in conditions when 
it is prudent for translation to be switched off (nutrient deprivation/hypoxia). This 
plethora of genes whose expression is upregulated by HIFs include; Vascular 
Endothelium Growth Factor (VEGF) (Forsythe, Jiang et al. 1996), Nitric Oxide 
Synthase 2 (N0S2) (Jung, Palmer et al. 2000), erythropoietin (Wang and Semenza
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1993) and Glucose transporter 1 (GLUTl) (Okino, Chichester et al. 1998), all proteins 
involved in decreasing levels of hypoxia. Cells then secrete these growth factors, 
which diffuse until they reach vasculature. These growth factors stimulate the 
endothelial cells (which make up capillaries and are the most likely to be damaged) to 
divide, secrete basement membrane degrading proteases, migrate towards this chemo- 
attractant, form lumen, complete an anastomosis and recruit supporting cells. This 
vasculature repair occurs concurrently with the tissue repair, ensuring that the newly 
replicated tissue is correctly perfused.
1.3 Pro and anti-angiogenic factors
Pro-angiogenic factor and receptor Anti-angiogenie factor and receptor
VEGFVEGFR + NRP-1 Endostatin/Integrins
PDGF/PDGFR T umstatin/Integrins
FGF/FGFR VEGFxxxbVEGFR
HGF/c-MET Angiostatin/ N/A*
Angiopoetin/ Tie2 PEDF/PEDFR
Table 1.3.1 A selection o f pro and anti-angiogenic factors which have been intensively studied; all are 
produced to some degree in all individuals. * N/A means that no mechanism has been proven, but 
possibilities have been hypothesised by (Geiger and Cnudde 2004)
1.3.1 Pro-angiogenic factor - Vascular Endothelium Growth Factor
There are five members of the Vascular Endothelium Growth Factor (VEGF) 
family, VEGF A-D and Placental Growth Factor (PIGF), all involved in the 
stimulation of vascular (VEGF A, B and PIGF) or lymphatic growth (VEGF C and 
D). VEGF A has been one of the most intensely studied angiogenic factors; as such, 
there is great detail available into its intraeellular and tissue level effects. The VEGF 
A gene is approximately 16Kbp long found at 6pl2, consisting of 8 exons which 
allows alternative splicing resulting in transcripts varying in length and eventually 
proteins of different weights (206, 189, 183, 165, 148, 145 and 121 amino acids long). 
Interestingly, the 8th exon contains 2 possible spliee sites (proximal and distal), which
generates two distinet genus’ of VEGF A in terms of function; those with the 
proximal splice site (PSS) (206-121 amino acids) are pro-angiogenie. Those whieh 
utilise the distal splice site (DSS) are termed VEGFxxxb (189b-12lb amino acids) and 
are anti-angiogenic through a mechanism that will be discussed later. In terms of 
protein sequence (and their funetions), all VEGF A variants contain a secretion signal 
(exon 1 and the beginning of exon 2), dimerization sites, VEGF receptor 1 (VEGFRl) 
binding site (found in exon 3), VEGFR2 binding site (found in exon 4), then there are 
varying levels of heparin binding regions due to the alternate splicing and a 
neuropilin-1 (NRP-1) binding region depending on the differential splicing (See 
Figure 1.3.1.1). VEGF A is a 46KDa di-sulphide bridged, glycoprotein, which 
circulates as a dimer (homo or heterodimer with other VEGF family members or 
splice variants) and activates VEGF receptors (VEGFRs) (Harper and Bates 2008).
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Figure 1.3.1.1 Location o f functional domains within the VEGF-A protein. Taken from (Harper and 
Bates 2008).
Humans have 3 types of VEGFRs termed:
VEGFRl, analogous to the mouse VEGFR Fit-1, highly expressed in thyroid 
tissue, binds VEGF A (Kd =15 pM), PIGF (IQ =170 pM (Sawano, Takahashi 
et al. 1996)) and VEGF-B (IQ unknown)
VEGFR2, analogous to murine Flkl/KDR, highly expressed in thyroid and 
lung tissue and is considered a marker of endothelial cells, binds VEGF A (IQ 
= 190 pM (Shinkai, Ito et al. 1998)), VEGF C (IQ = 410 pM (Joukov, Sorsa et 
al. 1997) and VEGF D (IQ ~ 6 nM (Leppanen, Jeltsch et al. 2011))
VEGFR3, analogous to murine Flt-4, highly expressed in lymph nodes, binds 
VEGF C (IQ =135 pM (Joukov, Pajusola et al. 1996)) and VEGF D (IQ ~ 120 
nM (Leppanen, Jeltsch et al. 2011))
These three receptors are responsible for the different responses required by 
VEGF signalling; control of vascular endothelial cell proliferation (VEGFRl and 
VEGFR2) and the proliferation of lymphatic endothelial cells (VEGFRS (Zhang, 
Zhou et al. 2010)). VEGF binding to its receptor has yet to be fully elucidated by x- 
ray crystallography or NMR, although there are some models from which we can 
draw some definite conclusions. It seems that the receptor with the most significant 
role in angiogenesis is VEGFR2 (as a heterodimer with NRP-1 (Soker, Takashima et 
al. 1998)). VEGF 165 (C terminus is CDKPRR) uses the variable loop region (Muller, 
Christinger et al. 1997) (hence the difficulty in crystallising the complex) that is the 
VEGFR2 binding domain (in the 2nd/3rd Immunoglobulin-like (Ig) domains of the 
receptor (Keyt, Nguyen et al. 1996; Fairbrother, Champe et al. 1998)), VEGF 165 also 
binds NRP-1 via exon 7 (Soker, Miao et al. 2002) and 8 (Jia, Bagherzadeh et al. 2006; 
Parker, Xu et al. 2012) which acts as a co-receptor and is thought to increase the 
functionality of the kinase domains. VEGFR2/NRP-1A^EGF dimerises (through 
interaetions in the last 4 Ig domains of VEGFR2 (Fuh, Li et al. 1998) and can be 
homodimers or any heterodimer apart from VEGFRl/3), this causes a conformational 
change of the intracellular split kinase domains (Shibuya, Yamaguchi et al. 1990), 
bringing them together and rendering them functionally active. Trans-phosphorylation 
of Tyr-1054 occurs, which leaves the ATP binding poeket open, leading to further cis- 
and trans-phosphorylation of the intracellular domain (Kawamura, Li et al. 2008). 
This multitude of phosphorylation events creates multiple protein binding sites 
including SHB (SH2 domain-containing adaptor protein B -  which leads to aetivation 
of the Phosphotidylinositol-3 Kinase survival arm (Holmqvist, Cross et al. 2004)), 
p38 (leading to Heat Shock Protein 27 induced migration (Matsumoto, Bohman et al. 
2005)), VRAP (VEGFR-assoeiated protein -  stimulates both migration and chronic 
permeability of capillaries (Wu, Mayo et al. 2000)) and PLCy (Phospholipase Cy, 
which induces proliferation by Protein Kinase C and effects Ca^^ levels, changing 
endothelial nitric oxide synthase efficiency and promoting vasodilation (Cunningham, 
Waxham et al. 1995; Sawano, Takahashi et al. 1997)). See Figure 1.3.1.2 for diagram.
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Figure 1.3.1.2 Diagram of known VEGFR signal transduction pathways. Taken from (Hoeben, Landuyt 
et al. 2004)
Much of this downstream signalling is prevented by VEGFxxxb’s, the C terminus 
of SLTRXD stops the binding of NRP-1 (due to the lack of Arginine to fit the 
Arginine binding pocket of NRP-l’s bl domain (Parker, Xu et al. 2012), NRP-1 is 
then not a part of the VEGF/VEGFR complex), this reduces the efficiency of VEGFR 
phosphorylation (thought to be due to lack of torsional rotation of the split kinase 
domains, generating an inefficient kinase domain) (Kawamura, Li et al. 2008).
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1.3.2 Pro-angiogenic factor - Platelet Derived Growth Factor
There are four members of the Platelet Derived Growth Factor (PDGF) 
family, PDGF A-D, all encoded by separate genes, all form homodimers in circulation 
apart from PDGF A and B which can form heterodimers with each other and all 
stimulate angiogenesis. Two separate gene products are responsible for a complete 
PDGFR, pdgfra (encodes the a  polypeptide) and pdgfrb (encodes the p polypeptide 
and is homologous to the viral oncogene v-sis), these can form homodimers or a 
heterodimer, which is then specific for the dimers of PDGF, however these receptor 
dimers only occur with PDGF binding. PDGFRaa binds PDGF AA, AB, BB and CO, 
PDGFRpp binds PDGF BB and DD, PDGFRaP binds PDGF AB, BB, CC and DD 
(Fredriksson, Li et al. 2004). Like VEGF and its receptor, PDGF and PDGFR bind 
together, the growth factor/receptor complexes dimerise, trans-phosphorylate at 
multiple tyrosines in the intracellular domain of the receptor and activate the 
following (but not limited to) survival and migration pathways: Src, PI-3-K, PLCyl, 
Ras, c-myc and FAK (Farooqi, Waseem et al. 2011).
1.3.3 Pro-angiogenic factor -  Fibroblast Growth Factor
There are 18 members in the family of Fibroblast Growth Factors (FGF 1- 
10 and 16-23), all encoded by different genes, that activate their receptors (FGFRl- 4 
all of which can demonstrate exon skipping and alternative splicing to allow 4 genes 
to yield a variety of receptors of varying specificities). FGF contains a heparin 
sulphate glucosaminoglycan (HSGSG) binding site which improves its stability and 
half-life (Zakrzewska, Wiedlocha et al. 2009), which then binds to the FGFR 
(FGF:HSGSG:FGFR = 1:1:1), FGFRs then dimerise, trans-phosphorylate and 
activates by phosphorylation PLCyl (activates PKC) and FGFR substrate 2a (FRS2a, 
activates the Ras pathway leading to MAPK activation). Activating mutations or 
overexpression of FGFRs are well observed in human cancers and FGF itself is 
considered a potent angiogenic factor (Beenken and Mohammadi 2009).
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1.3.4 Pro-angiogenic factor -  Hepatocyte Growth Factor
Hepatocyte Growth Factor (also termed Scatter factor, HGF/SF) and its 
receptor c-Met (or HGF receptor, HGFR, identified in the immortalisation of a human 
cell treated with carcinogen) is mutated to a constitutively active form in hereditary 
papillary renal carcinoma. HGF/c-Met signal endothelial cells to actively proliferate; 
whilst their action on adjacent tumour cells stimulates further VEGF to be produced 
creating an angiogenie feedback loop. c-Met can activate the Akt, MAPK, PI-3-K and 
JNK proliferation/survival pathways as well as FAK for alterations to motility, c- 
Met’s Tyrosine kinase domain can also be activated by the association with other 
Tyrosine kinase based receptors, integrins or g-protein coupled receptors (Organ and 
Tsao 2011).
1.3.5 Pro-angiogenic factor -  Angiopoetins
The Angiopoetins (ANGPTl-4) and their receptors Tyrosine kinase with 
Immunoglobulin-like and EGF-like domains (TIEl and 2), are a critical part of the 
angiogenesis process, but they are still undergoing detailed research as to their 
functionality. Classically, ANGPTl is a TIE2 angonist whilst ANGPT2 is its 
antagonist, with agonist binding, TIE2 dimerises (or multimerises) and 
transphosphorylates to activate. Once TIE2 is activated it activates multiple survival 
pathways (PI-3-K/Akt, Ras, N0S3 and DOcKing protein2 (D0K2)/PAK (p21 
Activated Kinase)) and inflammatory pathways (NF-KB via Vascular Cell Adhesion 
Molecule 1 or E-selectin). ANGPT2 can activate integrin aspi and modulate FAK and 
so endothelial migration (Huang, Bhat et al. 2010).
1.3.6 Anti-angiogenic factor -  Endostatin
Endostatin (ES) is classified as a matrix derived endogenous inhibitor of 
angiogenesis; as it is a 20kDa fragment of the C-terminus of collagen XVIII,
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generated by cathepsin L (Felbor, Dreier et al. 2000). As an endogenous inhibitor of 
angiogenesis, ES is produced in both healthy and cancer-affected individuals (Schips, 
Dalpiaz et al. 2007), as such, ES embodies a clinically useful anti-angiogenic 
treatment. The underlying mechanism for ES’s anti-angiogenic effects is complex and 
involves multiple pathways. It has been shown that ES binds to integrins aspi, ttvPs 
and ttvPs (Rehn, Veikkola et al. 2001; Wickstrom, Alitalo et al. 2002; Sudhakar, 
Sugimoto et al. 2003), glyplican-1 and 4(Karumanchi, Jha et al. 2001), as well as 
nucleolin, whieh has a very high affinity for ES (Kd = 2.3x10'^ M) (Shi, Huang et al. 
2007). ES also binds to heparin, this binding is essential to ES’s anti-angiogenic 
effects (Gaetzner, Deckers et al. 2005; Reis, Schuppan et al. 2005); which may help to 
explain some of its other downstream signals, however, it has been shown that this 
heparin binding is also important for ES’s association with nucleolin (Fu, Chen et al. 
2009). With the capability to bind integrins, ES has the opportunity to affect both 
endothelial and neoplastic cells. ES can be endocytosed by both caveolae/lipid rafts 
and clatrin-coated pits (Chen, Wang et al. 2011). ES has been shown to reduce 
migration (Skovseth, Veuger et al. 2005), increase apoptosis (by activation of 
Caspase-3 (Ling, Lu et al. 2009)), increase Gi/S phase stalling (via cyclin D inhibition 
(Hanai, Dhanabal et al. 2002)) and cause autophagy in endothelial cells (Nguyen, 
Subramanian et al. 2009), as well as decrease the numbers of smooth muscle actin 
presenting perivascular cells (Skovseth, Veuger et al. 2005). To explain these effects, 
many pathways have been examined and some of the genes down regulated by ES 
treatment are:
• c-fos, c-myc, MAPKl and 2, CDC25B, a- and P-tubulin (Shichiri and Hirata 
2001)
• PDGFB (Skovseth, Veuger et al. 2005)
• Bel-2, Bel-XL and p-catenin (Nguyen, Subramanian et al. 2009)
• VEGF, bFGF, Tumour Necrosis Factor-a (TNF-a) and Vascular Cell 
Adhesion Molecule 1 (VCAMl) (Xu, Ye et al. 2010)
ES treatment also caused endothelial cells to dephosphorylate ERK by protein 
phosphatase 2A, which would decrease the levels of pro-survival signals (Schmidt, 
Wenzel et al. 2006). Another noted feature is that ES reduces the levels of VEGF 
stimulated VEGFR2 tyrosine phosphorylation, possibly by its sequestration of
13
heparin, which is noted as a co-stimulator of VEGFR2, and eventually VEGFR2 
levels are reduced (Ling, Yang et al. 2007). It has been suggested that the PI-3- 
K/PKB pathway may play a part in ES’s intracellular effects (Kang, Shim et al. 2006), 
but the full explanation of this has yet to be elucidated. ES treatment has been shown 
to increase NF-KB activity in endothelial cells. NF-KB controls many anti-apoptosis 
signals; ES’s effect is therefore contradictory. When NF-KB was blocked, a reduced 
anti-angiogenic effect, caused by ES, was observed (Tabruyn, Memet et al. 2009). 
This would suggest that NF-KB is, in this case, a required signalling node for ES to 
elicit its anti-angiogenic effects. Pigment Epithelium Derived Factor (PEDF), a 
known anti-angiogenic agent in its own right, has been noted to be increased with ES 
treatment of endothelial cells (Xu, Ye et al. 2010). Also, ES treatment of lung cancer 
cells caused an increase in the levels of VEGF 165b (Li, Zhu et al. 2011). These two 
reports suggest that endostatin ean induce further anti-angiogenic signals (positive 
feedbaek), making it a rather attractive candidate as an anti-angiogenic treatment. ES 
also has the capability to bind the aetive site of Matrix MetalloProtease-2 and 9 
(MMP-2 and 9) (Kim, Jang et al. 2000; Lee, Jang et al. 2002; Nyberg, Heikkila et al. 
2003), and not be enzymatically cleaved, this will also help in the prevention of Extra- 
Cellular Matrix (ECM) remodelling that is required for cancer progression, 
angiogenesis and metastasis. In order to produce clinically useful amounts of 
recombinant ES (Eder, Supko et al. 2002), a histidine tag was added at the N-terminus 
to aid purification without affecting anti-angiogenic activity (Huang, Wong et al. 
2001; Song, Liu et al. 2005). ES has been evaluated in early phase clinical trials in 
advanced colorectal/gastric (Zhou, Zhou et al. 2011) and small cell lung cancers 
(Zhou, Zhou et al. 2011); however the most extensive studies have been performed in 
non-small cell lung cancer (NSCLC), where ES combined with paclitaxel and 
cisplatin improved the 6 month progression free survival (PFS) by 20% in late stage 
NSCLC compared to chemotherapy alone (Han, Xiu et al. 2011).
1.3.7 Anti-angiogenic factor -  Tumstatin
A 28kDa fragment of the a3 chain of type IV collagen is termed Tumstatin, 
which has been shown to have both anti-angiogenic and anti-tumour capabilities. 
Tumstatin can be generated by a variety of MMPs (2, 3, 13 and 9), of which MMP-9
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is most effective at generating fragments containing tumstatin from the collagen 
precursor (Hamano, Zeisberg et al. 2003). The anti-angiogenic properties of tumstatin 
derive from the N-terminus (amino acids 54-132, often termed Tum5) and are through 
tumstatin’s interaction with integrin UvPs on endothelial cells; causing Gi cell cycle 
arrest and inhibition of tube formation . It has been reported that these effects occur 
due to ttvPs prevention of PI-3-K/AKT activation, which in turn does not 
phosphorylate mammalian Target Of Rapamycin (mTOR), which doesn’t 
phosphorylate eukaryotic initiation factor 4E (eiF4E) binding protein (eif4e-BP) 
whieh remains bound to eiF4E, inhibiting protein translation (Sudhakar, Sugimoto et 
al. 2003).
1.3.8 Anti-angiogenic factor -  Vascular Endothelium Growth Factor xxxb
As previously discussed, VEGFxxxb isoforms of VEGF are generated by 
differential splicing to generate a different C terminus which possesses no NRP-1 
binding activity. Treatment with VEGFxxxb has been used in a pre-clinical manner in 
melanoma (Woolard, Wang et al. 2004; Rennel, Waine et al. 2008), colorectal 
(Rennel, Hamdollah-Zadeh et al. 2008; Rennel, Varey et al. 2009), neuroblastoma 
(Peiris-Pages, Harper et al. 2010), prostate (Rennel, Waine et al. 2008), renal (Rennel, 
Waine et al. 2008) and Ewing’s sarcoma (Rennel, Waine et al. 2008). This treatment 
option stems from the initial report that VEGFiesb expression is reduced compared to 
VEGF 165 in renal carcinoma (Bates, Cui et al. 2002); this observation has been 
repeated in melanoma (Pritchard-Jones, Dunn et al. 2007), colorectal (Varey, Rennel 
et al. 2008), prostate (Rennel, Waine et al. 2008) and neuroblastoma (Peiris-Pages, 
Harper et al. 2010).
1.3.9 Anti-angiogenic factor -  Angiostatin
Angiostatin is the result of multiple protease digestions of plasminogen; the 
Kringle domains within Angiostatin are responsible for its anti-proliferative and 
migration inhibition of endothelial cells and inhibition of tumour growth. Angiostatin 
has been shown to bind to cell surface ATP synthase (FI subunit) of endothelial cells
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(endothelial cells can express the catalytic subunit of ATP synthase on their cell 
surface and helps reduce the level of acidosis) (Moser, Stack et al. 1999), ttypa integrin 
(inhibition of integrin signalling) (Claesson-Welsh, Welsh et al. 1998) and 
Angiomotin (leading to activation of FAK and inhibition of migration) (Troyanovsky, 
Levchenko et al. 2001). NSCLC (Kurup, Lin et al. 2006) has been treated with 
Angiostatin and remains the only clinical result; pre-clinically, head and neck 
squamous cell carcinoma has been treated with a oncolytic vaccina virus with an 
Endostatin/Angiostatin frision gene, giving better tumour reduetion than previous 
variants (Tysome, Wang et al. 2011).
1.3.10 Anti-angiogenie factor -  Pigment Epithelium Derived Factor
Pigment Epithelium Derived Factor (PEDF) is a serine protease inhibitor 
and has effects in both epithelial and endothelial cells. PEDF is a gene in its own right 
and can associate with a number of surface proteins including its receptor. PEDF 
binds to VEGFR2 (Zhang, Wang et al. 2006), which can then associate with a and y- 
secretases to cleave the extra and intracellular domains (respectively) leading to more 
soluble VEGFR2 (which causes less VEGF to be free in the circulation) (Ablonczy, 
Prakasam et al. 2009) and inhibition of MAPK signalling which was previously noted, 
through cleavage of the intracellular signalling domains of VEGFR2. PEDF can also 
bind the p subunit of FI ATPase which is presented on endothelial cell surface could 
lead to a similar inhibition as Angiostatin (Notari, Arakaki et al. 2010). PEDF binding 
to its receptor on endothelial cells, activates the receptor’s phospholipase activity, 
however the binding occurs between transmembrane domains 3 and 4; the 
phospholipase active site is also loeated extracellularly (Notari, Baladron et al. 2006). 
PEDF activation of NF-KB (Yabe, Wilson et al. 2001), Nuclear Factor of Activated 
T-cells (NFAT) (Zaichuk, Shroff et al. 2004) and Peroxisome Proliferator-Aetivated 
Receptor (PPAR) y (Ho, Chen et al. 2007) remains to be elueidated; either these 
effeets are indueed by the intracellular domain of PEDFR or another receptor is 
involved. PEDF expression in melanoma is severely decreased with no correlation 
with N-ras or B-raf mutations; PEDF does inhibit aggressive melanomas and their 
ability to mimic vasculature (Orgaz, Ladhani et al. 2009).
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1.4 Bisphosphonates
Bisphosphonates have been described and used in the treatment of skeletal 
dysfunction for over 40 years (Smith, Russell et al. 1971). They all have a backbone 
of (PO^')-C-(PO^ ), the 2 remaining bonds to the carbon are taken by the groups Ri & 
R2 . Ri is always short and determines the pharmacokinetics of the drug, in most cases 
of bisphosphonates it is OH (Van Beck, Lowik et al. 1996), leading to renal excretion 
within a few hours of intravenous (I.V.) administration. R2 is of variable length and 
determines other properties of the drug such as its mode of action and strength 
(Papapoulos, Hoekman et al. 1989; Muhlbauer, Bauss et al. 1991; Green, Muller et al. 
1994; Goa and Balfour 1998).
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Figure 1.4.1 Bisphosphonate structure. General structure o f bisphosphonates with Ri and R2 groups 
attached to the central carbon atom, right, the structure o f Zoledronate (Zoledronic Acid, ZA, Reclast©, 
Novartis Pharmaceuticals, Basel, Switzerland)
The bisphosphonates ean be broadly divided into two groups depending on 
whether or not the R2 functionality contains nitrogen. Non-nitrogen containing 
bisphosphonates (non-NBPs) are the earliest generation and include Etidronate, 
Clondronate and tiludronate. The propensity of this group of drugs for bone tissue 
(Jung, Bisaz et al. 1973) is due to the phosphate group’s (and to a lesser extent, the 
OH attached in the Ri position (Van Beck, Lowik et al. 1996)) affinity for Ca^ ,^ 
whieh forms a large part of the skeleton’s inorganic component, mostly in the form of 
hydroxyapatite (Russell, Muhlbauer et al. 1970). This affinity for Ca^  ^ also makes 
bisphosphonates highly effective in the treatment of hypercalcaemia of malignancy
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(Ralston, Gallacher et al. 1989) (where bone metastasises eause substantial 
remodelling by promoting osteoelast aetivation, leading to the release of free Ca^^). 
The bisphosphonate is adsorbed into osteoclasts by fluid phase endoeytosis at the 
ruffled membrane, after which its probable acidification in the endosomal 
compartment allows its release into the cytosol (Thompson, Rogers et al. 2006). The 
non-NBPs closely resemble inorganic pyrophosphate (PPi), and are treated as such 
within the cell i.e. an attempt is made to incorporate them into Adenosine triphosphate 
(ATP) (Rogers, Russell et al. 1992) by the reversible reactions of class II aminoaeyl- 
transfer RNA synthetases, generating an APPeP molecule (Rogers, Brown et al. 
1996). Accumulation of these toxic metabolites (Auriola, Frith et al. 1997) results 
from the enzyme’s inability to cleave the PeP bond (in normal ATP it is PoP), 
eventually leading to cell death (Frith, Monkkonen et al. 1997). Osteoclasts are most 
affected cell type because their function to remodel bone causes the anchored 
bisphosphonates to be released, then absorbed and concentrated within osteoclasts.
Ri Side-Chain RjSide-Chain Ri Side-Chain R, Side-ChainAgent Agent
Pamidronate ■OH
RisedronateNeridronate -OH-OH
Olpadronate -OH
Alendronate -OH Zoledronate -OH
Ibandronate -OH
Table 1.4.1 List o f bisphosphonates. Non-nitrogen containing (left) and nitrogen containing 
bisphosphonates (right)
1.4.1 Nitrogen containing Bisphosphonates
Nitrogen containing bisphosphonates (NBPs) are the more recent generations 
(now into the 4th), their action is completely different to that of the nitrogen lacking 
bisphosphonates and is much more complex. As the clinical significance of 
bisphosphonates became apparent labs began synthesising new versions and it was 
found that those with Nitrogen in their Ri group (Opladronate (Papapoulos, Hoekman 
et al. 1989) and Pamidronate (Reitsma, Bijvoet et al. 1980)) were much more 
effective (at least 10-1 COX as effective (van Beck, Pieterman et al. 1999)) at 
inhibiting the differentiation of mature osteoclasts. Structure/activity investigations
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revealed that the nitrogen has to be a eritieal distance from the backbone and in a 
particular spatial orientation, a requirement that is unrelated to toxic metabolite 
formation. The crystal structures of Famesyl transferase (FTase) and Geranylgeranyl 
transferases (GGTase-I & II) (Reid, Terry et al. 2004) and now eo-crystallisation of 
Famesyl diphosphate synthase (FPPS) and Geranylgeranyl diphosphate synthase 
(GGPPS) with Alendronate and Zoledronate (Kavanagh, Guo et al. 2006) confirm 
previous suspicions that NBPs affect the mevalonate pathway. The mevalonate 
pathway is responsible for the biosynthesis of many lipid based molecules including 
heme A (Buhaescu and Izzedine 2007) and cholesterol (Berg, Tymoezko et al. 2002); 
however, this pathway also provides the substrates for the prénylation of proteins. 
Prénylation describes the anchorage of proteins into the plasma membrane and is 
essential for the correct function of those proteins. Small GTPase-like proteins such as 
Rho, Rae and Rab are important in many funetions performed by osteoclasts and are 
also prenylated (Zhang, Udagawa et al. 1995). In the normal situation the C terminal 
of the protein to be anchored into the plasma membrane determines whieh enzyme 
catalyses prénylation (and as such whieh lipid moiety is used). Prénylation occurs 
within a motif of amino acids that consist of CAAX (C=eysteine, A=any aliphatic and 
X=any amino acid and is the C terminus) (Reid, Terry et al. 2004) and the lipid 
modification is attached to the sulphur side-ehain of cysteine (Fu and Casey 1999). 
NBPs halt the synthesis of famesyl diphosphate (Dunford, Thompson et al. 2001) 
(and also prevent the formation of geranylgeranyl diphosphate, which requires FPP as 
a starting material (Buhaescu and Izzedine 2007)) by binding to the lipid binding 
poeket of FPPS and inserting the nitrogen into the active site (Thr-201 and Lys-200) 
(Kavanagh, Guo et al. 2006). NBPs mimic the carbocation transition state of famesol, 
and as such are not dissociated from the enzyme easily, the Ki values of NBPs being 
in the nM range (Martin, Arnold et al. 1999). This means that the essential small 
GTPases are not added to the plasma membrane, whieh can eause apoptosis of the 
osteoclasts (Luckman, Coxon et al. 1998).
This well documented effect of apoptosis induction and inhibition of the vital 
mevalonate pathway promoted research into activity of NBPs in cancer cell lines, 
both alone and in combination with clinically relevant chemotherapeutic strategies. 
NBPs have been shown to eause cell death in a p53-dependent manner (Sanli, 
Gommlu et al. 2009) and in a p53-independent manner (Kuroda, Kimura et al. 2004).
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They have been demonstrated to cause cell cycle arrest (Romani, Desenzani et al. 
2009), reduce invasiveness by inhibiting the production of matrix degrading proteases 
(Giraudo, Inoue et al. 2004), lower migration potential by decreasing integrin 
expression (Bezzi, Hasmim et al. 2003) and, critically for this line of research, 
decrease the level of angiogenesis (Fournier, Boissier et al. 2002; Wood, Bonjean et 
al. 2002; Bezzi, Hasmim et al. 2003).
1.4.2 The effects of the nitrogen containing bisphosphonate, Zoledronate, on 
endothelial cells
The first description of the anti-angiogenie potential of ZA was by Wood et al. 
Using multiple in vitro models, they demonstrated that after exposure to ZA, 
endothelial cell (EC) growth was inhibited and apoptotic EC death increased (Wood, 
Bonjean et al. 2002). An increased level of cells in S phase of the cell cycle was also 
observed. Further experiments using ex vivo rat aortal rings demonstrated decreased 
sprouting. Several in vivo experiments corroborated the in vitro data, and, even with 
exogenous growth factor stimulation, ZA sueeessfully inhibited ECs. This discovery 
has led to multiple attempts to elucidate ZA’s mechanism for cell death induction in 
ECs. Studies have demonstrated that treatment with ZA caused a reduetion in the 
amount of small GTPases embedded in the plasma membrane (Hasmim, Bieler et al. 
2007; Miehailidou, Brown et al. 2010), whieh implies dysregulation of these 
signalling pathways (e.g., Ras, Rho, Rap la  and Rae). ZA also causes decreased 
cellular adhesion via Uybs integrin (Bezzi, Hasmim et al. 2003), but there is some 
disagreement as to whether the integrin levels are altered (Bellaheene, Chaplet et al.
2007). In addition, ZA treatment leads to decreased integrin-mediated 
phosphorylation of focal adhesion kinase (Bezzi, Hasmim et al. 2003). ZA has been 
shown to inhibit the phosphorylation of protein kinase B, extracellular regulated 
kinase (ERK) and TNF-a-driven phosphorylation of Jun N-terminal kinase (Bezzi, 
Hasmim et al. 2003; Hasmim, Bieler et al. 2007). There are reports of synergy 
between ZA and TNF-a. The programmed cell death that results from this synergy 
was shown to be independent of easpase-3 (Bezzi, Hasmim et al. 2003). It has been 
observed that ZA treatment caused an accumulation of VEGFR2 in ECs but it was 
suggested that this accumulation may be owing to the inhibition of lysosomal 
degradation of the VEGF-VEGFR complex (Basi, Lee et al. 2010)
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The dose-dependent eytotoxie effect of ZA on ECs has also been 
demonstrated in endothelial progenitor cells (EPCs). The ability of these eireulating 
vascularizing cells to be recruited by tumours and incorporated into the neo- 
vaseulature is well established (Li Calzi, Neu et al. 2010). However, the rate and level 
of incorporation of these cells is a subject of intense debate. Only two studies have 
dealt specifically with EPCs and ZA. In the first study, EPCs were extracted, 
separated, cultured and identified as EPCs, before being subjected to ZA, which was 
then shown to eause dose-dependent apoptosis, and associated with decreased expres­
sion of VEGFR2 and VE-cadherin. This effect was partially reversed by eo-treatment 
with geranylgeraniol (Yamada, Tsuno et al. 2009), whieh, as the end product of the 
mevalonate pathway, should increase the insertion of prenylated proteins into the 
plasma membrane. The second study demonstrated a significant decrease in EPC 
number after 24 h of incubation with 50 pM ZA; however, without a stated method 
for this experiment it is difficult to objectively re-analyse the results (Ziebart, Pabst et 
al. 2011)
1.4.3 The effects of Zoledronate on tumour associated macrophages
Since angiogenesis is not solely dependent on the growth of ECs but requires 
the cooperation between multiple cell types, the effect of ZA on other cells, such as 
macrophages, has also been studied. Macrophages have been shown to release 
angiogenic factors (Hunt, Knighton et al. 1984), including matrix metalloproteinase 
(MMP)-9, whieh have been shown to play a critical role in malignant angiogenesis 
(Bergers, Brekken et al. 2000). In a model of cervical carcinoma, Giraudo et a l 
investigated the effect of ZA on MMP-9-expressing macrophages -  ZA was shown to 
significantly reduce vessel density (Giraudo, Inoue et al. 2004). ZA-treated tumours 
contained increased numbers of apoptotic ECs (shown by expression of caspase-3 and 
Meea-32 [an antibody recognizing the VEGF-VEGFR complex]). ZA treatment also 
significantly decreased MMP-9-expressing macrophage numbers. Investigation using 
MMP-9-knoekout mice demonstrated a significant reduction in the percentage of 
activated ECs (-70% decrease), a similar level to that of ZA-treated tumours, 
providing strong evidence that the effect of ZA was through the modulation of 
MMP-9 expression. A further study used an elegant method of high-dose radiation to
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kill the EC bed followed by perfusion with syngeneie bone marrow (BM) to measure 
the level of BM-derived cells in the vasculature in tumour models (Ahn and Brown
2008). They concluded that EPCs only provided a small percentage of the cells in the 
neo-vaseulature (<5%) in this model. Building on Giraudo et aVs work, they 
confirmed that MMP-9 is a major factor in tumour growth owing to its role in the 
remodelling of the extracellular matrix. They finally concluded that ZA’s protective, 
anti-angiogenie effect may be owing to decreased levels of MMP-9. In a further study 
Coseia et al. utilised a model of breast cancer, which was treated weekly with a dose 
of ZA which is achievable clinically. They observed decreased macrophage and 
endothelial cell numbers, but most notably they saw a repolarisation of macrophage 
phenotype from M2 (immune-suppressive, wound healing, tissue remodelling -  with 
VEGF and MMP-9 production) to M l (immune-stimulatory, low VEGF and MMP-9 
production). This phenotype repolarisation hypothesis was strongly supported when 
this model then had the gene for Interferon-y (INF-y) knocked out, subsequent 
treatment with ZA did not provide any preventative effects. Throughout these 
experiments, the authors provide evidence that these effects are due to ZA’s 
modulation of the prénylation process (Coseia, Quaglino et al. 2010).
1.4.3 Pre-clinical evidence of Zoledronate’s anti-angiogenic effects
The study of ZA in a preelinieal setting is variable, and dependent on 
experimental design and desired end points. When studying the effect on bone- 
homing tumour cells, the in vitro concentration that is representative of clinical doses 
is approximately 1 mM (Sato, Grasser et al. 1991). However, with solid tumours 
alone, a clinically relevant concentration is 1-2 pM (Chen, Berenson et al. 2002). 
When ZA is being used in an anti-angiogenie capacity, an effective dose is 10 pM. 
This variation in dosage is often overlooked at the in vivo stage of a study and 
warrants further investigation regarding the mechanism of ZA.
The animal models used to study the anti-angiogenie properties of ZA have 
been varied and ZA often is administered as a combination treatment, making the 
precise mechanism and contribution of ZA to the antitumor effect uncertain. The 
effect of direct exposure of osteosarcoma cells to ZA alone has been evaluated and
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resulted in a significant reduction of vessels in tumour tissue (Dass and Choong 
2007). However, ZA also has a cytotoxic effect on the osteosarcoma cells used in 
vitro, questioning the degree to whieh the anti-angiogenie effect was important. ZA 
has been used at elinieally relevant doses in the preelinieal treatment of multiple 
myeloma (Croueher, De Hendrik et al. 2003), where mice with slow developing, 
osteolytic lesions were treated with a clinically representative dosing schedule. It was 
shown that ZA decreased morbidity as well as mean vessel density. However, these 
results were not compensated for the eytotoxie effect of ZA, whieh has been 
previously demonstrated (Aparieio, Gardner et al. 1998). ZA was evaluated in a 
neuroblastoma model and demonstrated an antitumor (reduced viable tissue and 
increased apoptosis) and anti-angiogenie capability (reduced vessel number and 
length per tumour volume with an increase in vessel diameter) (Baekman, Svensson et 
al. 2008). This increase suggests an attempt to compensate for a reduetion in 
branching points. The effect of ZA on a renal carcinoma model has been thoroughly 
investigated (Soltau, Zirrgiebel et al. 2008); I C 5 0  values for endothelial lines, as well 
as the cancer lines, were calculated and a dose escalation was performed. Using a 
murine model, systemic treatment with ZA 100 pg/kg/day significantly reduced both 
vascular density in the tumour and circulating VEGF levels. Evidence for the anti- 
angiogenie effects of ZA have also been reported in models of breast cancer bone 
metastasis treatment (Bauerle, Merz et al. 2010). Using dynamic contrast-enhanced 
MRI and vessel size imaging (by computerized tomography) to monitor the 
métastasés, ZA treatment decreased vascularity and increased permeability of the vas­
culature. ZA also caused decreased collagen IV staining, suggesting fewer small 
vessels, corroborated by a significant decrease in the amount of blood within the 
métastasés. ZA has been used in combination with Sorafenib (a multi-reeeptor 
tyrosine kinase inhibitor) to treat hepatocellular carcinoma (Zhang, Zhu et al. 2010). It 
was established that the combination not only significantly decreased the tumour 
volume, but also greatly decreased the number of lung métastasés. A noted 
observation from this study was that Sorafenib increased intra-tumoural and 
eireulating macrophages (Dirkx, Oude Egbrink et al. 2006). In these models, 
macrophage numbers in animals treated with Sorafenib were returned to normal levels 
by treatment with ZA. Sorafenib caused increased eireulating colony-stimulating 
factor 1 (a known angiogenie factor (Aharinejad, Paulus et al. 2004)) and VEGF. 
However, as a combination, ZA and Sorafenib treatment normalized colony-
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stimulating factor 1 levels in one tumour model while normalizing VEGF in the other 
models of hepatocellular carcinoma (Zhang, Zhu et al. 2010). The effect of ZA and 
Sunitinib treatment on bone métastasés in lung adenocarcinoma was investigated. 
Although the combination provided no survival benefit (Catena, Luis-Ravelo et al. 
2011), the study suggested synergistic effeets between the two agents with the 
significant decrease in bone metastasis volume.
1.4.4 Effective drug combinations utilising Zoledronate
As a well tolerated and extensively studied therapy, ZA’s combination with 
standard chemotherapies is an attractive treatment option that has warranted, and 
received, further investigation. Over the last decade, ZA has been tested, at the in 
vitro level at least, with every class of chemotherapeutic, including the newly created 
tyrosine kinase inhibitors and monoclonal antibodies. However, the efficacy of these 
combinations is often limited to certain cancer types and they may be antagonistic in 
some other neoplasias. Synergism between concomitant ZA and paclitaxel has been 
demonstrated in breast cancer (Jagdev, Coleman et al. 2001), as has sequential ZA 
and doxorubicin treatment in a murine model of breast cancer (Ottewell, Monkkonen 
et al. 2008). Synergism between ZA and all trans-XQ^moio, acid in ovarian cancer has 
also been described (Karabulut, Karaea et al. 2010). One of the few studies that inves­
tigated ZA synergism, from an anti-angiogenie perspective, used paclitaxel 
(Miehailidou, Brown et al. 2010); concomitant ZA and paclitaxel was shown to 
synergistieally increase EC cycle stalling (in S phase) and inhibit tube formation in 
matrigel. Only one other paper suggests cooperation between ZA and another agent to 
affect ECs. Pre-treated with ZA, ECs respond with slightly greater cytotoxicity when 
exposed to TNF-a (Bezzi, Hasmim et al. 2003). Clinically, ZA has been combined 
with docetaxel (Faeehini, Caraglia et al. 2010), doeetaxel and vinorelbine (Di 
Lorenzo, Autorino et al. 2007), and gemeitabine and prednisone (Di Lorenzo, 
Autorino et al. 2007) in prostate cancer, and generally demonstrates improved clinical 
responses.
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1.4.5 Clinical evidence of Zoledronate’s anti-angiogenic potential
Clinical data regarding ZA and tumour-associated angiogenesis is sparse with 
most reports in multiple myeloma and breast cancer. BM-derived ECs and 
macrophages from multiple myeloma patients were used by Seavelli (Scavelli, Di 
Pietro et al. 2007) and Mosehetta (Mosehetta, Di Pietro et al. 2010) to test the effect 
of ZA. BM-derived ECs displayed dose-dependent inhibition of growth, migration 
and vessel formation, while, at the molecular level, secreted VEGF, VEGFR2 and 
phosphorylated ERK 1/2 were decreased (Seavelli, Di Pietro et al. 2007). Treatment of 
BM-derived macrophages demonstrated a dose-dependent inhibition of proliferation, 
migration and vessel formation, as well as inhibition of adhesion. ZA also appeared to 
inhibit the secretion of numerous growth factors from macrophages, and decrease 
phosphorylation VEGFR2 and ERK 1/2 levels (Mosehetta, Di Pietro et al. 2010). ZA 
treatment in breast cancer patients with (Ferretti, Fabi et al. 2005) and without 
(Vineenzi, Santini et al. 2005) bone métastasés resulted in a decreased serum VEGF 
level. In patients with métastasés, this decrease is transient and levels returned to 
baseline after 7 days. In a study of 18 patients with bone métastasés from breast can­
cer, it was noted that ZA treatment transiently decreased serum basic FGF (bFGF) and 
MMP-2 levels (Ferretti, Fabi et al. 2005), which positively correlated with IL-8 levels 
(involved in angiogenesis (Koch, Polverini et al. 1992) and a possible prognostic 
indicator of metastatic potential (Derin, Soy dine et al. 2007)), TNF-a levels (a 
possible prognostic factor (Papadopoulou, Tripsianis et al. 2010)) and bFGF levels. A 
total of two further studies demonstrated that ZA caused a long-term decrease in 
serum VEGF levels in patients with bone métastasés (Santini, Vineenzi et al. 2003; 
Santini, Vineenzi et al. 2007). However, these were small patient cohorts, with 
various types of cancer and VEGF levels were not compared with healthy controls. 
By contrast, other studies have failed to establish any relationship between angiogenie 
factors and bisphosphonates (Tas, Duranyildiz et al. 2008). Evaluation of serum levels 
of VEGF and bFGF between 7 and 28 days post-bisphosphonate infusion in 30 cancer 
patients demonstrated no significant changes compared with baseline. However, this 
was a small study, a heterogeneous group of malignancies and the time points for 
analysis of the angiogenesis markers varied widely.
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1.5.1 in vitro models of angiogenesis.
In order to assess the anti-angiogenie eapability of any drug, it is screened in 
both in vitro and in vivo assays. There are 27 cell lines of a vascular endothelial nature 
in the ATCC bio-repository as well as 8 primary endothelial cell sources, these form 
the basis of the in vitro assays performed, with the most popular being human 
umbilical vein endothelial cells (HUVECs) and human mierodermal vascular 
endothelial cells (HDMVECs). In order to accurately mimic tumour neo-vaseulature 
these cell lines should be undergoing replication, as such these cultures should be at 
approximately 70% conflueney when assays are used to determine cell survival. The 
wound assay assesses the ability of endothelial cells to migrate/replicate in the 
presence of a drug; ECs are allowed to grow to near conflueney, a scratch is made in 
the culture to remove cells and the number of cells repopulating the area is monitored 
and compared to untreated controls. Boy den chambers measure EC’s movement in 
response to a ehemoattraetant; ECs are cultured in an upper chamber whose floor is 
porous to migrating cells, this upper chamber is then immersed in a combination of 
ehemoattraetant and drug; ehemotaxis is measured by the difference in the number of 
cells in the bottom chamber of the drug treatment compared to the ehemoattraetant 
alone. Often the effect of a drug on EC’s ability to adhere to certain proteins, from 
whieh it is possible to infer whieh integrin is responsible for EC adhesion; trypsinised 
ECs with and without drug are subjected to culture on various ECM proteins (e.g. 
laminin only binds integrin aepi) and assessed for adhesion. One of the most 
informative in vitro assays is using matrigel to assess EC tube forming ability in 
response to the drug. Matrigel™ (BD Bioseienee, Oxfordshire) is a commercial 
mimic of the ECM composed of laminin, collagen and heparan sulphate 
proteoglycans which is fluid at low temperatures but solid at body temperature; it is 
derived from a murine Engelbreth-Holm-Swarm sarcoma, whieh secretes this ersatz- 
ECM as part of its normal biology. When ECs are embedded in Matrigel™ they self- 
organise into a network that closely resembles the maero-arehiteeture of capillaries in 
vivo. Addition of drug to the suspension of MatrigeE’^  and ECs allows the evaluation 
of inhibition of tube formation (a vital step in anastomosis) and the branching of these 
tubes.
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1.5.2 in vivo models of angiogenesis
in vivo models of angiogenesis are considered to be significantly more 
informative about the physiological process which is angiogenesis. Angiogenesis is 
the result of cooperation between multiple cell types to yield functioning vasculature; 
all these cell types are available in an in vivo model. The comeal angiogenesis assay 
involves the implantation of a small pellet containing a vascular stimulator with or 
without the dmg. Eventually blood vessels invade the cornea in response to the 
proliferative signals, the levels of whieh are compared to those treated with the dmg. 
Another method involves the use of the dorsal skin fold of mice, stretched to a state of 
translueency allowing the monitoring of blood vessel growth in response to vascular 
stimulation of dmg treatment. A variation of this method is to create an incision and 
pour in Matrigel™ or inject the mixture of MatrigeE^ impregnated with growth 
factor with or without the dmg treatment into the flank. Vessels will then invade the 
pseudo-ECM in response to the growth factor, the MatrigeE^ ean be excised and 
analysed for vessel growth, branching and length; parameters important in the 
assessment of a treatment’s anti-angiogenie potential. One of the more difficult in 
vivo evaluations of a treatment’s anti-angiogenie eapability is the xenograft tumour 
model; tumour cells (with or without Matrigel™) are implanted either subeutaneously 
or orthotopieally, treated, excised and evaluated for levels of angiogenesis. This 
method is can be rather cmde and biased without proper interpretation and 
background work; this is because some treatments affect both endothelial and 
neoplastic cells, the altered level of angiogenesis must be established as an effect on 
either or both cell types. The ChorioAllantoic Membrane (CAM) assay is another 
method to model angiogenesis; fertilised avian embryos produce a highly vaseularised 
membrane (that also incorporates stromal cells) during their development that allows 
the assessment of treatment as an anti-angiogenie agent.
1.6 The Chorioallantoic Membrane Assay
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With human domestication and farming, the observation of chicken embryo 
development has been performed since the time of Aristotle and its three week, 
season-independent, growth has made it an ideal model organism for studying 
embryonic development. Ovum fertilisation occurs in the oviduct of the chicken, with 
the fertilised embryo sitting atop the yolk developing into a blastoderm. The fertilised 
embryo is incubated here, where it undergoes continuous cell division and cleavage, 
by the time it is laid it contains approximately 20,000 cells. With 24 hours of 
incubation, stem cell differentiation has led to neural development as well as the 
formation of blood islands, whieh will be discussed later. A further 10 hours 
incubation yields the formation of the initial stages of brain, heart, gut, blood vessel 
and limb development. At day two of incubation, neural development has been 
paramount and that system is developing well, similarly, cardiovascular development 
has improved, though the heart is yet to beat. Finally, the gut exists as a simple tube at 
this stage and muscle and skeletal precursors are only more numerous rather than 
more differentiated. By day three of incubation the heart has started to beat, neural 
development is progressing well and blood vessels which tap into the nutrient reserve 
of the yolk are numerous. With the fourth day of incubation further limb development 
occurs (the formation of limb buds) and the four chambered heart develops. Further 
detail on chicken foetus development ean be found in Developmental Biology, 7* 
edition, by Seott F Gilbert. For our purposes, the embryo continues to develop and by 
day seven of incubation, the chorioallantoic membrane is suitable for 
experimentation, by day eleven an immune system is developing, by day fourteen 
feathers start to develop and in the late stages, day seventeen onwards the bones begin 
to calcify.
Cardiovascular development is paramount to the survival and progression of 
an embryo of a multi-system organism. Without it, in the case of the chick foetus, 
nutrients could not be moved from the yolk, waste could not be removed, oxygen 
would not be supplied to all tissues and eventually calcium would not be leached from 
the shell. All cardiovascular tissue is derived from mesoderm. Cardiogenic mesoderm 
is generated by Bone Morphogenetic Protein and Fibroblast Growth Factor 
stimulation by the anterior endoderm; cardiac precursors migrate to lateral of 
Hensen’s node. Here they form a pair of endocardial tubes, which merge when 
brought together by the folding of the splanehinie mesoderm. From here, at
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approximately 33 hours of incubation the primitive two chambered tube heart begins 
to rhythmically pulsate and circulate blood, throughout this blood vessels have been 
developing. Initially the lateral mesoderm forms blood islands, the outer cells 
becoming endothelium and the inner cells form red blood cells, from here the vitelline 
veins are formed. Vitelline vessels are responsible for the absorption of nutrients from 
the yolk and are the equivalent of umbilical vessels in mammals. From this 
vasculagenesis, angiogenesis occurs, whieh will provide sufficient surface area for gas 
exchange. From this point the two chambered tube heart loops, this then becomes the 
classical four chambered heart. As its name suggests, the chorioallantoic membrane 
(CAM) is the partial fusion of the chorion (outermost membrane of the embryo 
derived from the mesoderm) and the allantois (the membrane that encircles the yolk 
sac and helps to deposit nitrogenous waste), which occurs between the fifth and sixth 
day of incubation (Romanoff 1960). Eventually this CAM completely surrounds the 
egg content by the eleven or twelfth day of incubation (Freeman and Vinee 1974) and 
is made up of three distinet tissue layers. The first is the extodermal ehorionie 
epithelium (the outermost) and is responsible for anchoring to the inner shell 
membrane. Next is the intermediate mesoderm, where all of the blood vessel 
formation occurs (Narbaitz 1977), providing the maximal surface for gas exchange for 
the developing foetus. Finally is the allantoic epithelium whieh lines the yolk sac and 
is the site of nitrogenous waste deposition. The CAM plays a vital part in later ehiek 
foetal development as its close proximity to the shell to allow the mobilisation of 
calcium for the developing skeleton, this décalcification has a two-fold benefit, in that 
it also weakens the integrity of the solid egg shell, allowing an easier hatching 
(Johnston and Comar 1955).
Historically the CAM assay was first used nearly 80 years ago (Goodpasture, 
Woodruff et al. 1931), with its first use in cancer research in 1975 by Folkman 
himself (Klagsbrun, Knighton et al. 1976). With the advent of genetic engineering of 
murine models, the CAM assay increasingly fell from favour. However, in the past 
decade it has seen a resurgence in its inclusion as a technique in research papers. This 
increased use is most likely due to activist and public pressure with regard to rodent 
models.
The CAM allows for the cultivation of tumour cells if they are implanted 
before day 11 of incubation. After this point the embryo’s immune system develops,
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and any detection of ‘non-self proteins will elicit a strong, anti-tumour response. This 
means that, in effect, embryos are the same as Severe Combined Immuno-Defieient 
(SCID) mice but available at only a fraction of the purchase cost. Husbandry care is 
also negligible, as only the humidity and temperature needs to be carefully monitored. 
Infection and infertility are the main risks to survival rate, but with good suppliers and 
adequate sterile and technical skills, these risks are minimised. The one negative 
aspect of this technique is that it is labour-intensive with the opening, inoculating, 
cheeking, treating, observing etc. In terms of angiogenesis though, with the vessels 
clearly visible, many methods of determining anti-angiogenie potential are available, 
beyond standard, mean vessel density (MVD) immuno-histoehemical staining.
The basic variations of the CAM assay will be covered here, with what tumour 
cells that have been used, as well as treatments that have been trialled in this model 
since Ribatti’s review (Ribatti 2010) can be found in the appendix.
The CAM assay has 3 main variations that study angiogenesis, cancer or both.
1.6.1 The Chorioallantoic Membrane assay to trial anti-angiogenie treatments
The first variation of the methodology is the most widely used (-60% over the 
last 6 years), it involves the opening of the egg (either early or at the time of 
treatment) and the application of a test substance to the CAM. Major vessel sprouting 
is achieved by exogenous supplementation of known angiogenie factors (most 
commonly basic Fibroblast Growth Factor [bFGF], Vascular Endothelium Growth 
Factor [VEGF] or Platelet Derived Growth Factor [PDGF]). Whether a substance has 
the ability to interfere with measurable vessel parameters (e.g. number of branch 
points, length) leads to the determination of the effect on angiogenesis. The opening 
time and technique are crucial, possible trauma in the opening may lead to 
perturbations of the growth factor/inhibitor balance. Early opening trauma may 
increase anti-growth signals by the time of treatment. Conversely, treatment at the 
time of opening may increase the spectrum of pro-growth signals that will influence 
the vasculature.
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1.6.2 The Chorioallantoic Membrane assay to trial tumourigenicity
The second variation involves the implantation of tumourigenie cells on the 
CAM (-15% for the last 6 years). This also involves the opening of the egg (either 
early or at inoculation time). It is achieved by embedding the cells in a sponge or their 
suspension in Matrigel and application to a damaged blood vessel. The use of the 
sponge has been utilised for patient derived blood samples, tissue and cell lines. The 
Matrigel method is used for tissue from biopsies and cell lines. For both, single cell 
suspensions or small chunks of biopsy material are a requirement. The remarkable 
observation for this method is apparent in LoVo cells (a metastasis of human 
colorectal adenocarcinoma) implanted into the CAM start to self-organise and attempt 
to form lumina (Durupt, Koppers-Lalie et al. 2012) also see Figure 3.3.6.2. This 
suggests that this cell line derives from a stem cell whieh supplies the crypts of the 
intestine. It has been hypothesised that this variation of the CAM technique could be 
used to help improve the success rate of cell line generation from tissue biopsies. The 
amount of genetic deregulation required to survive in tissue culture means that 
successful cell line generation is rare. However, the CAM environment provides a 
bridge between patient and tissue culture whieh could allow the generation of a large 
number of cells from a small biopsy.
1.6.3 The Chorioallantoic Membrane assay to trial tumourigenicity and anti- 
angiogenie treatments
The third variation involves the inoculation of cells and then using the 
resulting tumour to test treatments (-25% over the last 6 years). There are 2 variations 
to this method; where cells are treated at the time of inoculation or when they have 
successfully grafted and developed a tumour. Treatment at inoculation time, involves 
either pre-treating the cells in vitro or suspending the cells in the anti-cancer or anti- 
angiogenie of choice before the procedure. Treatment after inoculation is topical, 
intra-tumoural or intra-venous and as before can be either anti-caneer or anti- 
angiogenie agents.
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Chapter 2
Materials and Methods
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All lines were obtained from ATCC, Middlesex, apart from the MZ-RCC lines 
and AY-27S. The MZ-RCC lines were acquired from the laboratories of Dr A Knuth, 
Frankfurt, Germany and Dr H. E. Gabbert, Düsseldorf, Germany. AY-27S was 
derived by transfecting the AY-27 line (a kind gift from Dr R. B. Moore, University 
of Alberta, Canada) with pGL4 CMV lue hygo and pcDNA3 HVEM. All lines were 
maintained at 37°C and harvested when confluency exceeded 70%. Complete culture 
media was aspirated and a suitable volume of trypsin/EDTA (0.5g/L-0.2g/L) solution 
(Sigma-Aldrich, Dorset) was added and the culture vessel returned to 37°C with 
appropriate CO2 for the cell line. If necessary, cells were washed with Dulbecco’s 
phosphate buffered saline B (PBS) (Oxoid, Hampshire) to remove any residual 
complete media before trypsinisation. Once all cells had detached from the culture 
surface, a similar volume of complete culture medium was added to the vessel to 
inactivate the trypsin and prevent further enzymatic digestion. The cells were then 
transferred to a Universal and spun at ISOOrpm for 3 minutes, after which the 
supernatant was discarded and the cell pellet resuspended in complete culture media 
ready for experimentation or sub-culturing.
2.1.1 Trypan blue dye exclusion method of cell counting
An Improved Neubauer Haemocytometer was purchased from VWR 
International, West Sussex, and was assembled to a complete chamber using a 
coverslip, with the volume equalling lOOnl. Cell suspensions were diluted 1 in 10 in 
trypan blue solution (Sigma, Dorset) and lOpl was pipetted into the sealed counting 
chamber. Bright, round cells in the 4 major comer areas (when cells were located with 
50% of their volume over the left or upper lines they were counted otherwise not), the 
total was divided by 4 to give cell concentration x 100, 000 per ml.
34
Cells/ml
Cell line 24hrs 48hrs 72hrs 96hrs
MZRCC 1770 3.0x10^ 2.0x10^ 2.0x10^ 2.0x10^
Renca 6.0x10'' 6.0x10" 3.0x10" 3.0x10"
HUVEC 8.0x10" 7.0x10" 6.0x10" 5.0x10"
B16F10 7.5x10" 3.0x10" 1.0 xlO" 1.0 xlO"
PC-3 6.0x10" 6.0x10" 3.0x10" 3.0x10"
HT-29 9.0x10" 9.0x10" 4.5 xlO" 4.5x10"
Table 2.1.1.1 Optimised cell numbers. Cell numbers optimised for each cell line to produce 70% 
confluency at each given time point, determined in 96-well plate format.
The table above shows the optimised cell number for each time point, in order 
to provide ideal culture conditions, complete culture media was replaced every 24hrs. 
These concentrations were used for all MTS and LDH assays, cell lysate and 
conditioned media preparations and RNA extractions
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2.2 Supernatant collection
Cells of interest were plated at a concentration to achieve their 70% 
confluency at the desired time-point and treated for the required time. Supernatants 
were collected and then stored at least -20°C.
2.3 Whole cell lysis
Cells were plated at the required concentration in 6-well plates and treated. 
Treatment media was aspirated after the desired length of time and the cells washed 
twice with cold PBS. 500pl complete RIPA buffer (RIPA buffer [Fisher Scientific, 
Louborough], lOpl/ml protease inhibitor cocktail [Fisher Scientific, Loughborough], 
lOpl/ml phosphatase inhibitor cocktail [Perbio Science UK, Cramlington], lOpl/ml 
0.5mM EDTA (5pM) [Fisher Scientific, Loughborough]) was added to each well and 
the plate placed on ice for 5 minutes, swirling occasionally. Complete shearing was 
achieved by use of a cell scraper followed by repeated movement through a 21 gauge 
needle. This aspirate was then spun at 13000 rpm for 5 minutes and the supernatant 
transferred to a fresh container, which was then stored at -80°C.
2.4 RNA extraction
The purpose of this procedure was to probe the transcriptome and investigate 
the level in certain genes. RNA extraction was performed according to the procedure 
for the Qiagen RNEasy Plus mini kit (Qiagen, Crawley). Cells were grown in 6 well 
plates and treated as required. Treatment media was aspirated after the desired length 
of time and washed with PBS. Cells were lysed using 500pl per well of RLT Plus 
buffer (containing lOpl of P-mercaptoethanol per ml of RLT Plus buffer) and 
homogenized using cell scrapers. The lysate was then transferred to a genomic DNA 
Eliminator spin column, which sits in a 2ml collection tube, and spun at 10, 000 rpm 
for 30 seconds. Genomic DNA by nature of its double helix contains twice the 
number of negatively charged phosphate groups so therefore can be separated by 
affinity column. The flow-through contains the RNA and proceeds to the next step, 
where it was diluted 1:1 with 70% ethanol and mixed well. 500pl was transferred to 
an RNeasy spin column and sat in a 2ml collection tube and spun at 10, 000 rpm for 
15 seconds, discard the flow-through and repeat for the other 500pl, also discarding
36
the flow-through. TOOpl of RWl buffer was then added to the spin column, spun at 
10,000 rpm for 15 seconds and the flow-through was discarded. 500pl of RPE buffer 
(containing 80% ethanol) was added to the spin column, spun at 10, 000 rpm for 15 
seconds and the flow-through was discarded. 500pl of RPE buffer (containing 80% 
ethanol) was added to the spin column, spun at 10, 000 rpm for 2 minutes and the 
flow-through was discarded. The RNeasy spin column was then placed in a new 2ml 
collection tube and spun at 10, 000 rpm for 1 minute. This long spin and new 
collection tube ensures no ethanol is carried over in the following spins as it could 
possibly effect experiments using this RNA. The RNeasy spin column is then placed 
in a new 1.5ml epindorf and 50pl of RNase-free water is added to the column, which 
is then spun at 10, 000 rpm for 1 minute to elute the RNA. This RNA is the total 
cellular RNA and is then stored at -80°C as this helps to prevent any further 
degradation.
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2.5 MTS assay
MTS, (3 -(4, 5-dimethylthiazol-2-yl)-5-(3 -carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium), is a modification of MTT (3-(4, 5-Dimethylthiazol-2- 
yl)-2,5-diphenyltetrazolium bromide) to reduce cellular toxicity. The supplied 
CellTiter 96® AQueous One Solution Proliferation Assay (Promega, Southampton) also 
contains phenazine ethosulfate (PES) which acts as an electron coupling agent, 
allowing the tétrazolium salt to form a stable solution within the tissue culture media. 
Upon reduction, the MTS maximal absorbance shifts to 490nm, this reduction occurs 
in the mitochondria and as such only occurs in living cells. Cells plated onto 96-F 
plates (Nunc, Fisher Scientific, Loughborough) and left to settle overnight. Treatment 
of cells was performed by aspirating 90% of the FGM used to settle the cells and 
replaced with lOOpl 2% FCS media with and without drug(s) for defined lengths of 
time, cells were retreated every 24 hours to ensure optimal survival of the untreated 
control. Finally, 90pl of treatment media was removed and replaced with lOOpl of 
10% MTS in 2% FCS media, the assay was returned to 37°C for suitable lengths of 
time to allow development of the assay. Assay plate was then inserted into a DTX 880 
multimode detector (Beckman Coulter, High Wycombe), shaken in an orbital fashion 
for 5 seconds at a medium intensity and then absorbance measured at 492nm. Optimal 
results were obtained when the untreated control gave an absorbance of 
approximately 1.0 after the background was subtracted. The percentage survival is 
calculated thus:
VosurvM  = [ Experimental-Background\^ 
y Untreated -  Background j
Equation 2.5.1Calculation o f percentage survival from MTS assay spectrophotometry data
I C 5 0  calculations are performed using the reciprocal i.e. the percentage 
affected, which is then expressed as a decimal and inserted into a Calcusyn (Biosoft, 
Cambridgeshire) which utilises the median effects method described by Chou and 
Talalay (Chou and Talalay 1984). All data was interrogated for validity by the linear 
correlation coefficient, r, of the median effect plot, for all tissue culture experiments r 
> 0.90 to be considered valid.
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2.6 Cell cycle analysis
G n /G
Figure 2.6.1 Diagrammatic representation o f the eukaryotic cell cycle.
The measurement of DNA levels via an intercalating, florescent agent allows 
us to determine which stage of the cell cycle populations of cells are in. After 
treatment cells were harvested by trypsinisation and complete media inactivation 
followed by centrifugation at ISOOrpm for 3 minutes. Each cell pellet was then 
washed twice with ice cold PBS and then resuspended in 300pl 50% Heat Inactivated 
FCS: 50% ice cold PBS. Then 900pl ice cold 70% ethanol: 30% deionised water was 
added dropwise whilst gently agitating the sample, which was then stored at 4°C for a 
minimum of 2 hours. The samples were washed twice more with ice cold PBS and 
then resuspended in 200pl Img/ml Ribonuelease A (Sigma, Dorset), 5pg/ml 
Propidium Iodide (PI) (BD Bioscience, Oxford) and incubated at 37°C for 30 minutes 
in the dark. All flow cytometry was performed on a MACS Quant flow cytometer 
(Miltenyi Biotech, Surrey).
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Figure 2.6.2Example of plots displayed by the MACSQuant software. Top left is the Forward and Side 
Scattering (FSC & SSC respectively), FSC indicates cell size and SSC indicates granularity. Top right 
is the plot of PI against PI (488nm excitation, 575nm emission) for all cells that pass through the flow 
cytometer, the gate PI is used as a preliminary gate in the analysis o f the cell cycle. Bottom left is the 
fluorescence intensity against number o f counted events (cells), gate P2 selects for cells with lower 
amounts o f fluorescence and gate P3 selects for cells with double the amount of fluorescence o f gate 
P2.
Samples were diluted in PBS, as necessary, to ensure that counts per pi did not 
exceed 5000. Counts >5000/pl do not allow for aecurate discrimination between 
doublets of cells in Gq/Gi and singular cells in G2/M.
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IFigure 2.6.3 Demonstration of gating for cell cycle analysis. Left demonstrates how dead cells were 
excluded by gating (P4 = 85.69% of the total counted events). Right, is the gated cells (arrow indicates 
where alteration has occurred) fluorescence against counts, with P5 and P6 having the same 
fluorescence as P2 and P4.
File na2010-10-29.001 .rnqd 29-Oct-2010 09:54
Sid control Descr. 96hrs 2%
Region % # Count Count/|il PI/PE Cy5 A Mean PI/PE-Cy5-A StdDev
na2010-10-29.001 100.00 52465 5646.3 356.80 224.39
P4 85.69 44956 4838.1 319.72 111.96
P5 80.18 27053 2911.4 266.60 26.28
P6 10.11 4545 489.1 521.03 32.40
Table 2.6.1 Example o f cell cycle analysis. Quantitive data from figure 2.6.3 (right) shows the 
percentage o f the gated cells in Gq/Gi (60.18%) and G2/M (10.11%)
Each sample was then interrogated and compared to the PBS or EDTA control 
to calculate the fold change and farther analysed to see how significant the change 
was.
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2.7 Chorio-allantoic membrane assay
The Chorio-allantoic membrane (CAM) assay has been an observed technique 
for at least a century, but recently has received renewed interest as a research model 
because it provides a stable platform to test both anti-cancer and anti-angiogenic 
treatments as an animal model. All experimental procedures were performed with the 
authority of the Home Office, following UK guidelines and in accordance with best 
animal practice. Fertilised chicken eggs were obtained from Henry Stewart & Co Ltd, 
Norfolk, upon delivery eggs were cleaned, acclimatised to room temperature and then 
incubated at 37°C (this is taken as Estimated Due Date [EDD] 1, hatching occurs on 
EDD 21). On EDD 4 the egg is washed vigorously with 70% ethanol and the CAM is 
exposed by puncturing the portion of the shell beneath which the air space resides 
with a 19gauge needle, careful removal of the shell with forceps and the delicate 
removal of the inner shell membrane with fine forceps. To help reduce infection rates 
forceps are washed every three eggs in 70% ethanol and the puncturing needle is 
changed every six eggs. The eggs are then returned to 37°C to recover. On EDD 7-10 
tumour cells (more than 1x10^, with the nominal number being 4 x 10 )^ were added. 
Cells were harvested by normal trypsinisation, inactivation with FGM and 
centrifugation. The cells were then resuspended in Hanks Balanced Salt Solution 
(HBSS [Sigma, Dorset]) to help prevent cell-cell adhesion and counted using the 
trypan blue exclusion technique (Method 2.1.1). The tumour cells must be implanted 
in a site of active vascular remodelling, this achieved by causing a micro-bleed in a 
blood vessel on the CAM, a delicate touch and twist with a sterile swab (Fisher, 
Loughborough). The requisite number of cells were then added suspended in 30pl of 
growth factor reduced matrigel (Beckton-Dickson, Oxford), to achieve minimal time 
in HBSS cells were resuspended in batches suitable for 5 eggs i.e. <20 x 10  ^cells. On 
EDD 14-20 treatments may be applied (topically, intratumoural or intravenous) or 
given a dose of radiation suitable for the embryo’s weight. On or before EDD 20 
embryos were terminated by refrigeration at 4°C for 4 hours, shells were broken and 
the CAM and tumour was dissected out. Tumours can be fixed in 4% 
paraformaldehyde for paraffin embedding and histological staining or suspended in 
RNAlater (Sigma, Dorset) and stored for later RNA extraction and RT-qPCR.
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2.7.1 in ovo imaging of cancer using luciferase
The CAM assay was performed according to protocol 2.7, on EDD7, 4x10^ AY-27S 
cells were implanted and grown until EDD20. At which point they were transported to 
the Institute of Cancer Research (ICR), injected with ~2.5mg of VivoGlo™ luciferin 
(Promega, Southampton) intra-tumourally, incubated at 37°C for approximately 15 
minutes then subjected to luminescent imaging using a IVIS® Kinetic (Caliper Life 
Sciences Ltd, Cheshire) set to a 5 second exposure time (units are 
photons/second/ cm^/steradian).
2.7.2 in ovo imaging of cancer using green fluorescent protein
The CAM assay was performed according to protocol 2.7, on EDD7, 4x10^ Renca 
cells were implanted and grown until EDD 18. Tumours were injected intra- 
tumourally with 50pl of 2x109 pfli Herpes Simplex Virus 1 (HSVl) transfected with 
GFP (HSVGFP) on EDD 18 or EDD 19. Eggs were imaged on EDD 20 using an 
IVIS® Kinetic (Caliper Life Sciences Ltd, Cheshire) set to a 1 second exposure time 
and for GFP detection.
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2.8 Tumour Processing
Process Solution Time (hours)
Dehydration
70% alcohol 1
90% alcohol 1
100% alcohol 1
100% alcohol 2
100% alcohol 2
Clearing
Toluene 1
Toluene 1.5
Toluene 1.5
Impregnation
Paraffin wax 2
Paraffin wax 3
Table 2.8. 1 Overnight processing program for formalin fixed samples.
A Shandon Citadel, automatic tissue processor, (Fisher, Loughborough) was 
used to process the tumours up to this point. Tumours were embedded in liquid 
paraffin, cooled and then stored at room temperature for later use.
2.9 ImmunoHistoChemistry (IHC)
4pm tissue sections were cut using a RM 2125RT microtome (Leica 
Microsystems, Milton Keynes) and adhered to IHC microscope slides (Dako, 
Cambridgeshire) by heating at 58°C.
2.9.1 Specific IHC
Sections were dewaxed and rehydrated followed by blockage of endogenous 
peroxidase by Methanol/0.3% H2O2 for 20 minutes. Non-specific binding of 
secondary (detection) antibody is prevented by a 20 minute incubation with 2.4% 
species specific serum in 1% BSA/PBS, species specific serum was included in the 
Vectastain ABC elite kit (Vector laboratories, Peterborough). Sections were incubated 
for 30 minutes with the primary antibody, washed, then incubated with the 
biotinylated secondary antibody (supplied in kit).This was followed by a 30 minute 
incubation with the Vectastain elite ABC Reagent, then incubated with the peroxidase 
substrate solution and counter-stained with Hematoxylin QS (Vector Laboratories, 
Peterborough).
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2.9.1.1 Reovirus detection
Anti-reovirus antibody (primary antibody, goat anti-reovirus) was used at 1 in 3,000, 
little detail is available on this antibody as it is under a Oncolytics Biotech (Calgary, 
Canada) patent. The secondary antibody (rabbit anti-goat) was used at a concentration 
of 1 in 3,000, DAB (Vector Labs, Peterborough) staining (briefly, 5ml dHiO 
combined with 2 drops of buffer stock solution, 2 drops of H2O2 solution and 4 drops 
of DAB stock solution and applied to sections) was performed with Hematoxylin 
counter-staining.
2.9.2 Hematoxylin and Eosin (H&E) staining
Sections were dewaxed, rehydrated and stained with Harris’s Haematoxylin 
solution (Sigma-Aldrich, Dorset) for 15 minutes. Differentiation was achieved by 5- 
10 second incubation with 1% HCl/70% ethanol, sections were then checked by 
visual microscopy to ensure correct nuclear stain level and differentiation. Sections 
were then stained in 1% eosin (VWR international. West Sussex) for 2 minutes, 
dehydrated, cleared in xylene and the coverslip mounted using SPX mountant (VWR 
international. West Sussex).
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2.10 Apoptosis detection
The detection of apoptosis by the binding of Annexin V to phosphatidylserine, which 
is trafficked to the outer surface of a cell undergoing apoptosis, is a well documented and 
accepted technique. Cells were plated and an apoptosis inducing agent control was included 
in each experiment. Cells were harvested by trypsinisation, spun at 1500rpm for 3 minutes 
and washed twice in PBS, aspiration was performed using Pasteur pipettes to ensure maximal 
cell recovery. Pellets were resuspended in 1 X Binding buffer (as part of PE Annexin V 
Apoptosis detection kit 1, BD Bioscience, Oxford) (lOmM Hepes/NaOH (pH 7.4), 140mM 
NaCl, 2.5mM CaCC), and 8pi of a 1:1 mixture of 7-Amino-Actinmycin (7-AAD) and PE 
Annexin V was added to each sample. Samples were incubated for 15 minutes at room 
temperature in the absence of light and then read immediately by FACS.
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Figure 2.10.1 A representative apoptosis assay o f Renea cells after 48 hour PBS treatment. Upper left panel 
shows adjusted scatter dot plot, whilst upper right shows 7-AAD against Annexin V staining dot plot (where
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UL8 are necrotic cells (Annexin V negative, 7-AAD positive), UR8 are late apoptotic cells, LR8 are early 
apoptotic cells and LL8 are viable cells).
Figure 2.10,1 is an example of the process of modifying the settings to correctly read 
the assay. Initially, an untreated sample is run to determine the FSC and SSC characteristics. 
Then lasers for PE and 7-AAD are adjusted equally to ensure compensation between lasers 
does not occur. Histograms of PE and 7-AAD (lower left and right of figure 2.10.1, 
respectively) are then used to adjust the quadrant to the correct position. Correct placement is 
then assessed by the measurement of cells treated with a compound to ensure cell death (high 
control. Figure 2.10.2).
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Figure 2.10.2 Demonstration of positive control settings for cell cycle analysis. Example o f Renca cells treated 
with 50pM cisplatin for 48 hours, cells demonstrate a major shift into early apoptosis, with confirmation that 
quadrant is correctly placed.
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Once correct placement of the quadrant has been confirmed, and a significant number 
of cells sampled, measurement of apoptosis induction by the treatment under investigation 
can be performed.
2.11 Caspase activation detection
Cysteine-Aspartate Proteases (Caspases) are powerful proteases which are activated 
during apoptosis during apoptosis. With wide specificity, their activation by proteolytic 
cleavage of their attached inhibitor (pro to active state) initiates a cascade that can lead to 
cellular destruction. Caspase-3, an executer caspase, is one of the first to be activated by 
apoptosis and as such a measure of its activation can be a measure of apoptosis. Cells were 
plated and treated for defined lengths of time, at the end of which the supernatant was 
removed and kept and the cells trypsinised. Cells and supernatant were centrifuged at 1,500 
rpm for 3 minutes, resuspended in 500 pi of PBS, then washed with a further 500 pi to ensure 
maximal recovery and spun at 13,000 rpm for 4 minutes. Supernatant was discarded and 
pellet resuspended in a further 1 ml of PBS and respun. Utilising the EnzChek® Caspase-3 
Assay Kit #2 (Invitrogen, Paisley), cells were subjected to 100 pi lysis buffer and incubated 
on ice for 30 minutes with 6 vortexes to ensure membrane disruption. Samples were 
centrifuged at 5,000 rpm for 5 minutes and 50 pi of the supernatant was subjected to 
Caspase-3 activity investigation with the Z-DEVD-RllO substrate. A further 50 pi of 
substrate was similarly tested but with addition of the inhibitor, Ac-DEVD-CHO, to ensure 
florescence was a result of caspase-3 activation. Samples were then read using a DTX 880 
multimode detector (Beckman Coulter, High Wycombe), with a orbital shake followed by 
florescence measurement (excitation wavelength = 496nm, emission wavelength = 520nm).
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2.12 DNA digestion
Presence of genomic DNA, after nucleic acid purification with selection for single 
stranded molecules, is undesirable, especially if further experiments requiring high quality 
RNA are to be performed. Utilising Ambion’s DNA-free™ kit (Applied Biosystems, 
Warrington) following method 2.5. RNA concentration was measured by spectrophotometry 
via a NanoDrop ND-1000 (Thermo Scientific, Wilington, Denver, USA) and samples were 
diluted to 200 ng/pl or less depending on extraction efficacy, 50 pi of sample was used. 6pl 
of lOX DNase I buffer and Ipl of rDNase I were added to each sample, gently mixed by 
pipetting and incubated at 37°C for 25 minutes. Samples were transferred to ice, where 6pl of 
DNase inactivation reagent was added and mixed well by pipetting, then the samples 
incubated at room temperature mixing twice in that time. Samples were then centrifuged at 
10,000g for 90 seconds, the supernatant was carefully removed to avoid contamination with 
the DNase inactivation reagent that formed the pellet. Samples were relabelled and stored at - 
80°C for later use.
2.13 Assessment of RNA Purity
RNA purity is essential for the validity of the further analyses that will be performed. 
Briefly, RNA samples were defrosted on ice and assess by spectrophotometry (NanoDrop 
NDIOOO, Labtech Intemation Ltd, East Sussex) to determine RNA concentration and detect 
impurities. Analysis of the shape of the spectrum and the ratio of absorbances at 230nm, 
260nm and 280nm allows the effective assessment of RNA purity. The AidoiAiso should be 
greater than 1.8 and the A26o‘A23o should be approximately 2.0. All RNA samples fulfilled 
these criteria before being used in further experiments.
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2.14 Microarray
Microarrays can be used to investigate the level of genome-wide gene expression (at 
the mRNA level) of cells and further direct qPCR analysis. RNA was extracted (according to 
protocol 2.4), assessed for purity (protocol 2.13) and treated with DNase I (as protocol 2.12 
dictates) before being used. Cyanine-3 (Cy-3) labelled cRNA was generated using Quick 
Amp Labelling Kit, One Colour (Agilent Technologies, Edinburgh) by first reverse 
transcription followed by transcription in the presence of Cy-3 cytosine triphosphate. Briefly, 
700ng of sample RNA was combined with 1.2pl of T7 Promoter Primer mix and 3.5pl of 
Spike-In Mix (contains known concentrations of known, non-subject transcripts, allowing the 
assessment of sensitivity and accuracy) and incubated at 65°C for 10 minutes, followed by 5 
minutes on ice. To generate cDNA, the following was added to each sample; Ipl of Murine 
Leukemia virus reverse transcriptase, 0.5 pi RNAse out, 1 pi lOmM dNTP mix, 2 pi O.IM 
Dithiothreitol and 4 pi of 5X First strand buffer were added, incubated to 40°C for 2 hours, 
followed the 15 minutes at 65°C and transferred to ice for 5 minutes. Each cDNA sample 
must now be converted into labelled cRNA. To generate cRNA, the following was added to 
each cDNA sample; 2.4 pi Cyanine 3-CTP, 0.8 pi T7 RNA polymerase, 0.6 pi Inorganic 
pyrophosphatase, 0.5 pi RNase out, 6.4 pi 50% polyethylene glycol solution, 8 pi NTP mix, 
6 pi Dithiothreitol, 20 pi 4X transcription buffer and 15.3 pi nuclease free H2O and incubated 
at 40°C for 2 hours. This was then purified by RNeasy® plus mini kit (Qiagen, Crawley), 
briefly, 20 pi nuclease free H2O was added to each sample, mixed with 350 pi RLT buffer 
and 250 pi 70% ethanol was added. From here protocol 2.4 was adhered to and the final 
product was assessed for specific activity (pmole Cy-3/pg RNA), in a similar manner to 
assessing RNA purity i.e. by Nanodrop spectrophotometry. All samples used generated a 
yield of greater than 1.65pg and a specific activity of greater than 9.0 pmol Cy-3 per pg 
cRNA. 1.65 pg of each cRNA sample was then fragmented by incubation in 2.2 pi 25X 
fragmentation buffer, 11 pi lOX blocking agent and brought to 55pl with nuclease free H2O 
and incubated at 60°C for 30 minutes. 55 pi of 2X GEx Hybridization Buffer HI-RPM was 
added to each sample to halt the fragmentation and spun at 13,000rpm for 60 seconds. lOOpl 
of fragmented, labelled cRNA was hybridised to a species specific 4x44K cDNA chip 
(Agilent, Edinburgh) overnight at 65°C at lOrpm. The loading order for arrays was as 
follows:
1. Control -  in vitro cells where the RNA was extracted before in ovo implantation (2
biological repeats).
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2. in ovo -  in ovo tumours, directly lysed and RNA was extracted (2 biological repeats, 
with at least 3 replicates of each).
3. in ovo to in vitro -  in ovo tumours were dissociated (protocol 2.18) and returned to 
tissue culture. Confluency was established and after 8 passages at 1:5, RNA was 
extracted. This ensures that not only were there little to no avian derived cells (2.6 x 
10'  ^ original, assuming no replication) remaining and establish that the cell line was 
still viable (2 biological repeats, with at least 3 replicates of each and matched to the 
original in ovo tumour).
4. in vivo -  in vivo murine tumours (protocol 2.19.2) were directly lysed and RNA was 
extracted (2 biological repeats, with at least 3 replicates of each).
Slides were washed, briefly, gasket/slide was dissembled in GE wash buffer 1 (Room 
temperature) and incubated for 5 minutes in fresh, circulating GE wash buffer 1, transferred 
to circulating GE wash buffer 2 and incubated at 37°C for 5 minutes, transferred to 
circulating 100% acetonitrile (Sigma, Dorset) for 5minutes and finally transferred to 
circulating Stabilization and Drying solution (Agilent, Edinburgh) for 5 minutes. Slides were 
removed, slowly to minimise droplet formation and loaded into slide holder, which were 
immediately loaded into the scanner. Slides were scanned using a High-Resolution C Scanner 
(Agilent, Edinburgh), briefly, the profile was set to the generic one colour setting, adjusting 
the scan resolution to 5pm and enabling extended dynamic range. The software automatically 
detects the barcode, providing a unique identification and assigns the array type (in this case 
4x44K). TIE files generated by scanning were imported into Feature extraction software, and 
the extraction protocol used was “GEl-v5_95_Feb07”, exporting to an .xml format, this 
experiment was then saved and set to start extracting features. Quality control of each array 
was performed to ascertain the validity, all arrays showed correct comer identification, 
Poisson distribution of signal plots and linear amplification of Spike-In Mix. The gene 
expression was analysed by GeneSpring GX vll.O  software (Agilent, Edinburgh), briefly, 
feature extraction files (.xml) are imported and a guided workflow is performed, arrays are 
named and arranged, the quality control here is based on multiple arrays (since only one of 
each cell line is performed here, this step mostly disregarded), probeset were filtered on 
Present, Marginal and Absent, Significance analysis performs a one way ANOVA with in 
vitro as the control condition, the fold change threshold was set to 2.0, with in vitro as the 
control condition, the Gene Ontology analysis was performed. The entities identified by 
significance analysis were then analysed by hierarchical clustering and self organising feature
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map (SOFM) analysis (within which, each cluster of the SOFM was subjected to significant 
pathway analysis, to identify genes differentially expressed in the control conditions.
2.15 Reverse Transcription
Reverse transcription is the first step in quantitive polymerase chain reaction. RNA 
must be converted into copied DNA (cDNA) for primers to bind and DNA polymerase to 
function. Briefly, using the cloned AMV first strand cDNA synthesis kit (Invitrogen, 
Paisley), Ipg of sample RNA in 10 pi DEPC treated water was reverse transcribed. Each 
reaction contained; 4pl 5X reaction buffer, 1 pi Dithiothreitol, 2 pi deoxynucleotides 
triphosphate (lOmM), Ipl oligo deoxythymidine, Ipl RNAse OUT, Ipl cloned avian 
myeloblastosis virus reverse transcriptase. Reactions were incubated at 50°C for SOminutes, 
85°C for 5 minutes, chilled on ice, centrifuged to collect condensate, 80pl DEPC treated 
water to a final volume of lOOpl and stored at -20°C.
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2.16 quantitative Reverse Transcription Polymerase chain reaction
Polymerase Chain Reaction is the enzymatic reaction by which DNA is replicated. 
Using DNA intercalating dyes (SYBRII) and real time measurement of their florescence, it is 
possible to calculate the starting amount of mRNA or relate it to the amount produced by a 
house-keeping gene (quantitative Real Time PCR [qRT-PCR]). 5pi of cDNA from the 
reverse transcription is combined with 6.25pi water, 12.5pl 2X SYBR master mix (Sigma, 
Dorset), 0.25pl ROX reference dye, 0.5pl forward primer (lOOpM), and 0.5pl reverse primer 
(lOOpM) (See Table 2.16.1). This is then run on the Stratagene MX3005P using the 
following thermal profile; 95°C for lOminutes, then 45 cycles of 95°C for 30s, 60°C for 60s 
and 72°C for 30s. The raw data points (Ct values, obtained by the AACt method) were re­
arranged in an Excel spreadsheet and then analysed. The analysis consists of normalising the 
level of expression of your gene of interest against that of a ubiquitously and constitutively 
expressed house keeping gene (HKG), in this case, Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH). All primers were checked that their reaction generates a product of 
expected size by both thermal melt curve analysis and ethidium bromide stained agarose gel 
electrophoresis.
Species Gene Forward Sequence Reverse Sequence
mm SENP6 TAAGGCGGAGCAAGACTGAC TGCGGTGCTTTCACTCAGTT
mm IGFBP3 ACGCGTGCGGCGTCTA CGGACTCACTGATGTTTCCTGGAG
mm P actin GATCAAGATCATTGCTCCTCCTG AGGGTGTAAAACGCAGCTCA
mm GAPDH AAGGGCTCATGACCACAGTC CAGGGATGATGTTCTGGGCA
mm NC0A3 TCAGCGACATCGACAACTTC TCACCACAAACAGGAAACCA
mm AHRR GTTCTGCATTGTGGCACCAG TTTTGCCCTTGAGTCCATCGT
hs AHRR CCGAGCCACTCATGACGAT GCGCGCTCCTCATTTTCATC
hs NC0A3 TCATGAGACCCCGGACAAAC TTAAGAAAACCCTGCTGGGAG
hs IGFBP3 GCGCCAGGAAATGCTAGTG CAACTTTGTAGCGCTGGCTG
hs P actin GAGCACAGAGCCTCGCCTTT TCATCATCCATGGTGAGCTGG
hs GAPDH AATGGGCAGCCGTTAGGAAA GCCCAATACGACCAAATCAGAG
hs SENP6 AAACTTTGAAAGGCAACCCAA TTTCGGTCCAGACTGCTTTG
Table 2.16.1 Primers for qRT-PCR, all supplied by Invitrogen, Paisley, shown in 5’ to 3 ’ direction, designed 
with a melting temperature (Tm) o f 60°C. mm = Mus Musculus, hs = Homo Sapiens, SENP6 = SUMOl/sentrin
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specific peptidase 6, IGFBP3 = Insulin-like growth factor-binding protein 3, NC 0A3 = nuclear receptor 
coactivator 3, AHRR = aryl-hydrocarbon receptor repressor.
2.17 Ethidium bromide stained agarose gel electrophoresis
Agarose gel electrophoresis allows separation of DNA by size, by its ability to 
migrate when challenged with an electric field. Briefly, using the E-gel system (Invitrogen, 
Paisley), -lOOng DNA was combined with loading buffer (lOmM Tris-HCl, ImM EDTA 
(pH 7.5), 0.005% bromophenolblue, 0.005% xylene cyanol FF) and brought to 20pi with 
deionised water. Gels were run for 30 minutes and then examined under UV light for 
presence of unwanted PCR products.
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2.18 Tumour dissociation
Generation of single cell suspensions from tumour material allows the investigation to 
the degree that cell lines are probed. Tumour material (either derived from the CAM assay 
[Method 2.7] or directly from patients) was sliced finely using sterile scalpel and forceps and 
loaded into dissociative C tubes (Miltenyi Biotec, Surrey) with 3 ml of trypsin (Sigma- 
Aldrich, Dorset). The dissociation process starts with using the gentleMACS™ Dissociator 
(Miltenyi Biotec, Surrey) on programs “h_tumor_01.01”, “h_tumor_02.01” and
“h_tumor_03.01”, followed by a 20 minute incubation at 37°C on a gentleMACS’’^  Rotator 
(Miltenyi Biotec, Surrey). Programs and incubations were repeated twice to yield an almost 
fully dissociated cellular suspension. The trypsin was then inactivated by addition of RPMI 
containing 10% FCS. For cell line work, this was considered an acceptable level of 
dissociation and as such could be used from this point on. For patient material, multiple, 
further purification steps were performed, the most successful is as follows. The sample is 
layered onto a Ficol gradient (Sigma-Aldrich, Dorset) and centrifuged at 2,000rpm for 20 
minutes; the cell layer is then aspirated and then spun at l,500rpm for 3 minutes to pellet the 
cells. This pellet is the subjected to 7 minutes suspended in red blood cell lysis solution 
(Qiagen, Crawley). The sample was then resuspended in HBSS and spun at l,500rpm for 3 
minutes, it was noted that this final pellet was then either placed in tissue culture in 10% 
RPMI or directly implanted into eggs between EDD7-10.
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2.19 Murine models
Xenografting human tumour cells into immunologically compromised mice and then 
treating the resulting tumours is considered one of the final stages in treatment development, 
before clinical trials. All experiments performed were approved by the University of Surrey 
Ethics Committee and conducted with best practice guidelines.
2.19.1 RENCA murine model
6 week old BALB/C female mice were inoculated on the left flank with 5 x 10^  
RENCA cells suspended in a 1:1 mixture of Matrigel and HBSS. When tumours developed, 
they were measured and the tumour volume was calculated as demonstrated in Equation 
2.19.1:
. diameterX x diameter'^'Volume = -----------------------------
2
Equation 2.19. 1 Calculation o f tumour volume. Diameters 1 and 2 are separated by 90° and Diameter 2 is the 
smallest.
Mice were organised by tumour volume and grouped to give a relatively equal average 
tumour volume across the groups. Treatment of mice consisted of two experiments: a 50 pi 
intra-tumoural injection, 3 times per week (2 biological repeats, n>8 for each), or a 50 pi 
intra-tumoural injection once and termination 3 days later (2 biological repeats, n>4 for 
each). Mice received a treatment of one of the following:
1. lOOpMZAin PBS
2. 250 pg/ml 5, 6-Dimethylxanthenone-4-Acetic Acid (DMXAA)
3. 50 ng/ml murine VEGF
4. 100 pM ZA and 50 ng/ml murine VEGF
5. PBS
Tumour dimensions were measured 3 times per week, as well as animal health, when a 
tumour exceeded 15mm in any dimension, the animal was immediately culled by a suitable 
schedule I method. After which, the tumour was dissected from the animal, imaged and
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bisected with 1 half being preserved in 10% formalin, for later paraffin embedding, and the 
other half being frozen at -20°C in RNAlater, for RNA analysis.
2.19.2 Lovo murine model
6 week old athymie, female, nude miee were inoculated on both flanks with 5 x 10^  
Lovo cells suspended in a 1:1 mixture of Matrigel and HBSS. Tumours were grown to 
maximal diameter stipulated in the project licence (15mm). Tumours were dissected out and 
lysed with RLT plus buffer (Qiagen, Crawley) and M-tubes on the program “RNA-Ol.Ol” 
(Mitenyi Biotech, Surrey). The lysate was then centrifuged at 15,000rpm for 3 minutes to 
pellet any proteinaceous debris then subjected to protocol 2.5 for RNA extraction.
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Chapter 3
Establishment and 
investigation of the 
chorioallantoic membrane
assay
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3. ESTABLISHMENT AND INVESTIGATION OF THE 
CHORIOALLANTOIC MEMBRANE ASSAY
3.1 INTRODUCTION
The ehorioallantoic membrane assay was first deseribed nearly 80 years ago, with its first 
use in eaneer research in 1956 (Kaufman, Kinney et al. 1956) and in anti-angiogenic research 
in 1975 (Brem and Folkman 1975). However, with the advent of genetic engineering, this 
model increasingly fell from favour, which is being overturned with every passing year. 
Genetieally modified miee are the gold standard for cancer research, but require at least three 
months for the tissue spécifié tumours to develop; these tumours best represent spontaneous 
tumours that develop in humans. Unfortunately with genetieally modified mice, there must be 
a diagnostie criterion (whether biochemieal or symptomatic) involved in the experiment, 
without risking the treatment of what are at that point, technically, healthy miee. With the 
lack of immune system before the eleventh day of incubation, the comparator of the CAM is 
athymie or Severe Combined Immune Deficiency (SCID) mice, there is no detection of non­
self antigens and so there is no anti-tumour response. Some of the main advantages of this in 
ovo method are that it is cheaper (less than £5 per dozen eggs versus at least £50 per nude 
mouse) and more ethical in terms of animal distress (foetal stage versus adult) compared to 
murine models. There are three variants of the CAM assay; they can assess angiogenesis, 
tumourigenieity or anti-angiogenic or anti-tumour effects:
1. Vessel sprouting is stimulated by application of a vascular growth factor (VEGF, 
FGF, PDGF among others) in an early term embryo, generally before day ten of 
incubation. Vessel sprouting is then eompared between negative control (PBS), 
positive control (growth factor) and treatment plus positive control. Sprouting is 
assessed by the number of vessels around the filter disk, the spoked wheel 
appearance. This is normally judged microscopically in relatively large treatment 
groups to ensure accuracy.
2. Tumour cells, either patient biopsy or cell line, are implanted onto damaged 
vaseulature and incubated. A single cell suspension is the most effective, however 
with patient derived biopsies, this is not always possible so mineed tissue 
approximately Imm^ will also work. This established tumour can then be 
disassociated again and re-grafted onto a fresh CAM, this method has been 
hypothesised to possible help in the success rate in eell line generation (able to
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generate large numbers of cells, some of whieh will possess the genetic deregulation 
required to survive in tissue culture).
3. As with method 2, tumour eells are implanted, most efficacious of which are cell 
lines, from here there are two options, to treat the eells at the time of engraffment, or 
to allow them to engraft, subvert a blood supply and then treat the tumour (topically, 
intra-tumourally or intravenously). This is a in vivo tumour model, the difference 
between chicken and mice being this is a much shorter time-course experiment.
These three variations are all possible to do either in ovo or ex ovo, where the embryo is 
removed from the shell early in the incubation and transferred to sterile plasticware. Both 
methods have advantages and disadvantages, in ovo is the correet maturation of the embryo, 
with fully ealcified bones, whieh can then assess whether bony métastasés are possible, ex 
ovo will decrease the volume of ineubator required dramatically, as cylindrical petri dishes 
can be stacked efficiently.
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3.2 AIM AND HYPOTHESIS
The aim of this body of work is the refinement of the chieken chorioallantoic 
membrane (CAM) assay for cancer cell modelling. This would focus on the cancer associated 
neo-angiogenesis, which would allow us to evaluate this model as whether it is effective to 
judge whether treatments have direct anti-angiogenic effects in solid tumours. This model 
would then be compared to murine grown tumours to assess positive and negative attributes 
and whether this model is at least the equal of murine models. The hypothesis of this body of 
work is that the CAM assay provides a suitable platform for the assessment of a compound’s 
anti-tumour or anti-angiogenic effect.
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3.3 RESULTS
3.3.1 Photographic description of the in ovo CAM assay
Figure 3.3.1.1 Demonstration o f egg opening (part one). A 19 gauge needle is used to puncture the air sac found 
in the round end of the egg, it is then used to lever up the cracked part o f the shell.
Figure 3.3.1 2 Demonstration of egg opening (part two). Fine forceps are used to enlarge the hole, followed by 
wider forceps up to the level o f the junction o f the inner shell membrane between the shell and the air space.
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Figure 3.3.1.3 Demonstration o f egg opening (part three). Inner shell membrane is removed with fine forceps to 
expose the chorioallantoic membrane (CAM). Rotation of the egg is paramount to the correct removal o f the 
covering inner shell membrane. Image o f what an FDD 4 chicken embryo looks like after opening.
Figure 3.3.1.4 Demonstration o f tumour cell inoculation. A sterile cotton swab is used to damage, generally a 
medium sized vessel at a bifurcation to ensure acceptable blood supply, physical damage stimulates regrowth 
which can be further corrupted by tumour cells. Ice cold cell and matrigel mix is then pipetted directly onto the 
damaged blood vessel (helps to coagulate, preventing possible exsanguination) and returned to the incubator 
rapidly to allow the matrigel to solidify.
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Figure 3.3.1.5 Example o f fully functional incubator and dissection. Left is a picture o f the operation o f the 
Binder BF240 at full capacity, with all three stages o f experiment (EDDl-4, 5-8 and 9-20) being performed on 
concurrent batches. Right is an image o f dissection o f a Renca tumour, chicks are refrigerated for four hours at 
4°C. The shell was then cut using curved dissecting shears to expose the interior; the chick was then decapitated 
to ensure termination. Highlighted is the tumour grown on the CAM.
3.3.2 Incubator optimisation
Before the purchase of a Binder APT.line™ BF115 with R3.1 controller (VWR, 
Leicestershire), we used a combination of an Rcon 20 egg incubator (P&T poultry ltd., 
Powys, Wales) and a Forma Scientific tissue culture incubator (Fisher, Loughborough). There 
are major negative qualities to both of these incubators; the Rcon 20 only can incubate 24 
eggs at one time, the Forma scientific incubator, was inaccurate in temperature homeostasis 
and lacked specific humidification capability. With the purchase of the BF240, optimisation 
of settings was required to achieve optimal conditions. The temperature setting was optimised 
at 37.8°C, the air vent set to fractionally open, fan speed set to 18%, which would provide 
sufficient air circulation and the humidity pans, multitudinous and filled with SigmaClean 
solution (Sigma Aldrich, Dorset) so that the humidity is regularly greater than 60%, yet still 
remaining sterile.
3.3.3Control of contamination
Prevention of bacterial or fungal growth in either the incubator or the eggs themselves 
is of paramount importance, as infection alters the overall health of the foetus, at best 
retarding tumour growth, and at worst contaminating 3 whole experiments. The starting 
material is vastly important, for this reason fertilised eggs from chickens vaccinated against 
mycoplasma, salmonella and other pathogens are purchased. When the eggs are received, 
they are washed in warm water (not too hot as to damage the developing blastoderm) with 
bare hands to better abrade detritus and faecal matter from the shells. When the eggs are
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opened, they are washed in 70% ethanol and vigorous physical washing is also applied, to 
help decrease the chance of contaminant growth. The instruments used in opening require 
high levels of sterility as they come in direct contact with the shell (consider contaminated for 
argument’s sake) and tear the inner shell membrane above the CAM (consider as aseptic). 
Forceps are washed and thoroughly scrubbed in detergent before autoclave sterilisation, 
during procedure they are immersed in 70% ethanol every 3 eggs to try and limit 
contamination between eggs, also 19 gauge needles used to puncture the shell are replaced 
every 6 eggs for the same reason. The incubator itself is kept clean, however, with large 
turnover, contamination can start to become an issue, from personal experience the optimal 
number of batches is 8 between deep cleans (which involves washes of detergent, deionised 
water then 70% ethanol followed by 2 hours at 100°C). With such high levels of humidity, 
prevention of contaminant growth is difficult, another tool in the struggle to combat this is the 
inclusion of detergent (SigmaClean, Sigma, Dorset) and/or copper sulphate in the evaporation 
trays, with daily checks on their levels and turbidity. This whole procedure is performed in 
what was previously a cancer vaccine preparation room, and kept to the same standards of 
cleanliness. With the procedure and the incubator being located in the same room in close 
proximity also helps to reduce infection rates, major movement between tissue culture hood 
and incubator provides an excellent chance for bacteria to take hold, especially when the egg 
is first opened. Personal attire also plays a factor, in order to maintain high levels of sterility, 
disposable, sterile, surgical gowns (Molnlycke health care, Bedfordshire) and sterile gauntlet 
gloves (WRP, Norway) are worn.
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3.3.4 Rate of successful engraftment of Renca cells
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Figure 3.3.4.1 Graph o f the suceessflil growth o f Renca cells as an in ovo tumour, n>5 eggs challenged with 
4x10^ Renca cells.
The ability to generate tumours from cell lines is the core of this work, and is 
demonstrated, it is now possible to induce tumours in about 70% of the eggs challenged with 
the Renca cell line. The large jump in success between batch 5 and 6 is marked by the 
dramatic increase in the number of eggs set, opened and inoculated with cells; also, the basics 
of the technical skills required for this model were well versed and as such this increase is to 
be expected. This level of success allows the generation of cell line tumours, with a similar 
rate to some murine xenograft models, paving the way for the use of this variant of the 
chorioallantoic membrane assay as an effective tumour model.
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3.3.5 Growth curves of cell lines in ovo
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Figure 3.3.5.1 Growth curve for in ovo Renca tumours. 4x10® Renca cells implanted onto the CAM on EDD 8 in 
30pl o f matrigel (Becton-Dickson, Oxford) and measured optically using Equation 2.15.1 every day from 
visible tumour development, error bars indicate SEM, n=2 experiments o f at least 3 eggs.
The exponential curve of this graph (r^=0.3929, doubling time = 1.301 - 1.732 - 2.589 
days (95% Cl)) shows that Renca cells are duplicating at a rate that is just under that which is 
specified on the ATCC website (stated as “approximately 24 hours”). This suggests that at 
this stage, these cells are not rate limited, either by availability of oxygen, nutrients or waste 
removal. Also given that EDD 16/17 seems to be an ideal day for treatment, given that the 
tumour volume appears to enter the exponential phase of growth. With the shape of the Renca 
tumours it is obvious they possess the capability to invade through the CAM and usurp its 
blood supply, which means that distal métastasés are more than a possibility. As such, at 
necropsy, chicks were inspected for liver and lungs for distal métastasés, in the more than 
300 chicks challenged with Renca cells, only one ever displayed a liver metastasis, 
suggesting that matrigel is excellent at the initial enclosure of cells and that the blood supply 
to this type of tumour is sufficient to negate the evolutionary pressure of metastasis. The 
reason for the error bars beginning to widen at EDD 19 and 20 is that some tumours exceeded 
the 15mm, in any dimension, limit that we has placed on the experiment and needed to be 
terminated as per Home Office regulations.
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Figure S.3.5.2 Growth curve for in ovo LoVo tumours. 4x10 LoVo cells were implanted onto the CAM on 
EDD 8 in 30pl o f matrigel (Becton-Dickson, Oxford) and measured optically using Equation 2.15.1 every day 
from visible tumour development, error bars indicate SEM, n=2 experiments o f at least 3 eggs.
The linear growth of this cell line in eggs, although it varies quite widely around the 
line of best fit (r^=0.09616) demonstrates that LoVo cells grow in this version of the CAM 
assay. Visual observations confirm the cells do not invade the CAM as thoroughly as Renca, 
suggesting that there are rate limiting impositions on this cell line in this model, helping to 
explain the only linear growth. What is slightly strange is that this cell line is derived from a 
supraclavicular lymph node metastasis; suggest that this cell line is rather far down the cancer 
evolutionary pathway; however LoVo cells still express wild type p53. It may be this 
presence of some anti-growth signals whieh limit the growth of these cells in this 
environment. Another possible explanation could be that Renca are renal carcinoma, a cancer 
type known to express a plethora of angiogenic and oncogenic growth factors, LoVo’s as 
colorectal carcinoma, may only produce a limited spectrum of angiogenic factors and as such 
their growth would be limited. A further experiment comparing the growth factor levels in 
fresh compared to conditioned media would provide the answers to confirm this hypothesis.
3.3.6 Growth of in ovo tumours from multiple cell lines
-
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Figure 3.3.6.1 Renal carcinoma cell line histology from egg grown tumours. 4x10 Renca cells were implanted 
on EDD 8 and the tumour was harvested on EDD 20. Sample was stored in formalin, embedded in paraffin 
according to Method 2.8 and H&E stained according to Method 2.9.2, magnification is X200.
Renca cells derive from a spontaneous renal carcinoma of a male BALB/C mouse. It 
is favoured in the literature for its mimicry of the progression of human metastatic renal 
carcinoma, especially its preferred metastatic sites of lung and liver. In mice and egg tumours 
the tissue architecture is very anaplastic, judged to be Fuhrman grade IV. This histological 
example shows large nucleoli (>20pm), multi-lobular nuclei and few defined cell 
membranes, all characteristics of grade IV renal carcinoma. This tumour grew well in eggs 
(successfully invaded the CAM and usurped a good blood supply) and regularly some 
tumours exceeded the maximal diameter to which we are limited by Home Office guidelines.
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Figure 3.3.6.2 Colorectal cell line histology from egg grown tumours. 4x10^ LoVo (above, XlOO magnification) 
and HT-29 (below, X200 magnification) cells were implanted on EDD8 and 7 respectively and the tumours 
were harvested on EDD20. Samples were stored in formalin, embedded in paraffin according to Method 2.8 and 
H&E stained according to Method 2.9.2.
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LoVo cells are derived from a Duke’s type C, grade IV metastasis of an 
adenocarcinoma of the colon. The form relatively small, quite poorly vascularised tumours 
when grown in eggs. Histopathologically, these tumours represent well to moderately 
differentiated colorectal adenocarcinoma i.e. architecturally they reform the glandular 
structure synonymous with colorectal cancer. This in itself is remarkable, a cell line, adapted 
for tissue culture that then self-assembles into an architecturally complex, three dimensional 
and is representative of human disease is a goal of in vivo experiments whieh has previously 
only been realised with whole model organism genetic modification. However, these tumours 
are relatively small (rarely exceeding 5mm after 12 days in ovo growth) meaning that we 
were sometimes limited with the experiments we could perform. Figure 33 .63  shows 
LoVo’s previously grown in ovo, in murine flank models and our own murine flank model. 
Previously, only Durupt et al. demonstrate this complex in ovo architecture that incorporates 
stromal interaction in tumour histology. Various hypotheses have been suggested for this 
self-assembly of architecture; one of the strongest arguments is that LoVo cells have retained 
some of the genetic characteristics of crypt mono-potent (nearly fully differentiated) stem 
cells (possibly that the tumour originated from this cell type) and this with the complex 
interaetions with the stromal cells of the CAM allows the partial re-eonstruetion of 
architecture. This theory is partially supported by the architecture of LoVo cells grown on the 
flanks of nude mice; an anaplastic tissue with little overall architecture, the one component 
which is lacking is the stromal/tumour interaction. When the cells are in contaet with the 
stroma (Figure 3.3.6.3 lower right), they start to reeonstitute their lumen forming capability. 
These images suggest that cells in contact with the stroma are replicating, they receive a 
signal to fold inward, forming almost crypt-like structures and then seal themselves into 
spheroids. However, it should be noted that this phenomenon has only been observed in one 
tumour bearing mouse (out of five). HT-29 cells are described as colorectal adenocarcinoma 
cancer cells on the ATCC website. They grow as fairly small, rather poorly vascularised 
tumours in ovo. Histopathologically, they can be deseribed as moderately to poorly 
differentiated, however, there are still some areas that have the lumen forming ability seen so 
commonly in LoVo in ovo tumours. One note of contention is that anti-angiogenie therapy 
(particularly Avastin) is a well-documented, adjuvant treatment for colorectal 
adenocarcinoma, yet these slides show a fairly poorly vascularised tumour. Sequence analysis 
comparing human VEGF A and VEGFR2 to the chicken protein sequenees reveals 
remarkable homology, with conservation of critical residues for binding, only a functional 
substitution (aspartate to glutamate) in the NRP-1 binding C-terminus, leading to the
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conclusion that human VEGF can bind to chicken VEGFR2 and can activated chicken 
endothelial cells to replicate.
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Figure 3.3.6.3 Examples o f LoVo tumours from literature and in vivo models. LoVo cells grown in ovo (top left 
and centre, (Stan, Radu et al. 1999), top centre (Durupt, Koppers-Lalic et al. 2012)) and in murine flank model 
(top right, (Nyati, Maheshwari et al. 2004)) and our own in-house LoVo flank tumours (bottom left and right, 
both XlOO magnification, 1x10^ LoVo cells suspended in matrigel were injected sub-cutaneously into both 
flanks of female nu/nu nude mice and left to grow until they exceeded 1cm in diameter).
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Figure 3.3.6.4 Prostate cell line histology from egg grown tumours. 4x10^ LnCAP (above) and PC-3 (below) 
were implanted on EDD8 and the tumour was harvested on EDD20. Sample was stored in formalin, embedded 
in paraffin according to method 2.8 and H&E stained according to method 2.9.2.
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Both of these prostate cell lines produce small, poorly vascularised in ovo tumours. 
This is not unexpected, as prostate cancer cells are some of the slowest growing. 
Histopathologically, they are both Gleason grade 5, although LnCAP is slightly less dysplasic 
than PC-3. Both of these cell lines generate a very poorly differentiated tumour, not wholly 
unexpected for prostate cancer cell lines. PC-3 tumours are generally poorly perfused, the 
same could be argued for the LnCAP tumours are the red blood cells are completely 
extravasated from any apparent blood vessel. However, LnCAP tumours do maintain their 
PSA positivity in this model, lending credence to its use as a tumour model.
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3.3.7 in ovo imaging of cancer using luciferase
Figure 3.3.7.1 Demonstration o f luciferase activity in ovo. Eggs were inoculated with 4x10^ AY-27S cells (rat 
transitional bladder carcinoma) on EDD 7 and left to grow until EDD 20. At which point they were transported 
to the Institute o f Cancer Research (ICR), injected with ~2.5mg o f VivoGlo™ (Promega, Southampton) intra- 
tumourally, incubated at 37°C for approximately 15 minutes then subjected to luminescent imaging using a 
IVIS® Kinetic (Caliper Life Sciences Ltd, Cheshire) set to a 5 second exposure time (units are 
photons/sec ond/cm^/steradian).
The purpose of this experiment was to establish whether luminescent imaging 
techniques are feasible to our in ovo CAM assay. This rather successful experiment shows 
that luminescent systems are efficient in this model. The result was that luminescence was 
confined to the visible tumour, proving that it is the implanted, genetically modified, cancer 
cells whieh are converting the injected luciferin to photons. This technique would be 
beneficial due to the ability to quantify the emission in real time. The one drawback is that it 
would require an injection (of a sterile solution) under sterile conditions and imaging under 
the same conditions, the injection, if performed incorrectly can exsanguinate the chick or 
cause a significant bleed which can obscure the tumour visually.
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3.3.8 in ovo imaging of cancer using green fluorescent protein
Figure 3.3.8.1 Demonstration of GFP activity in ovo. Renca tumours were injected intra-tumourally with SOgl 
of 2x10^ pfu Herpes Simplex Virus 1 (H SVl) transfected with GFP (HSVGFP) on EDD 18 (bottom) and EDD 
19 (top). Eggs were imaged on EDD 20 using an IVIS® Kinetic (Caliper Life Sciences Ltd, Cheshire) set to a 1 
second exposure time and for GFP detection.
Using Green Fluorescent Protein (GFP) as a reporter assay for the growth of tumour 
cells in the CAM model has been published previously (Lugassy, Torres-Munoz et al. 2009) 
and has shown to be very effective. Here, HSVl containing GFP driven by the CytoMegala 
Virus (CMV) promoter was injected intra-tumourally one or two days before imaging. There 
is definite GFP expression in the excised tumours, suggesting the virus has managed to infect 
some tumour cells and begin hijacking the tumour cell. However, as can be seen from the 
complete in ovo images, there is definite GFP expression throughout the whole embryo. This 
may be because as an oncolytic virus, HSVl has a tropism for rapidly dividing cells, which 
defines the whole embryo and not just the tumour in this case. To further ascertain the 
viability of GFP as a biomarker in ovo, it would be prudent to express GFP in a cell line and 
then engraft it in an embryo before repeating this experiment.
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3.3.9 Reovirus treatment of in ovo tumours
. ' # # # '  
. c l f f  i f f  • ^
^  \
n
f  ,  Y  ;  ; Y  "  t -
& \
w' , 4
* ï : t ,  ' i4%»
*  * î iM %
6* »
Figure 3.3.9.1 Treatment o f in ovo LoVo tumours with reo virus. LoVo in ovo tumours were grown until EDD 
18, then injected intra-tumourally with lOgl o f 3x10^ plaque forming units/ml (pfu/ml) reovirus or PBS. 
Tumours were excised 48 hours later, fixed in formalin, embedded in paraffin and subjected to 
immunohistochemistry as described in (Comins, Spicer et al. 2010). Top left is LoVo tumour treated with PBS 
and stained for reoviral protein, XlOO magnification, top right is reovirus treated, X40 magnification, lower left 
is reovirus treated, XlOO magnification, lower right is reovirus treated, X200 magnification. Staining courtesy of 
Dr Gerard Nuovo of Ohio State University, USA.
Viruses which are trialled in the treatment of cancer have the ability to replicate in 
cancer cells (genetically abnormal) but are unable to lyse normal cells; certain viruses show 
tropisms for cells or structures (neo-angiogenesis and microtubules). Here we evaluated the 
chorioallantoic membrane assay for efficaey of an oncolytic virus for local cancer therapy; 
this treatment was not designed to induce mass cytotoxicity but to be able to track the viral 
proteins experimentally. This in ovo model of tumour growth has previously been reported as 
potentially allowing the evaluation of oneolytic adenoviruses (Durupt, Koppers-Lalic et al. 
2012) as a cancer treatment. However, there are no reports regarding in ovo tumours treated 
specifieally with reovirus. Both Renca and LoVo tumours were treated with volumes of stock 
revirus (BxlO^pfu/ml) appropriate to the tumour size (Renca in ovo tumours were large and
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could stand injection of a greater volume). However, no Renca in ovo tumour stained positive 
for reovirus. Previous experiments within our laboratory demonstrate that Renca cells are 
very vulnerable to reovirus induced cell death. This lack of staining combined with high 
susceptibility of reovirus infection, leads to two hypotheses; the initial measure of high 
susceptibility is incorrect or that in the experiment, little reovirus remained within the tumour 
to directly affect the cells. This hypothesis of decreased reovirus availability within the 
tumour could be due to the well vascularised nature of Renca in ovo tumours, possibly that 
the reovirus was transported somewhere elsewhere, other than the tumour. 100% of LoVo 
tumours treated with reovirus stained positively by immunohistochemistry, whilst no reovirus 
staining was observed in the PBS treated controls. Reovirus proteins did not accumulate in 
any intracellular or architectural structures. This work shows similarity to the work with 
adenoviruses, reovirus can be considered a potential local treatment of cancer and that the 
chorioallantoic membrane assay provides another model with which to test its efficacy.
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3.3.10 M icroarray of Renca in ovo tumours
The ability of eaneer cells to adapt to a new environment (e.g. tumourigenieity, in 
vitro to in vivo) must require alterations in gene expression for those eells to survive. This 
experiment arrayed initial tissue culture against in ovo tumour and that in ovo tumour 
returned to tissue culture to investigate which genes are responsible for in ovo survival and in 
vitro propagation.
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Figure 3.3.10.1 Microarray of Renca cells from tissue culture, Renca tumours grown in eggs and those tumours 
dissociated, grown in tissue culture for 8 passages, splitting 1:5. 700ng of RNA of each pooled condition was 
reverse transcribed and arrayed (biological repeats n=2, technical repeats within each biological repeat for egg 
tumour and tumour to tissue culture, n>3). This figure demonstrates genes that show a twofold or greater
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change in abundance across the 3 conditions, with initial tissue culture as the control condition. GO analysis 
(Genespring v l 1.0 Agilent Technologies, Edinburgh) showed no significant pathway group alterations.
The above graph represents 4430 separate genes that are differentially expressed 
across these 3 conditions. In order to start to gain some understanding of such a large cohort, 
further, computer based, examinations of the data were performed. Every gene is termed an 
entity and the numerical value for each condition (that gene’s expression level) forms the 
basis for clustering analysis. Clustering analysis brings genes whose expression profiles are 
similar into the same cluster (grouping). Cluster distance, is a term for the similarity in a 
group of genes expression levels i.e. clusters a short distanee from one another, have slightly 
different expression patterns, whilst those further away vary more. An analogous example 
would be taxonomy; humans are in a taxon close to that of ehimpanzees, but further away 
(but not completely dissimilar from) the taxon containing chickens. Genes with a similar 
expression pattern may perform a similar biological function and would be clustered close 
together.
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B  Egg Tumour
B  Tissue Culture
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Figure 3.3.10.2 Hierarchical clustering dendogram of the twofold change in Renca gene expression with initial 
tissue culture as the control condition. The hierarchical clustering algorithm clustered on entities (genes), using 
the Euclidean similarity measure (a simple measure o f vector distance between two points) and a centroid 
linkage rule (the generated clusters are maximally different). The first column is tissue culture, the second egg 
tumours and the third is egg tumours dissociated to tissue culture.
To bring further clarity and identify specific pathways, a self organizing feature map 
(SOFM) was performed. This analysis displays clusters separated by their expression 
profiles, allowing further probing of the molecular changes that occur in the generation of in 
ovo tumours.
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Figure 3.3.10.4 Diagrammatic aide mémoire o f the condition from which each RNA was selected from. Tissue 
culture is RNA extracted from unaltered Renca cells as supplied by ATCC (ATCC, Middlesex), these cells were 
then implanted in ovo and the resulting tumours were bisected. Half the tumour was lysed immediately and was 
subjected to RNA extraction, whilst the other half was dissociated and returned to tissue culture. Once 
monolayer was re-established, cells were subjected to 7 passages at 1 in 5 in identical conditions to the original 
cells.
In figure 3.3.10.3 genes are grouped into clusters, within these clusters, these genes 
have similar expression profiles. Clusters 0 , 1 , 4  and 8 show the profile of active expression 
in tissue culture, switched off in the egg tumours and not reactivated when the cells were 
returned to tissue culture. This suggests that either these genes are non-essential to survival in 
a tissue culture environment, or that these genes must be switched off for tumour formation 
on top of their non-essentiality. Pathway analysis of each cluster with the parameters of 
simple analysis type and direct interactions algorithm allows the extraction of pathways and 
genes that are affected in each cluster phenotype Ifom the lists which are often hundreds of 
entities long. Examples of genes that fit this profile are Cyelin Dependent Kinase 5 regulatory 
subunit 1 (Cdk5rl, Cluster 0), Histone deaeetylase 1 (Hdacl, Cluster 1), General transcription 
factor IIH, polypeptide 3 (Gtf2h3, Cluster 4, affecting cell division cycle 2 homolog A -  one 
of the major controlling kinases of the cell cycle) and phospholipase C, gamma 2 (plcg2. 
Cluster 4). This reduction in the expression of Hdael and therefore its effect on the epigenetic 
expression of genes (Spiegel, Milstien et al. 2012) could help to explain why this profile 
represents approximately one quarter of the genes which show a twofold or greater change in 
expression. Genes whose expression is high in both initial and after tumour tissue culture 
environments but low in tumours suggest that these genes are either essential to tissue culture 
or must be switched off for tumour formation and switched back on for tissue culture. Only 
cluster 9 represents this profile, pathway analysis revealed that the process of transcription is 
affected by this cluster with Myb and cAMP response element binding-binding protein 
(CREBBP) displaying this profile. Myb itself is an oncogene (Prouse and Campbell 2012) 
and the lower levels of CREBBP in ovo may suggest that e-fos (downstream of CREB 
(Sassone-Corsi, Visvader et al. 1988)) is a requirement for in ovo tumour formation. Genes
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with low expression in both initial and after tumour tissue culture environments and high 
expression within in ovo tumours indicate that either the expression of these genes is 
beneficial for tumour formation or not required for tissue culture survival. Only cluster 3 
presents this profile, with pathway analysis suggesting that the process of apoptosis is 
affected, tyrosine-protein phosphatase non-receptor type 6 (ptpn6) follows this profile and 
has been shown to be expressed in renal tumours (Kuroda, Hayashi et al. 1998), suggesting 
that its phosphatase activity may aid in tumour formation. Another gene, of a high profile 
family, signal transducer and activator of transcription 6 (STAT6), demonstrates this profile 
and feeds into the process of apoptosis via Interleukin-4 (lL-4) (Hebenstreit, Wimsberger et 
al. 2006). STAT6 has been shown to interact with CREBBP (McDonald and Reich 1999) 
suggesting that the reciprocity of these two gene’s expression is an important molecular 
pathway for the formation of in ovo tumours. Genes that are downregulated in initial tissue 
culture but upregulated in tumours and tissue culture following tumours may be required for 
tumour formation and provide a proliferation advantage once returned to tissue culture. 
Clusters 7 and 11 represent this profile of which the proto-oneogenes AKTl and AKT2 
belong to cluster 11, as well as Wnt3. Ran GTPase activating proteinl (RanGAPl) also 
displays this profile. All of these genes’ expression profile have been altered and may help to 
explain why cells dissociated from in ovo tumours replicate faster than the parental cell line.
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3.3.11 Microarray of LoVo tumours
Figure 3.3.11.1 Hierarchical clustering dendogram of the twofold change in LoVo gene expression with initial 
tissue culture as the control condition. The hierarchical clustering algorithm clustered on entities (genes), using 
the Euclidean similarity measure (a simple measure o f vector distance between two points) and a centroid 
linkage rule (the generated clusters are maximally different). The first column is tissue culture, the second egg 
tumours, the third is egg tumours dissociated to tissue culture and the fourth is tumours grown in mice.
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Figure 3.3.11.3 Microarray of LoVo cells from tissue culture, LoVo tumours grown in eggs and those tumours 
dissociated, grown in tissue culture for 8 passages, splitting 1:5. 700ng of RNA of each pooled condition was 
reverse transcribed and arrayed. This figure demonstrates genes that show a twofold or greater change in 
abundance across the 3 conditions, with initial tissue culture as the control condition.
This fold change graph represents nearly 7000 genes which show at least a twofold 
change in their expression across these three conditions. Although the same conditions as 
those of the Renca microarray, there is a more than a 50% increase in the number of 
differentially regulated genes. Performing the same hierarchical clustering as before yields 
the following heatmap and SOFM maps:
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Figure 3.3.11.4 Hierarchical clustering dendogram of the twofold change in LoVo gene expression with initial 
tissue culture as the control condition. The hierarchical clustering algorithm clustered on entities (genes), using 
the Euclidean similarity measure (a simple measure of vector distance between two points) and a centroid 
linkage rule (the generated clusters are maximally different). The first column is tissue culture, the second egg 
tumours and the third is egg tumours dissociated to tissue culture
Once more, SOFM analysis was performed to aseertain the elustering of genes that 
follow a spécifié expression profile aeross these three conditions.
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Figure 3.3.11.6 Diagrammatic aide mémoire o f the condition from which each RNA was selected from. Tissue 
culture is RNA extracted from unaltered LoVo cells as supplied by ATCC (ATCC, Middlesex), these cells were 
then implanted in ovo and the resulting tumours were bisected. Half the tumour was lysed immediately and was 
subjected to RNA extraction, whilst the other half was dissociated and returned to tissue culture. Once 
monolayer was re-established, cells were subjected to 7 passages at 1 in 5 in identical conditions to the original 
cells.
Genes of similar expression patterns are organised into clusters by SOFM analysis. 
Pathway analysis was performed on each cluster, again simple analysis type and direct 
interactions algorithm to distil genes and pathways that follow the cluster gene expression 
pattern, once again this list can be hundreds of genes long, from which the most striking are 
reported here. Genes that are switched on in tissue culture and switched off in in ovo tumours 
and remain off in dissociated tumours returned to tissue culture, can be deemed as non- 
essential to tissue culture or that their reduced expression provides an advantage. Cluster 2 
demonstrates this expression profile; kinase activity and bone resorption were two 
highlighted processes, the results of an interactions of FOSB and chemokine ligand 2 and 
calcitonin related polypeptide alpha and the calcitonin receptor. Interestingly, a number of 
keratin genes (4, 13, 20, 31, 32, 33B, 34, 35, 37, 38, 75, 81, 83 and 85) follow this expression 
pattern; it has been noted that keratin 4 and 13 are both down-regulated in oral squamous cell 
carcinoma (epithelial cells) (Sakamoto, Aragaki et al. 2011), possibly suggesting that in ovo 
provides a platform for LoVo cells to behave in a more aggressive manner than in vitro. 
Clusters 1, 4 and 5 show high expression in initial and tissue culture after tumour growth but 
low expression in in ovo tumours; this suggests that either the genes are essential for tissue 
culture or that these genes must be switched off for an in ovo tumour to form. The one 
process highlighted in cluster 1 is progression through the cell cycle, which is under the 
influence of cyelin H (Patel and Simon 2010) and E2F transcription factor 1 (Shen, Uray et 
al. 2008), this low expression in in ovo tumours could help to explain the greater than 6 day 
doubling time. Cluster 4 demonstrated that the function of GTP is affected, with the genes 
responsible being septins 5 and 11. Septins help to control cytokinesis and exocytosis 
(Mostowy and Cossart 2012), the down-regulation in ovo could reflect the multi-nucleation
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that is seen, especially in the cells which form the lumen (figure 5.3.6.2). The processes of 
transcription and cell motility are highlighted in the analysis of cluster 5, of which there are 
475 genes in this cluster. Both of these processes are dependent on Jun, JunB and JunD, 
proto-oncogenes, suggesting that increased Jun expression is a prerequisite for LoVo cell 
survival in a tissue culture environment. Low expression in initial and following tumour 
tissue culture with high expression in ovo would suggest that switching these genes on is 
essential for tissue culture. Cell growth is a highlighted process in cluster 7, under the control 
of insulin-like growth factor (IGF) 2 and IGF binding protein 3(IGFBP3), both show a 
similar gene expression profile. The association of IGF2 and IGFBP3, sequesters IGF away 
leading to prolonged signalling (Heidegger, Pircher et al. 2011) , suggesting that whatever 
signalling that occurs is required for in ovo tumour formation. IGFBP 4 and 5 were present in 
cluster 10, which displays the same profile as cluster 7. Cluster 11 contained 
carcinoembryonic antigen cell adhesion molecule 7 (CEACAM7), which has been shown to 
be a mark of normal bowel (Scholzel, Zimmermann et al. 2000); this is most peculiar since 
LoVo cells are most definitely tumourigenic. Genes that are downregulated in initial tissue 
culture but upregulated in tumours and tissue culture following tumours may be required for 
tumour formation and provide a proliferation advantage once returned to tissue culture. 
VEGFA is present in cluster 8 which demonstrates the described profile; this is not 
unexpected, angiogenesis is one of the requirements for tumour formation and VEGFA is a 
potent endothelial cell mitogen. Cluster 10, which displays the same expression profile, 
contains VEGFC, another vascular cell mitogen that is involved in both angiogenesis and 
lymphangiogenesis.
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OFF ON ON OFF ON OFF ON OFF ON ON ON OFF ON OFF OFF
ARFl ACAN AHRR CACNA2D2 IL7
USP47 AEBPl ARHGEF12 GRIK5 LTF
CCDC88C AHNAK ASB16 LRRC18 PIKFYVE
FCGBP FCH02 FAM131B RASGEFIC AN02
GTF2A2 FMNl FGFRl RG Sll KRTAP3-1
GZFl IGFBP3 HNRNPAB TSLP
ARHGEFll IGLLl HOMERl
IRX3 KRT14 IMPACT
KRITl NCOA3 JUND
KRTCAP3 PILRA NAT15
LADl RGR NUDC
LENGl RPS6KA5 PHTF2
CBFA2T2 RUFY2 P0LR2C
PLEKHA7 RXRA RAB5B
P0LR2H SLC2A9 RBMX
PPA2 SLC5A1 RRPl
PURE SYNE2 SENP6
RAB43 TBCK SPATA24
RPL26 TET3 SREBF2
RPL5 TSEN54 TMX3
RPL7A WDR60 TTC25
FOXQl XAFl WDR3
GIPR
SDK2
SMPD3
SPlOO
SRRM3
LRRC28
MBOAT2
M0N2
MUC13
MXD4
NEUR0D2
0PA3
PEG
PPPIRIA
RAPIGAP
RASA4
SLC2A9
S0X12
TNFRSF14
ZDHHC21
Table 3.3.11.1 Genes whieh share expression profiles in both Renca and LoVo in ovo tumours. Genes which 
display the same expression profile from tissue culture to in ovo tumours, those tumours dissociated and 
returned to tissue culture in both Renca and LoVo microarrays.
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The preservation of genes with similar expression profiles within this model, despite the 
results deriving from very different cancer cell lines, provides hints as to which molecular 
pathways are conserved in this tumour model.
f tissue culture, '\in ovo tumour, tumour returned to tissue culture
Structural Differentiation Metabolism
Immune
function Apoptosis Unknown
ACAN AHNAK RGR AEBPl NCOAS* TBCK
AHNAK IGFBP3t RPS6KA5 IGLLl XAFl WDR60
FCH02 TET3 RUFY2 PILRA
FMNl RXRAJ
KRT14 SLC2A9
SLC5A1
SYNE2
TSEN54
Table 3.3.11.2 Genes which share expression profiles in both Renca and LoVo in ovo tumours. Genes from both 
Renca and LoVo arrays which display low expression in initial tissue culture, higher expression as in ovo 
tumours and lowered expression when in ovo tumours were returned to tissue culture; all categorised by general 
gene function, f ,  J and * demonstrates a link between this table and table 3.3.11.3 and emboldened text 
represents links within tables.
The structural genes which conserve this expression profile are likely to be important 
in the formation of tumours in ovo. Keratins are cytoskeletal proteins, keratin 14 (KRT14) 
combines with KRT5 to achieve its purpose, recent reports demonstrated that low levels 
correspond with decreased tumourigenicity (Alam, Sehgal et al. 2011), probably through 
decreased proliferation/eell cycle progression, through either the P1-3-K/AKT or Notch 1 
pathways. RUN and FYVE domain containing 2 (RUFY2) has been indicated to play a part 
in late-onset Alzheimer’s disease. Recent reports (Shin, You et al. 2011) have identified it as 
a gene that is frequently mutated in cell lines which demonstrate high levels of microsatellite 
instability, suggesting that the frameshift mutation capability provides a survival advantage in 
ovo. Nuclear receptor coaetivator 3 (NC0A3, also known as steroid receptor co-activator 3), 
belongs to a class of proteins which act as powerful co-activators of transcription of genes 
which promote survival or angiogenesis (Xu, Wu et al. 2009). The post-translational 
modification status of NCOAs determines their effieiency, specificity or degradation. Their 
overexpression in coloreetal cancer has been noted and is assoeiated with p53 positivity and 
higher grade (Xie, Sham et al. 2005). NC0A3 and retinoie acid receptor alpha (RXRA) have 
been shown to interaet (Chen, Lin et al. 1997); a hypothesis of the product of this interaction 
(after phosphorylation of NC0A3) is increased RXRA indueed transcription, followed by 
later RXRA degradation. This association, on top of its other pro-survival functions, may
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suggest that NCOAS may be a requirement for in ovo tumour formation.IGFBPS also 
interacts with RXRA (Liu, Lee et al. 2000), their interaction induces apoptosis, suggesting 
that there is a number of both pro and anti-apoptotic signals (even emanating from the same 
proteins) required for in ovo tumourigenesis.
ttissue culture, iin  ovo tumour, f tumour returned to tissue culture
Metabolism Apoptosis/survival
Neuronal
signalling Transcription Unknown
NAT15 AHRR* HOMERl PHTF2 ASB16
SENP6Î ARHGEF12 P0LR2C FAM131B
SREBF2 FGFRl RRPl IMPACT
TMX3 JUND WDR3t SPATA24
NUDC HNRNPAB TTC25
RABSB
RBMX
Table 3.3.11.3 Genes which share expression profiles in both Renca and LoVo in ovo tumours. Genes from both 
Renca and LoVo arrays which display high expression in initial tissue culture, lower expression as in ovo 
tumours and increased expression when in ovo tumours were returned to tissue culture; all categorised by 
general gene function, f ,  J and * demonstrates a link between this table and table 3.3.11.2 and emboldened text 
represents links within tables
Heterogeneous nuclear ribonucleoprotein A/B (HNRNPAB) belongs to a family of 
proteins which are produced ubiquitously, whose function, once fully associated with other 
proteins and RNA, is to aid in mRNA splicing (the editosome). HNRNPAB has 2 RNA 
recognition motifs which allow the protein complex to bind the pre-mRNA transcripts 
(Sinnamon, Waddell et al. 2012). HNRNPAB’s high expression only in tissue culture 
environments may suggest that there is a requirement for certain transcript splice variants 
which allow survival in an in vitro environment. JunD belongs to the Jun family of proto­
oncogenes; proteins which make up half of the powerful AP-1 transcription factor. This 
transcription factor is responsible for the production of genes which promote survival. JunD’s 
increased expression in tissue culture environments could suggest that pro-survival genes 
produced by JunD’s effects are required for successful in vitro culture. Rho guanine 
nucleotide exchange factor 12 (ARHGEF12) helps small signalling GTPases (such as Ras, 
Rho, Rac etc.) to release GDP (inactive signalling) and exchange it for GTP (active signalling 
-  signal transduction and amplification) (Kourlas, Strout et al. 2000). Although, to date, there 
are no reports of ARHGEF12 interacting with RabSb, it does interact with a multitude of 
small G-protein linked receptors. The increase seen in tissue culture environments of this
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gene may be due to cancer cells requiring increased survival signalling for proliferation in an 
in vitro setting.
The association between Insulin like growth factor binding protein 3 (IGFBP3) and 
WD repeat 3 (WDR3) is thus; Insulin like growth factor l(lG Fl) is bound by IGFBP3, IGFl 
induces the expression of WDR3 (McMahon, Ayllon et al. 2010); with the reciprocal 
expression patterns i.e. WDR3 is expressed in vitro but not in ovo, whilst 1GFBP3 is 
expressed in ovo suggests that the IGF pathway is important in this CAM model of 
tumourigenesis. The link between aryl-hydrocarbon receptor repressor (AHRR) and NC0A3 
is that NC0A3 binds AHR (Ahmed, Al-Saigh et al. 2012), a protein which also binds a 
nuclear translocator protein, ARNT, which AHRR binds competitively (Mimura, Ema et al. 
1999). AHRR’s mRNA levels are only raised in vitro suggesting that a product of AHR 
stimulated transcription may provide a survival benefit to tumours developing in vivo. 
SUMOl/sentrin specific peptidase 6 (SENP6) uncouples small ubiquitin-like modifiers 
(SUMOs) from proteins, in this case SENP6 desumolyates RXRA (Zhu, Santos et al. 2009), 
which detargets RXRA for proteosomal recycling, negating the repression of transcriptional 
activity that SUMO modification induces on RXRA. SENP6 has also been associated with 
ARNT (Tojo, Matsuzaki et al. 2002), SUMO modification of ARNT and AHRR are 
important in determining their protein-protein interactions and therefore the eventual 
transcription of genes downstream of this pathway. The post-translational modification of 
proteins helps to modify their functionality and durability, providing another level of control 
for cellular biochemistry; however, without in-depth analysis of SENPb’s interactions in 
these conditions of in vitro and in ovo conclusions are difficult to draw. It may be possible 
that the SUMO modification pathway is important in regulating proteins that are responsible 
for in ovo tumours forming.
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tissue culture, '[in ovo tumour, ttumour returned to tissue culture
Structural Metabolism Apoptosis/survival Transcription Unknown
FCGBP ARFl USP47 GTF2A2 KRTCAP3
LADl PPA2 CCDC88C GZfl LENGl
PLEKHA7 RPL26 ARHGEFll IRX3 SRRM3
SDK2 RPL5 KRITl P0LR2H 0PA3
M0N2 RPL7A CBFA2T2 PURB
MUC13 GIPR RAB43 SPlOO
LRRC28 FOXQl MXD4
MB0AT2 SMPD3 NEUR0D2
PLG RASA4 S0X12
PPPIRIA TNFRSF14
RAPIGAP
SLC2A9
ZDHHC21
Table 3.3.11.4 Genes which share expression profiles in both Renca and LoVo in ovo tumours. Genes from 
both Renca and LoVo arrays which display low expression in initial tissue culture, high expression as in ovo 
tumours and continued increased expression when in ovo tumours were returned to tissue culture; all categorised 
by general gene function.
With the course of this experiment, diverse gene changes are expected, this table 
demonstrates genes that are upregulated in ovo and remain at a similar level when returned to 
in vitro conditions. A noted observation for the cells returned to tissue culture is that they 
replicate faster than their parental cell line, changes in the expression of these genes help to 
explain this phenomenon. The ribosome is a combination of proteins and RNA which is 
responsible for the translation of mRNA into protein and consists of 40S and 60S subunits. 
Ribosomal proteins (RPL 26, 5 and 7A) are proteins which make up the 60S subunit. The 
increase in the expression of these transcripts proteins may suggest that these cells that have 
been selected for survival in tissue culture, in ovo and back again with increased protein 
synthesis capability, allowing the decreased cycling time observed with these cells. The 
forkhead box Q1 (FOXQl) protein is a transcription factor which has been implicated in 
promotion of epidermal-mesenchymal transition and chemoresistance in cancer cell lines 
(Qiao, Jiang et al. 2011). The increase in this transcript (whose complete interactions and 
effects are as yet not completely understood) have been a cell line’s evolutionary solution to 
an environmental pressure; not only encouraging its survival, but providing survival 
advantage later on. The Ras superfamily (represented here by RAB43 and ARFl with the 
supporting proteins RAPIGAP, RAS A4 and ARHGEFll) are small GTPases which are
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signal transduction proteins, converting extracellular signals into responses in gene 
expression to promote growth. Activating mutations of Ras (an oncogene family) are some of 
the most common mutations observed. Their conversion of GTP to GDP (active to inactive 
states) must be aided and controlled by accessory proteins (guanine nucleotide exchange 
factors, GEFs and GTPase activating proteins, GAPs). GAPs are considered to be inhibitors 
of Ras signalling because they promote the conversion of GTP, moving the protein into an 
inactive state. RAPIGAP binds RAPl leaving RAS proteins to produce survival signals 
unhindered. RASA4 is another GAP, it uses intracellular calcium to dimerise and this affects 
its GAP function (to a degree), with specificity for both Ras and Rap. With high intracellular 
calcium, RASA4 dimerises and preferentially binds Rap, with intracellular calcium Ca^ "^  
being an important secondary messenger, the alteration in RASA4 expression may suggest 
that there is high Ca^^ from multiple stimulation pathways leading to prolonged Ras activity 
(Dai, Walker et al. 2011). ARHGEFll is a Rho specific exchange factor, increasing the 
signal amplification to which Rho has responded (Rumenapp, Blomquist et al. 1999). All of 
these modulations of gene expression suggest that they provide a survival advantage to cells 
compared to their tissue culture predecessors.
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This experiment was designed to draw comparisons between in ovo and in vivo. In 
vivo is considered to be the gold standard for the modelling of the cancer situation, we wished 
to evaluate the molecular differences between in vitro and in vivo and compare those to the 
differences between in vitro and in ovo.
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Figure 3.3.11.7 Microarray of LoVo cells from tissue culture, LoVo tumours grown in eggs and LoVo tumours 
grown in mice. 700ng of RNA of each pooled condition was reverse transcribed and arrayed. This figure 
demonstrates genes that show a twofold or greater change in abundance across the 3 conditions, with initial 
tissue culture as the control condition.
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Figure 3.3.11.8 Hierarchical clustering dendogram of the twofold change in LoVo gene expression with initial 
tissue culture as the control condition. The hierarchical clustering algorithm clustered on entities (genes), using 
the Euclidean similarity measure (a simple measure o f vector distance between two points) and a centroid 
linkage rule (the generated clusters are maximally different). The first column is tissue culture, the second egg 
tumours and the third is murine grown tumours.
99
j  i  t '  '
'  -  !  - -  !  - - -V
i _ . . . i  J - . !  - i -  .
;
Im
XTT
§1
w
o'
§o
f
S
I
(N
I
01Oon
I(w1300
o\
I
bC<
X
a
bûC
-§0
1
W)
ê<D
1
■a
g
Io
tT3■&
I
I
I
O
tI 'i
a  :g
bû .S
I 3 
1 ? 
I II f  
g I 
I =
Figure 3.3.11.10 Diagrammatic aide mémoire of the condition from which each RNA was selected 
from. Tissue culture is RNA extracted from unaltered LoVo cells as supplied by ATCC (ATCC, 
Middlesex), these cells were then implanted in ovo and the resulting tumours were bisected. Half the 
tumour was lysed immediately and was subjected to RNA extraction. Parental LoVo cells were also 
engrafted in vivo flank setting where they were left to grow until they exceeded 10mm in any 
dimension; they were then harvested and bisected, with half being subject to RNA extraction 
immediately.
This SOFM analysis compared the gene expression changes of in vito against 
in ovo against in vivo. Genes that are upregulated in the two tumour environments 
compared to tissue culture can be considered to be either required for tumour 
development or as a response to adapting to these tumour growth environments; this 
profile is represented by clusters 4 and 8. IGF2, IGFBP2, MYCN and interleukin 1 
(beta subunit) (ILlb) display this profile in eluster 4; a previous report demonstrated 
that IGF2 stimulated colorectal cancer cells to increase their proliferation rate in vitro, 
which ILlb synergised with (Makins and Ballinger 2005). With this cluster of pro­
tumour genes upregulated in both tumour environments compared to in vitro strongly 
suggests their involvement in tumour formation and growth. Cluster 8 shows that 
hepatocyte growth faetor and VEGFA are upregulated in the tumour environments, 
this presenee of angiogenie factors in vivo and in ovo confirms the validity of our 
CAM tumour model compared to that of the elassieal murine flank model. Clusters 3, 
6 and 7 display the gene expression profile of high in tissue culture and low 
expression in both tumour models, which would suggest that the genes found in these 
clusters must be switehed off for tumour formation and growth. IGFl, FosB and 
chemokine ligand 2 display this profile; with IGF2 displaying the opposite expression 
profile, the inputs from activation of specific IGF receptors may be critical for tumour 
growth. The direct interactions analysis of cluster 6 is complieated by the presence of 
the insulin gene, as one of the most thoroughly studied proteins, its interactions are 
numerous and well defined; however, for our purposes, it has little to do with caneer 
research. The cAMP response element-binding binding protein (CREBBP) has low
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expression in our tumour models but high expression in initial tissue culture, 
suggesting that there may be more free CREB in tumours activating the transcription 
of protein kinase A dependent genes. The analysis of cluster 7 is complicated by the 
fact that there are 806 genes in this cluster that were identified by pathway analysis, as 
well as 12 processes that were deemed to have been affected, with this taken into 
consideration this cluster is uninformative as to the moleeular processes that its 
occupants control. Genes whose expression must be downregulated in ovo are 
identified by cluster 2, in which the cell cycle is highlighted as an affected process, 
controlled by cyelin H and the E2F1 transcription factor, with cyclin dependent kinase 
inhibitor 2A (CDKN2A) also displaying this expression profile. Genes whose 
expression is upregulated are defined in clusters 9 and 10. Cluster 9 shows that the 
processes of cell growth and transcription are affected; cell growth can be inhibited by 
the interaction of low density lipoprotein-related protein land IGFBP3 (Huang, Ling 
et al. 2003) and transcription by the modulation of CREBl and phosphoprotein 
associated with glycosphingolipid microdomains 1. VEGFA is also deemed to be a 
pathway that is better expressed in ovo than in vivo. Cluster 10 would indicate that the 
process of chromatin remodelling, combining with the influence of gastrin and 
proline-rich protein BstNI subfamily 2 causes more serine protease inhibitor clade B 
member 2 to be expressed in ovo compared to in vivo. Genes which are 
downregulated in vivo compared to in ovo and in vitro are deseribed by cluster 11 ; 
pathway analysis suggests nuclear export as a process that is affected by the genes in 
this cluster. Cyclin D l’s low levels in vivo would suggest that this would benefit 
tumour growth by allowing mitotic exit, cyclin dependent kinase inhibitor lA ’s 
similar levels would suggest that LoVo cells can escape Gi stalling of the cell cycle. 
In vivo upregulation of genes suggests that their function is the key to the growth of 
LoVo cells in that environment, which is described by clusters 0, 1 and 5. One of the 
most interesting result within cluster 0 is the presence of caspase-1 and matrix 
metalloprotease-2 (MMP-2); active caspase-1 proteolytically activates ILlb 
(discussed in cluster 4), further suggesting that the pro-inflammatory properties of 
ILlb are important in LoVo growth in vivo, the increased level of MMP-2 (which 
degrades type IV collagen, a major component of the basement membrane 
(Khoshnoodi, Pedchenko et al. 2008)) would suggest a co-ordinated angiogenic 
response throughout tumour growth. Cluster 1 contains Tie-1, an important receptor in 
the angiogenic response. Tie-1 is only expressed in endothelial cells, in this two-
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organism tumour model (human cancer cells recruiting murine support cells) this 
therefore may be an erroneous microarray result due to homology between murine 
and human Tie-1 mRNA sequence. The results of pathway analysis on cluster 5 
would suggest that the process of transcription is adversely affected by the increased 
expression of AMLl-EVI-1 fusion protein.
3.3.12 qRT-PCR of microarray identified targets
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Figure 3.3.12.1 IGFBP3 expression by qRT-PCR in Renca (right) and LoVo (left). Briefly, Ipg o f each 
sample RNA was reverse transcribed and subjected to RT-PCR, IGFBP3 expression was normalised to 
the expression o f the house keeping gene, GAPDH. Error bars denote SEM; LoVo in vitro n=2, in ovo 
n=6, in ovo to in vitro n=6, Renca in vitro n=2, in ovo n=6, in ovo to in vitro n=6.
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Figure 3.3.12.2 SENP6 expression by qRT-PCR in Renca (right) and LoVo (left). Briefly, Ipg o f each 
sample RNA was reverse transcribed and subjected to RT-PCR, SENP6 expression was normalised to 
the expression o f the house keeping gene, GAPDH. Error bars denote SEM; LoVo in vitro n=2, in ovo 
n=6, in ovo to in vitro n=6, Renca in vitro n=2, in ovo n=6, in ovo to in vitro n=6.
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Figure 3.3.12. 3NCOA3 expression by qRT-PCR in Renca (right) and LoVo (left). Briefly, Ipg o f each 
sample RNA was reverse transcribed and subjected to RT-PCR, NC 0A3 expression was normalised to 
the expression o f the house keeping gene, GAPDH. Error bars denote SEM; LoVo in vitro n=2, in ovo 
n=6, in ovo to in vitro n=6, Renca in vitro n=2, in ovo n=6, in ovo to in vitro n=6.
These normalised qRT-PCR analyses of Renca and LoVo, in vitro, in ovo and in ovo 
returned to in vitro, were designed to validate the results of the mieroarrays of those
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cell lines. The results for IGFBP3 and SENP6 were successful in that they validate the 
expression patterns generated by the SOFM analyses e.g. IGFBP3 has elevated 
expression in ovo and decreased expression in in vitro environments and SENP6 has 
elevated expression in in vitro environments and decreased expression in ovo. The 
result of NC0A3, which shows the inverse of the expression pattern suggested by 
microarray analysis, would suggest that this gene result was an artefact in this 
technique, emphasising the importance of validation by alternative methods. The large 
error bars seen in the results for Renca IGFBP3 in ovo and Renca SENP6 in ovo to in 
vitro demonstrate one of the weaknesses of this experimental design. These large error 
bars show high expression in some samples, the microarray experiment utilised RNA 
of all the samples pooled together as conditions. This methodology allowed the 
maximal amount of data for the minimum financial expenditure i.e. only one array per 
cell line was performed. However, this methodology is flawed in that a single high 
expressing sample will be detected and not represent the median expression level. 
Also, this methodology, without multiple arrays, means that the quality control and 
statistical capabilities of GeneSpring are severely limited.
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3.3.13 Human tumour samples 
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m
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Figure 3.3.13.1 Images of HNCl, a patient derived tumour from a right pyriform fossa tumour. Patient 
material was diced with a scalpel, processed according to protocol 2.18. A) cells in tissue culture 5 days 
post dissociation B) cells in tissue culture 10 days post dissection proliferating well C) 8x10^ tissue 
cultured HNCl cells were implanted in an EDD8 egg, imaged EDDIO D)EDD15 of HNCl cells in ovo.
The tumourigenic ability of an in vitro cell line is utilised in many in vivo 
models, the growth rate in vivo varies greatly and is dependent on the cell line. 
Previous work (Gronau, Thess et al. 2006) has shown that survival of tissue biopsies 
is possible in the CAM assay, which could possibly mean the advent of fast, biopsy 
based, personalised cancer treatment. We evaluated three specimens of head and neck 
cancer (courtesy of Ms Liza Pitkin of the Royal Surrey County Hospital) of which, 
HNCl grew successfully. This was largely due to the relatively large tumour that was 
resected from that patient. The optimisation of protocol 2.18 was based on the work of 
dissociation of cell line derived tumours grown in ovo, with some modifications. We 
found that head and neck cancers have a robust extracellular matrix, making 
dissociation very difficult. Further analysis and research to understand the protein
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composition of these types of tumours would guide the future choice of digestive 
enzyme, possibly leading to the more successful release of tumour cells. HNCl 
appears to have a fibroblast-like morphology in vitro, which has led to questions to 
the tumourigenic nature of these cells. They were implanted in ova and appeared to be 
growing well initially (Figure 3.3.12.1C), but this then failed to grow as would be 
expected in cell line tumours (Figure 3.3.12.ID). Upon dissection there was no 
tumour mass located above or below, just a distinct amount of clotted blood. Further 
work is on-going with multiple tumour types engrafted into this model, which will 
hopefully yield results which will enhance the CAM assay’s reputation as a worthy 
experimental model.
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3.4 DISCUSSION
The chorioallantoic membrane (CAM) assay is potentially, an effective 
platform for the testing of the efficacy of anti-angiogenic drugs/treatments and the 
establishment of murine and human tumours from cell lines. The developing avian 
embryo’s lack of immune system allows the engraftment of xeno-transplanted cells 
without immune destruction, effectively an immune-deficient model. As angiogenesis 
and vasculogenesis are still underway in the developing embryo, this provides 
aggressively replicating cells the opportunity to co-opt this natural process for their 
own gains. Recent publications have shown that the interaction between the stromal 
and tumour cells in the CAM model provides an effective representation which 
previously has only been available in genetically manipulated murine models. Over 
recent years the CAM model has been increasingly included in experiments designed 
to test the capability of a treatment to perturb angiogenesis and its establishment as an 
effective tumour model. This has led to the establishment of the CAM model in this 
laboratory as one of our prominent in vivo models.
The establishment of the CAM model provided a distinct challenge. The 
model described here provides ample opportunities for permutations; what time to 
open, which instruments to use, day of cell engraftment etc. In the course of 
experimentation, a number a combinations of forceps were used to open before 
settling on examples which provide sufficient fine detail and grasping ability. In terms 
of the covering of the opened eggs, some reports use sterile paraffin film, our 
variation was to seal the lids with petroleum jelly to help reduce infection; this led to 
the loss of a whole batch as the sealed lids allowed insufficient gas exchange leading 
to the halting of embryo development. The development of the correct opening 
technique, its refinement and ultimately its instruction to others is one of the 
cornerstones of this technique and, personally, proved the most challenging. The 
whole assay is dependent on the quality of opening; enough shell removed to 
visualise, the inner membrane removed without CAM tearing or contamination.
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TRAMP
Subcutaneous or 
orthotopic xenograft
in ova
Pro
Accurate representation 
of prostate cancer
Reasonably cheap, easy, 
reproducible
Cheap, quick, reproducible, 
visible tumours
Con
Costly, lengthy, treatment 
of "healthy" mice
Not an accurate 
representation o f prostate 
cancer
Not an accurate representation 
of prostate cancer, labour 
intensive
Table 3.4.1Assessment o f the positive and negative attributes o f the current in vivo models o f prostate 
cancer as an example. TRansgenic Adenocarcinoma o f the Murine Prostate (TRAMP).
One of the major advantages in the CAM assay is price; a comparing an 
immune defieient mouse to an egg, approximately 1/100* of the cost. The CAM also 
represents two of the three R’s (Reduce, Refine, Reuse), which should be utilised 
before any in vivo experiment takes place. The foetal state means that the stress on the 
subject is greatly reduced, allowing the Refinement of the dose and then the effective 
Reduction of the number of rodents per treatment group, to generate statistically 
significant differences. However, one of the main interests that drew our group to 
adopt this model is tumour architecture. Cancer cell lines which survive in vitro are 
inherently genetically abnormal from their tissue of origin, with some of our cell lines 
(LoVo), there is the possibility for the self-organisation to form human disease 
representing tumours, which does not happen in murine xenografts. Due to the short 
time course associated with these experiments, without the use of specialist equipment 
differences between treatment groups is difficult to detect, as such, those laeking this 
equipment should limit their drug choiee to those that are likely to have a dramatic 
effect. Some of the most critical disadvantages to this technique are the large amounts 
of labour and the level of technical skill required to perform this assay to a level 
similar to other in vivo models. Finally, like other immuno-deficient tumour models, 
there is no immune recognition of the tumour (as cells are engrafted before immune 
development), which handicaps the model in its representation of human disease. 
However, this phenomenon raises the question of which tumour antigens provide the 
majority of ‘self signals to the host immune system and whether there is a manner in 
whieh to stimulate the immune recognition of tumours, possibly opening this model 
up to its use in immunotherapy experiments. It may also be possible to manipulate the
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in ovo tumour microenvironment to better represent the human condition e.g. injection 
of an anti-reovirus antibody to simulate humans with pre-existing immunity.
Whether or not to remove an avian embryo from its shell for experimentation {in 
vs. ex ovo) is dependent on the type of experiment that will be performed. One of the 
main advantages for the ex ovo technique is its effective space utilisation, chicken 
embryos can fit in 10cm diameter petri dishes and quail embryos can fit into each well 
of a 6 well plate; this leads to better space utilisation and labelling capability. The 
three main disadvantages to the ex ovo variation:
• The chance of infection is greatly increased (greater surface area open 
compared to in ovo)
• The late development leaching of calcium from the shell to calcify the bones 
does not oecur (Tuan 1983; Tuan and Lynch 1983)
• New technical skills must be mastered for this model to work correctly
Our choice to utilise the in ovo variation in these experiments was due to this 
being the establishment of this technique in our laboratory, in the future it may be that 
further experiments will be performed as a shell-less model. The interesting tumour 
architecture observed in in ovo LoVo tumours may not be confined to that cell line, 
future experiments, utilising other colorectal cancer cell lines, should be performed to 
investigate this model’s ability to induce the self-organising behaviour that is 
observed. Furthermore, other cancers which present with a complex histological 
architecture in human disease e.g. pancreatic adenocarcinoma, should undergo 
investigation in the context of this model to further probe the CAM assay’s 
usefulness.
The use of surrogate biomarkers of tumour growth, presence or metastasis is well 
used in murine models, with the equipment required well designed. Here we 
demonstrated that it would be feasible to use a luciferase reporter gene to track 
tumour growth. The use of GFP (directly transfected into the cells prior to grafting)
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has been used previously, unfortunately no such cell line was available for these 
experiments, and therefore a viral vector was used in an attempt to affect gene 
transfer. Further refinement, possibly in the choice of the virus would further validate 
this model as a worthy experimental model. Micro computerised tomography (CT) 
was attempted on the in ovo model, however, no internal structure was detectable; 
without increasing the photon energy (penetration ability) this will remain the case. 
The embryo was then refrigerated and removed from its shell; the cradle used to 
contain the embryo eliminated any sense of relative location of the tumour. However 
it did suggest that ex ovo would work in a micro CT environment and as such would 
allow detailed examination of the tumour. Further work using surrogate biomarkers 
should include an initial experiment to see if luciferin can be applied topically to 
negate the risk of I.V. or intra-tumoural injection. From this, this luciferase, which is 
aheady well documented in rodents, could be used to track tumour growth on a daily 
basis and compare treatment in their efficacy in this model. In order to validate the 
CAM model in respect to GFP, a cell line transfected with a GFP construet, should be 
assayed in this model, removing the requirement for another method of introduction 
of the biomarker gene.
Our moderate success with oncolytic viruses (reovirus and herpes simplex) as well 
as published reports (Durupt, Koppers-Lalic et al. 2012), suggest that the CAM model 
would be suitable to produce an animal representation of human disease. With the 
benefits of architecture, reduced cost, as well as accurate reovirus deteetion, this 
model may provide an adequate bridging step between in vitro and in vivo testing. 
Although little external, macroscopic change was discernible with reovirus treated 
LoVo tumours, the internal microscopic changes were dramatic and exciting, 
suggesting that the effects of some treatment should be investigated at the 
microscopic scale, such as Zoledronate. With the negative result of Renca in ovo 
tumours treated with reovirus, the sensitivity of Renca cells to reovirus should be 
retested at the in vitro level to eliminate this hypothesis from the investigation. An 
interesting further experiment would be concomitantly treat LoVo in ovo tumours 
with reovirus and an anti-reovirus antibody to model the situation that occurs in 
humans with the adaptive immune response. Further work on reovirus treated in ovo 
LoVo tumours could include performing Caspase or Proliferating Cellular Nuelear
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Antigen (PCNA, Ki-67) to establish whether reovirus induces cell death compared to 
PBS control, it would also be possible to fluorescently stain for reovirus protein as 
well as a marker of cell death/life to further confirm reovirus’s cytotoxicity of this cell 
line in this context. Furthermore a microarray of in vitro LoVo cells untreated and 
treated with reovirus, as well as in ovo LoVo tumours untreated and treated with 
reovirus, could provide a vital insight into the overall transcriptional changes which 
occur in reovirus infection.
The Renca microarray investigated the molecular changes which occurred in these 
cells in their adaptation from in vitro to in ovo and back again. More than 4000 genes 
altered their expression by two-fold or more, which greatly complicated the analysis. 
The LoVo microarray consisted of initial tissue culture, in ovo, in ovo to tissue culture 
and murine in vivo flank tumours. This mieroarray detected more than 10, 000 genes 
with differing levels of expression across the conditions. The identification of the 
TGFp and EGFR pathways as important to LoVo cells validates the CAM model and 
provides a point from which to stage further investigations. The direct comparison 
between LoVo and Renca arrays revealed a host of genes that have a similar 
expression profile in both arrays, suggesting a shared functionality, but also allows the 
further investigation of the CAM model with other cell lines to further validate these 
targets. This data should be viewed with caution without further investigations; the 
sheer number of genes in each expression profile may suggest that some of the shared 
genes are just a function of random chance. The molecular comparison between in 
ovo and in vivo produced several interesting differentially expressed genes. Although 
the aim was to compare CAM against murine, the number of differentially expressed 
genes across the conditions could be construed as irreconcilable differences between 
the two models. However, it may be argued that there are more similarities than 
differences between the two experimental models and that those differences are 
essential for the benefits that are observable with the CAM model i.e. architecture. It 
should be noted that all these analyses are based on microarray data. It is possible that 
the probes used in these microarrays may have homology to the host organism’s 
transcripts and therefore the result could be erroneous. Also, some microarray results 
are artefactual and disproved once investigated by reverse transcription quantitive 
polymerase chain reaction (RT-qPCR), so the hypotheses posited above may be 
disproved, such as that of NC0A3. Genes with conserved expression patterns between
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both tumour models must be further investigated by RT-qPCR to validate the 
conclusions drawn from the microarray results. The RT-qPCR results for SENP6 and 
IGFBP3 agreed with the expression patterns uncovered in the Renca and LoVo 
microarrays. Further analysis, by RT-qPCR of the genes identified in both these 
arrays as having similar expression profiles may help to establish some of the 
expression characteristics which allow cells to adapt to this environment. As 
mentioned previously, this experimental design of pooling the repeats of each 
condition has a flaw in that a highly expressing outlying data point can invalidate the 
median gene expression levels. When further work is performed, with different cell 
lines, each sample should be run on separate arrays, this will allow the use of the 
quality control and statistical capabilities of GeneSpring to be properly utilised. This 
data can then be used to refine the list of genes with conserved expression patterns, 
narrowing down the list of genes whose function is important in the CAM assay. 
Further RT-qPCR work should be performed to confirm more of the conclusions 
drawn from microarray analyses, speeifieally those of RXRA and WDR3. In an 
attempt to track an established oncogene through tissue culture to in ovo and back, c- 
myc, established as present in LoVo cells (Trainer, Kline et al. 1988), was traeked by 
Western blotting (data not shown). However, due to the antibody’s lack of specificity, 
this data was stricken; further work to validate the CAM model at the protein level is 
on-going.
In ovo propagation of human tumours directly from source is not a new concept. 
Our attempts to grow head and neck cancer specimens could be described as partially 
suecessful; however determination of the obtained cell’s characteristics has yet to be 
performed, in situ fluorescent microscopy with an antibody for a fibroblast marker 
would provide the backbone for the elucidation of the type of cell cultured. Work with 
fiirther head and neck cancer samples, as well as other tumour types, continues. The 
main requirement for this experiment is excellent communication between clinical 
and scientific departments, with forethought and warning, this experiment is a 
possibility for all tumour types available from a research amenable hospital.
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In conclusion, this body of work represents a good beginning for the validation of 
the chorioallantoic membrane assay as a tumour model. Further, repeated and in depth 
investigations must be performed in order to validate the benefits seen with the use of 
this model.
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Chapter 4
Zoledronic acid, a potential 
anti-angiogenic treatment
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4. ZOLEDRONIC ACID, A POTENTIAL ANTI-ANGIOGENIC
TREATMENT
4.1 INTRODUCTION
Tumour utilisation of the biological process of angiogenesis (often termed neo- 
angiogenesis) is one of the hallmarks of cancer (Hanahan and Weinberg 2000; Hanahan and 
Weinberg 2011) and without whieh, tumours cannot grow beyond l-2mm^ (Folkman 1971). 
Tumour associated neo-angiogenesis can be explained by the “angiogenic switch” (Bergers 
and Benjamin 2003) or “open wound/hypoxia” hypotheses. In normal healthy adults, 
vasculature is not undergoing active remodelling as all tissues are correctly perfused and, as 
such, the actions of pro-(such as VBGF, FGF, PIGF etc.) and anti-angiogenic factors (PEDF, 
endostatin, thrombospondin etc.) are balanced. Solid tumours hijack the wound healing 
process, which allows them to become vascularised and continue to grow. When a trauma has 
occurred, tissue specific cells are damaged, physically removed or hormonally regulated; as 
well as the cells that make up the vasculature supplying them. Once the blood has clotted, the 
process to repair these tissues begins; the tissue specific cells are replaced from the unipotent 
stem cell bed, at which point this specific area becomes hypoxic. To counteract this Hypoxia 
Inducible Factor (HIF) is stabilised, which leads to the expression of a number of genes that 
promote angiogenesis, of which VEGF is the most notable. With this laek of oxygen the 
electron transport chain ceases to work, which leads to a decrease in available ATP levels and 
a backing up of substrates all the way to the Kreb cycle (Koivunen, Hirsila et al. 2007). 
Under normoxia HIFs are hydroxylated at highly conserved proline residues, they are now 
targets for the VHL ubiquitin E3 ligase, from here ubiquitinated HIFs are rapidly degraded by 
the proteosome. However, under hypoxic conditions, HIF prolyhydroxylases cease to 
funetion as they require oxygen as a co-factor, which means that HIFs are not targeted for 
destruction, they then migrate to the nucleus and stimulate the transeription of genes that will 
restore homeostasis (Majmundar, Wong et al. 2010; Keith, Johnson et al. 2012). In normal 
wound healing, once the defect has been repaired, cells cease to replicate and secretion of 
pro-angiogenic factors stops. However, cancer cells possessing the hallmark of indefinite 
replicative potential continue to divide, causing hypoxia, and leading to a sustained 
angiogenic response. However, this sustained angiogenic response is not physiological; the 
vaseulature that is created poorly perfijses the tumour, leaks interstitial fluid and is prone to
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spontaneous rupture (Baban and Seymour 1998). Targeting this vasculature and thereby 
tumour destruction, is the goal of anti-angiogenic therapy.
Vascular Endothelium Growth Factor A (VEGF) is a 46KDa, di-sulphide bridged, 
glycoprotein, exists as homodimers within the circulation and upon binding to its receptors 
(VEGF Receptor 1 [VEGFRl] and VEGF Receptor 2 [VEGFR2] with the co-receptor 
neuropilin-1 [NRP-1]) on endothelial cells, stimulates them to divide, migrate and form new 
vessels (Koch, Tugues et al. 2011). VEGF exists in multiple isoforms (generated by 
differential splicing of the pre-mRNA transcript) divided into two distinct families of 
opposing functionality (Harper and Bates 2008). All VEGF isoforms have dimérisation 
sequences and VEGFR-1 and 2 binding sites. The alternative splicing determines the number 
and affinity of the heparin binding domains. In the variants denoted VEGFxxxb’s, the C 
terminus, generated by the use of a distal splice site, SLTRKD, stops the binding of NRP-1, 
this reduces the efficiency of VEGFR phosphorylation and its activation (thought to be due to 
lack of torsional rotation of the split kinase domains, generating an inefficient kinase domain) 
(Kawamura, Li et al. 2008).
To date, the most prolifieally investigated anti-angiogenic therapy is Avastin® 
(Bevacizumab (Genetec/Roche)) and is under investigation in practieally every solid tumour 
type. A recombinant human IgGl antibody against VEGF, Avastin is approved by the 
National Institute for Clinical Excellence (NICE) for the following:
• Second line treatment of metastatic colorectal cancer with fluorouracil with/out 
irinotecan
• Advanced/metastatic renal cell carcinoma with interferon-a2a
• First line treatment of unresectable, metastatic or recurrent non-small cell lung cancer
Until recently (Oct 2011 and results of AVADO (Miles, Chan et al. 2010; Pivot, Schneeweiss 
et al. 2011) and RIBBON 1 (Robert, Dieras et al. 2011) trials) Avastin was used as a first line 
treatment of metastatic breast cancer in combination with paclitaxel.
Nitrogen containing bisphosphonates (NBPs) are at least 10 times more effective at 
inhibiting osteoclasts than their non-nitrogen containing (nNBPs), earlier, forms (van Beek,
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Pieterman et al. 1999). NBPs also inhibit a completely different pathway (the mevalonate 
pathway) speeifieally the biosynthesis of famesyl pyrophosphate (FPP) and geranylgeranyl 
pyrophosphate (GGPP) (Russell 2007). Both FPP and GGPP are the substrate for the 
prénylation of proteins, the process by which proteins are anchored to the plasma membrane, 
which is often essential for the protein’s (and the cell’s) correct function (Leung, Baron et al. 
2006). Zoledronic acid (Zoledronate, Zometa^M (Novartis, Basel, Switzerland), ZA) is a 
fourth generation bisphosphonate that is used clinically to prevent osteolytic métastasés in 
both prostate and breast cancer, as well as the associated hypercalcaemia. Bisphosphonates 
achieve this function by mimicking the pyrophosphate portion of the skeleton. This 
hydroxyapatite binding potential of bisphosphonates allows them to bind with high affinity to 
the human skeleton (Ki of ZA for human skeleton is 80.8pM (Leu, Luegmayr et al. 2006)) 
and from there, are only released from areas of the skeleton that undergo remodelling i.e. 
when tumours seed to bone, as tumour cells and osteoelasts start to resorb and alter the bone 
matrix. This high affinity for bone means that bisphosphonates are released at a continuous 
low level (detectable in serum 6 months post single inftision (Reid, Brown et al. 2002)) as 
10% of the skeleton undergoes remodelling at any one time.
The novel anti-angiogenic properties of ZA were first noted in 2002 (Wood, Bonjean 
et al. 2002), with many further investigations including, but not limited to, ZA’s effect on 
endothelial progenitor cells, macrophages and synergy with conventional therapeutics 
(reviewed in (Metcalf, Pandha et al. 2011)). The initial investigation into ZA’s properties 
towards human umbilical vein endothelial cells (HUVECs) showed inhibition of 
proliferation, induction of apoptosis and increase in S phase accumulation, all by multiple 
techniques. It was also demonstrated that pre-treatment prevented HUVEC adhesion to 
multiple proteins (Hasmim, Bieler et al. 2007). In vivo, ZA was shown to inhibit 
angiogenesis, especially in growth factor stimulated conditions. Further work into synergy 
with paclitaxel has established that concomitant treatment with these to therapeutic agents is 
the most effective treatment regime (Michailidou, Brown et al. 2010). This study, conducted 
with human dermal microvasculature endothelial cells (HDMVECs), also noted increased S 
phase accumulation and apoptosis, probably due to accumulation of unprenylated proteins. A 
study on the effect of ZA on endothelial progenitors showed that low doses of ZA were 
capable of inducing apoptosis and decrease expression of VEGFR2 and VE-cadherin 
(Yamada, Tsuno et al. 2009). The effect of ZA on macrophages has been addressed in a
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number of well designed and complete studies (Giraudo, Inoue et al. 2004), with ZA being 
able to normalise macrophage numbers, as well as switeh them to a M l phenotype (immune 
activating), both of which are very desirable in the treatment of cancer (Coscia, Quaglino et 
al. 2010).
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4.2 AIM AND HYPOTHESIS
The goal of this chapter was to determine ZA’s effect on human umbilical vascular 
endothelial cells, in comparison to known anti-angiogenic treatments, and whether an in vitro 
model of the in vivo situation would provide a different result. We established ZA had a 
cytotoxic effect on endothelial cells, whilst other, established, anti-angiogenics had no such 
effect. In our in vitro model of an established tumour recruiting vasculature, we demonstrate 
that these cells are more resistant to ZA than those not exposed to growth factors. The 
hypothesis of this body of work is that ZA is a successful anti-angiogenic treatment in vitro, 
comparable to other, established, anti-angiogenic therapies.
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4.3 RESULTS
4.3.1 ZA treatment of HUVECs causes decreased survival over long periods.
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Figure 4.3.1.1 The effect o f ZA on human umbilical vascular endothelial cells (HUVECs) over a protracted time 
course. A) the raw percentage survival, compared to untreated control, o f HUVECs treated over 96 hour time 
course, B) the calculated I C 5 0  values for ZA at the noted time points, n > 4 for this experiment, error bars denote 
SEM.
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48hrs 72hrs 96hrs
Mean (pM) 97.3 18.12 8^7
Std. Error 30.42 3.907 1.666
Lower 95% Cl o f mean 12.83 7.272 4.244
Upper 95% Cl o f mean 181.8 28.97 13.5
Table 4.3.1.1 HUVEC IC50 values. Calculated IC50 dose o f HUVECs treated with ZA for the time points 
indicated.
In order to affirm the work of Wood et al. (2002), human umbilical vascular 
endothelial cells (HUVECs) were plated in such a manner as to achieve 70% conflueney at 
the desired time points. They were then treated with titrated concentrations of ZA in 2% PCS 
media and the survival was determined by MTS assay. Under these experimental conditions 
we determined that an IC50 value was possible for all time points greater than 24 hours. The 
ICso’s at 48, 72 and 96 hours were 70.69pM (Standard error of the mean (SEM) = 19.03), 
18.12pM (SEM = 3.907) and 8.87pM (SEM = 1.666), respectively, all within acceptable 
parameters for Calcusyn (Biosoft, Cambridge) log dose effect calculation. All results were 
repeated at least 4 times to ensure validity of the data. All experiments contained an ethylene 
diamine tetraacetie acid (EDTA) treatment in order to control for calcium chelation, the 
results of whieh showed little effect on cellular survival.
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4.3.2 Classifying ZA’s effect on HUVECs
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Figure 4.3.2.1 The effect o f 48 hours o f ZA exposure on HUVECs. Data was analysed by a 2 way ANOVA and 
no statistical difference in the ZA treatment groups could be discerned, n = 2 for this experiment, error bars 
denote SEM.
To further understand ZA’s effect on HUVECs, these cells were treated and then 
assessed for a measure of apoptosis, the expression of Annexin V and whether free DNA is 
present. All samples were prepared as described in method 2.10 and immediately read by 
fluorescence activated flow cytometry and gated as described in method 2.10. Results (shown 
in Figure 4.3.2.1) were analysed by 2way ANOVA with Bonferroni post-test using both PBS 
and EDTA treatment as the controls, no significant difference (p > 0.05) was observed for 
any of the ZA treatments. The only significant changes, by both analyses, were observed in 
the SOpM cisplatin treatment, in both viable and late apoptotie events, confirming cisplatin’s 
use as an apoptosis inducing agent. The use of cisplatin as a high control to calibrate the 
assay also demonstrates a previously known result, that normal, relatively genetically stable.
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endothelial cells are more resistant to conventional ehemotherapeuties than the cancer cells 
which recruit the endothelial cells.
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Figure 4.3.2.2 The effect o f 96 hours o f ZA exposure on HUVECs. Data was analysed by an unpaired Student’s 
t-test and statistical difference (* = p < 0.05) was observed for the increase in apoptotie (phosphatidyl serine 
presenting) cells for HUVECs treated with 40pM ZA, n = 2 for this experiment, error bars denote SEM.
To further understand ZA’s effect on HUVECs, these cells were treated and then 
exposed to apoptosis analysis utilising the expression of Annexin V and whether free DNA is 
present. All samples were prepared as described in method 2.10 and immediately read by 
fluorescence activated flow cytometry and gated as described in method 2.10. Figure 4.3.2.2 
was analysed by unpaired Student’s t-test utilising EDTA treatment as the controls, the 
observed, statistically significant, increase in apoptotie cells in HUVECs treated with 40pM 
ZA for 96 hours gives a strong indication that ZA is cytotoxic to endothelial cells.
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Figure 4.3.2 3 The effect o f 48 hours o f ZA exposure on HUVECs by measurement o f Caspase-3 activation. 
PBS treatment was applied as 100% caspase-3 activation (n=2). ** denotes p < 0.01 as determined by an 
unpaired Student’s t-test, error bars denote SEM.
Caspase activation is one of the defining eharacteristies of apoptosis and Caspase-3, 
as an executer Caspase, is rarely excluded from this cascade. The results of Figure 4.3.2.3, 
mirrors those obtained in the evaluation of apoptosis by the Annexin V and 7-AAD FACS 
method, that at 48 hours there is no increase (of statistical significance) in any measurement 
of apoptosis of HUVECs treated with ZA. Results were analysed by One way ANOVA 
analysis of variance, with a Dunnett’s post-test with lOOpM EDTA as the control.
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Figure 4.3.2.4 The effect o f 96 hours o f ZA exposure on HUVECs by measurement o f Caspase-3 activation. 
PBS treatment was applied as 100% caspase-3 activation (n=2). * denotes p < 0.05 as determined by an 
unpaired Student’s t-test, error bars denote SEM.
The effect of ZA on HUVECs detected by the Annexin V/7-AAD FACS method 
showed an increase in apoptotie cells, which is reflected in the activation of caspase-3 (Figure 
4.3.2.4), but this increase is not statistically significant because of the wide variance between 
repeats.
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Figure 4.3.2.5 The effect o f 48 hours o f ZA exposure on the HUVEC cell cycle progression. Upper: the raw 
percentage of the cells in different phases of the cell cycle. Lower; the percentage change in the phases o f the 
cell cycle compared to lOOpM EDTA treatment, n = 2 for this experiment, error bars denote SEM.
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The work of Wood et a l in 2002 showed that there was a statistically significant 
increase of sub-Gi and S phase in HUVECs treated with lOOpM ZA for 48 hours. 
Unfortunately we were unable to replicate these findings to statistical significance. When 
both the raw (Figure 4.3.2.S upper) and the percentage data (Figure 4.3.2.S lower) was 
analysed by 2way ANOVA, no significant difference was detected. The increase in the levels 
of sub-Gi normalised to EDTA, although it was not statistically significant. Generally, the 
levels of HUVECs that are in S phase decreased. To fiirther investigate these results, 
HUVECs were exposed for 96 hours to ZA to see if any of the effects on the cell cycle was 
potentiated.
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Figure 4.3.2.6 The effect o f 96 hours o f ZA exposure on the HUVEC cell cycle progression. Upper: the raw 
percentage o f the cells in different phases o f the cell cycle. Lower: the percentage change in the phases o f the 
cell cycle compared to lOOpM EDTA treatment, n = 2 for this experiment.
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Following on from the 48 hour exposure of HUVECs to ZA, 96 hours demonstrated 
similar results (Figure 4.3.2.6). By 2 way ANOVA there were no significant changes in the 
cell cycle, however, it should be noted that there was an increase in the sub-Gi quotient at the 
higher concentrations of ZA but none of them achieved statistical significance.
4.3.3 The effect of VEGF and ZA on HUVEC survival
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Figure 4.3.3.1 HUVEC survival when exposed to ZA for 72 hours relative to HUVECs pre-treated for 24 hours 
with Vascular Endothelial Growth Factor (VEGF). n < 3 for all experiments, error bars denote SEM.
Recently, it was shown that pre-treating murine melanoma tumours with Vascular 
Endothelial Growth Factor (VEGF) and oncolytic reovirus improved the survival of the mice 
drastically (Kottke, Hall et al. 2010), along with the previous work by Wood et al. With this, 
we decided to model the situation observed in an existing cancer, secretion of growth factors, 
causing faster than normal endothelial cell replication. In this situation the percentage 
survival is calculated using HUVECs pretreated with VEGF (recombinant human VEGF, 
Sigma Aldrich, Dorset) as 100% survival. These VEGF treated HUVECs generally 
proliferated -20% more than those grown in 2% FCS F-12K media. As is obvious in Figure 
4.3.3.5, any exposure to VEGF, especially before ZA exposure, provides HUVECs with a 
statistically significant survival advantage. This posits a further hypothesis that VEGF or 
other growth factor ablation would improve anti-angiogenic or direct anti-tumour therapies.
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Further to this we investigated other time course exposures to VEGF to see if there were any 
differences in the observed survivals.
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Figure 4.3.3.2 HUVEC survival when exposed to ZA for 96 hours compared to HUVECs pre-treated for 24 
hours previous VEGF. n < 3 for all experiments, error bars denote SEM.
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Figure 4.3.3.3 HUVEC survival when exposed to ZA for 96 hours compared to HUVECs treated concomitantly 
with VEGF. n < 3 for all experiments, error bars denote SEM.
Here (Figure 4.3.3.3), HUVECs were treated with ZA and VEGF for 96 hours in a 
concomitant manner, however, only exposure to 5ng/ml VEGF provides a statistically 
significant (unpaired Student’s t-test, p < 0.05) improvement in survival (see Figure 4.3.3.5). 
This improved survival again reinforces the hypothesis that growth factor ablation before 
commencing further anti-angiogenie treatment would improve efficacy.
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Figure 4.3.3.4 HUVEC survival when exposed to ZA for 96 hours compared to HUVECs treated for 72 hours 
with ZA and VEGF. n < 3 for all experiments, error bars denote SEM.
Here (Figure 4.3.3.4), HUVECs were treated for 24 hours with ZA, after which, the 
media was changed and replaced with ZA and a pair of concentrations of VEGF. Analysed by 
Student’s unpaired t-test, supplementation of VEGF after ZA exposure provides a statistically 
significant (p < 0.01) survival advantage compared to unsupplemented. Again, the percentage 
survival of the VEGF treated cells was calculated using HUVECs exposed to VEGF for 72 
hours.
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Figure 4 .33 .5  All the statistically significant outcomes for timings o f VEGF and ZA treatment, a) HUVECs 
treated with ZA for 96 hours compared to those treated with ZA and VEGF concomitantly for 96 hours, 
analysed by unpaired Student’s t-test (p < 0.05). b) HUVECs first treated with concentration o f VEGF for 24 
hours followed by 72 hours treatment o f ZA and VEGF compared to those treated for 72 hours with ZA alone, 
analysed by one way ANOVA with a Dunnett’s post-test, using 72 hours o f ZA treatment as the control (p < 
0.05 for both), c) HUVECs treated with ZA for 96 hours compared to those treated for 24 hours with ZA 
followed by 72 hours o f ZA and VEGF, analysed by unpaired Student’s t-test (p < 0.01). d) HUVECs first 
treated with concentration o f VEGF for 24 hours, followed by 96 hours o f ZA and VEGF treatment compared to 
HUVECs treated for 96 hours with ZA alone, analysed by one way ANOVA with a Dunnett’s post-test, using 
96 hours ZA alone as the control (p < 0.001 for both), n < 3 for all experiments, error bars denote SEM.
These results confirm reports that VEGF is a powerful pro-angiogenic factor and that 
the presence of VEGF, ZA’s cytotoxic capability is attenuated for endothelial cells (see 
Figure 4.3.2.2 for apoptosis induction). These results lend credence to the hypothesis that 
VEGF ablation before further anti-angiogenic therapy will more efficacious.
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4.3.4 Effects of alternative anti-angiogenic therapies on HUVECs
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Figure 4.3.4.1 Time course treatments of HUVECs treated with recombinant human endostatin. No significant 
change in cell proliferation was appreciable. Error bars denote SEM, n=3.
Previous studies have demonstrated that both endostatin (O'Reilly, Boehm et al. 1997; 
Hu, Zhu et al. 2008) and thalidomide (D'Amato, Loughnan et al. 1994; Li, Jiang et al. 2011) 
have anti-angiogenie potential. Unlike other reports, we could not replicate the inhibitory 
effect of endostatin (Sigma Aldrich, Dorset) on HUVECs over a protracted time period. Also, 
like other reports, we managed to repeat the slight reduction in viability of HUVECs, when 
treated with thalidomide (Sigma Aldrich, Dorset), but an IC50 was not achieved. Thalidomide 
is noted to have multiple angiogenesis inhibiting capabilities, but its effect is judged to not 
directly affect endothelial cells, these results help to corroborate these effects.
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Figure 4.3.4.2 Time course treatments o f HUVECs with thalidomide. No significant change in cell proliferation 
over solvent control was detectable. Error bars denote SEM, n=2.
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4.4 DISCUSSION
There are several approaches to targeting the Vascular Endothelial Growth Factor 
(VEGF) driven growth of tumour neo-vasculature; VEGF capture (Bevacizumab and 
Aflibercept), competitive inhibition of the receptor (VEGFxxxb) and inhibition of the 
signalling pathway (Sorafenib, Sunitinib and Pazopanib). Multiple studies have shown that 
treatment with these anti-angiogenic therapies provides a significant survival advantage in 
combination with conventional chemotherapeutics.
Zoledronic acid (ZA) is a nitrogen containing bisphosphonate that is used routinely 
and frequently to prevent and treat cancer associated bone degeneration in cancer patients. 
The induction of apoptosis in endothelial cells at low concentrations of ZA was completely 
unexpected because ZA’s design was based on previous bisphosphonates, whose modalities 
were to prevent osteoclast resorption of the skeleton. Conventional chemotherapies affect 
rapidly dividing, genetically unstable, cells, generally leaving the slightly slower dividing, 
more genetically stable, endothelial cells unaffected.
The cytotoxic effect of ZA on cultured endothelial cells was measured by multiple 
methods. The prolonged (up to 96 hours) exposure to ZA brought about lower ICso’s, as well 
as survival plateauing at higher concentrations, both of which is to be expected. This partially 
replicates the work of Wood et al., who stated that the IC50 for 24 hours incubation with ZA 
in low FCS media was 4.1 ± 0.6pM (SEM). We were unable to generate this cytotoxicity at 
such a low time point, the closest we achieved was 8.87 ± 1.666pM (SEM) at 96 hours 
exposure. A possible explanation for this is that Wood et al. utilised research grade ZA 
(disodium hydrated salt [4 H2O]) whilst we used pharmaceutical grade ZA (monohydrate). It 
may be that the binding of all the ligands of the P-C-P backbone allows easier adsorption into 
a cell out of the endosome (ZA is uptaken by adsorptive endocytosis). Another possible 
hypothesis could be that the complete binding prevents any modification and targeting for 
excretion from the cell. Another possible reason for the difference between ICso’s and the 
associated time-points could be the method used to assess inhibition; Wood et al utilised 
bromodeoxyuracil (brdU) incorporation into DNA, whilst we used MTS reduction by actively 
respiring mitochondria. It may be that, under the stress which ZA places the cell; DNA
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replication (and mitosis) is halted, as it is complex biosynthetic process, at a much earlier 
stage. Actively respiring mitochondria are required until the final stages of cellular survival, 
as such; their shut down may be a more reliable method of assessing cellular viability.
Previous work by Wood et al. showed that 100 pM ZA could induce Phosphatidyl 
Serine (PS) presentation after 48 hours exposure, a result we were, unfortunately, unable to 
replicate (Figure 4.3.2.1). Even up to the four times the 100 pM dose that Wood et al. used, 
no significant difference in apoptosis was detectable compared to that of HUVECs treated 
with 100 pM EDTA. However, after 96 hours exposure to 40 pM ZA a statistically 
significant difference in percentage of apoptotic cells were detectable compared to 96 hours 
of 10 pM EDTA. However, the result for this measure of apoptosis was not replicated with 
the detection of Caspase activity. Although the mean Caspase level for HUVECs treated with 
40 pM ZA is greater than that of those treated with 10 pM EDTA, the result is not 
statistically significant. This data would be improved by further repetition, however, due to 
the prolonged period required to generate sufficient cell numbers for experiments, only the 
limited number of repeats stated were possible. Further work to ascertain cell cycle stage 
after ZA treatment provided no conclusive answers unlike the work of Wood et al. In 2002 
they reported a 270% increase in the sub-Gi fraction of cells (cells with lower than haploid 
levels of DNA) also with a 72% increase in S-phase cells with the associated decrease in the 
percentage of cells in the Gi phase with a 48 hour exposure to 100 pM ZA. We were unable 
to replicate these results, however, there was an increase in the sub-Go/Gi fraction after 96 
hours ZA exposure but it was not statistically significant. This lack of statistical significance 
is concerning, espeeially given the strength of the MTS data, however, it is our opinion that 
there are mitigating factors in this. Again Wood et al. used research grade ZA, whilst we 
utilised pharmaceutieal grade once more. Wood et al. purchased their HUVECs from 
Promocell (Heidleberg, Germany) and used the suggested culture conditions, which contains 
supplementary epidermal growth factor and basic fibroblast growth factor. This 
supplementation of growth factors may induce faster replication in HUVECs and possibly 
leave them more suseeptible to ZA’s cytotoxic effect. If further repetition were possible we 
believe that the error would be decreased and therefore the results would become statistically 
significant. As such, future work would consist of performing another repeat of 48 and 96 
hours exposure to ZA and performing Annexin V binding and Caspase assays, as well as cell 
cycle analysis.
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Further work in the same report by Wood et ah showed that pre-ZA treatment with 
VEGF (10 ng/ml in vitro and 2 pg/ml in vivo) significantly increased endothelial cell 
resistance to ZA mediated cytotoxicity. To further this work, we investigated alternative 
timings for VEGF treatment; coneomitant, pre-ZA treatment and post-ZA treatment. 
Concomitant treatment of 5ng/ml VEGF and ZA has been shown by Wood et a l to produce 
an increase in IC50 that is statistically significant. Treating HUVECs with VEGF for 24 hours 
before ZA treatment produces some of the most striking results, either concentration of 
VEGF (5 or 25ng/ml) provided a survival advantage to HUVECs compared to non VEGF 
treated comparators (e.g. the doubling of IC50 of VEGF treated HUVECs treated for 72 hours 
with ZA compared to controls. Figure 4.3.3.5). Post ZA treatment with 25ng/ml VEGF also 
significantly improved HUVEC survival. This pre-treatment with VEGF is a limited in vitro 
model of tumour neo-angiogenesis. Neo-angiogenesis is caused by tumours reaching their 
maximal size without angiogenesis, then hypoxic zones are created, followed by the 
evolutionary selection of clones which have accrued mutations to promote angiogenesis, then 
pro-angiogenic factors are released locally which then stimulates the existing vasculature to 
grow. With this model we mimic one of the stimulations that the endothelium receives in 
neo-angiogenesis, which allows us to give a more clinieally appropriate assessment of ZA’s 
anti-angiogenic capability. Peripheral serum levels of VEGF in healthy controls rarely exceed 
2ng/ml, whilst it is very common for VEGF levels in the peripheral serum to be raised in 
cancer patients, therefore the estimation of VEGF levels confined in the tumour is always 
likely to exceed this. Overall, the activation of survival pathways, by VEGF binding to 
VEGFR2 and activating the MAPK pathway, outweighs activation of apoptosis signals by the 
presence of ZA.
In order to assess the efficacy of ZA as an anti-angiogenic treatment, we compared it 
to other anti-angiogenics currently available. HUVECs were treated with concentrations of 
endostatin and thalidomide that have been noted to produce a reduction in endothelial cell 
viability. Endostatin is a 20kDa internal C terminal fragment of Collagen XVIII shown to 
have anti-angiogenic capability at a concentration of 5pg/ml. Thalidomide, a well know 
teratogen, has been shown to have anti-angiogenic properties, once metabolised. Both of 
these anti-angiogenic treatments were applied to HUVECs, however, neither worked
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successfully. A possible reason for the lack of response for endostatin could be the means of 
production; previous labs generated their own expression systems whilst ours was purchased 
from Sigma Aldrich, expressed in Pichia pastoris. It could also be that the protein had 
suffered deterioration in its 3D structure or disulphide bridges. Finally endostatin can bind 
heparin sulphate proteoglycans, HUVEC media (F-12K) is supplemented with heparin, so the 
endostatin may have remained bound in the media rather than affecting the HUVECs. 
Thalidomide generally exerts its anti-angiogenic effects on tumour cells themselves not on 
endothelial cells directly (Therapontos, Erskine et al. 2009) i.e. prevention of pro-angiogenic 
growth factor production. The anti-angiogenic effect is produced when thalidomide is 
metabolised by CYP2C19, effective treatment only occurs in multi system organisms (Li, 
Jiang et al. 2012). The future experiments to complete this body of work should focus on 
repeating the treatment of HUVECs with endostatin in serum reduced media without heparin; 
as well as performing the metabolising step to convert thalidomide into its active, endothelial 
specific, form and then treating HUVECs with this active form.
The presence of ATP synthase on the cell surface of endothelial cells (termed ectopic 
ATP synthase) has been described for over a decade (Moser, Stack et al. 1999) and is 
proposed as one of the mechanisms by which endostatin produees its effects. Non-nitrogen 
containing bisphosphonates are known to create non-hydrolysable ATP analogues (Rogers, 
Brown et al. 1996). Further work should investigate ZA’s effect on ectopic ATPase and 
whether its inhibition contributes to ZA’s anti-angiogenic effect.
In conclusion, ZA has modest anti-angiogenic action and requires further evolution in 
animal models to ascertain its potential use and overall suitability as a clinically useful anti- 
angiogenic agent.
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Chapter 5
The effect of Zoledronic acid 
on models of renal carcinoma; 
in vitro, in ova and in vivo
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5 THE EFFECTS OF ZOLEDRONIC ACID ON MODELS OF RENAL 
CARCINOMA; IN VITRO, IN OVO AND IN VIVO
5.1 INTRODUCTION
5.1.1 Renal cancer
There are 5 main histological subtypes of renal caneer, which describe the cell type that 
the tumour cells resemble. In the order of most common, they are:
1. Clear cell, resembling cells from the proximal tubule (70-75% of cases)
2. Papillary, resembling cells from the proximal tubule (10-15% of cases)
3. Chomophobe, resembling intercalated cells type B from the cortieal collecting duct 
(2-5% of cases)
4. Oncocytoma, resembling intercalated cells type A from the cortical collecting duct 
(5% of cases)
5. Collecting duct, resembling cells of the medullary collecting duct (~1% of cases)
Using an age standardised model, the rate of incidence in the UK of renal cancer is 4.4 
per 100,000. Of this, men are twice as likely to be diagnosed (6.0 per 100,000) than women 
(3.1 per 100,000), a disparity that remains through all age groups and is similarly represented 
in mortality. Staging of renal cancer is the usual Tumour Node Métastasés (TNM) method; 
increasing tumour size and confinement describe T stage, whether a tumour has metastasised 
to one or more lymph node describes the N stage, presence of distant métastasés (prevalence 
for lung, bone, brain, liver and kidney are most common) describes the M stage. 5 year 
survival probability decreases with increasing stage, with an approximate 75% 5 year 
survival for stage 1 which decreases to approximately 25% 5 year survival for stage 4. The 
treatment for early stage renal cancer is a surgical approach of either partial or complete 
nephrectomy with or without lymph nodes depending on stage. With advanced stage kidney 
cancer there are few treatments, previously interferon a and interleukin-2 treatment was the 
standard of care. Recently, utilising rational design of therapies, new effective treatments are 
available for late stage renal cancer, most notably Sunitinib (Pfizer), Avastin 
(Genetech/Roche) and Everolimus (Novartis), which will be discussed below as they belong 
(although not exclusively) to a class of treatments deemed to be anti-angiogenic.
5.1.2 The use of anti-angiogenic treatments in renal cancer
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Sunitinib (a Tyrosine Kinase Inhibitor - TKI) is an ATPase inhibitor, that targets 
multiple, intracellular, tyrosine kinases including PDGFR, VEGFR, RET, KIT and CSF-IR 
(Mendel, Laird et al. 2003; Murray, Abrams et al. 2003; Kim, Jo et al. 2006). It is currently 
the first line treatment of choice for non-confined renal carcinoma. This efficacy across 
multiple tyrosine kinases means that Sunitinib has both anti-tumour and anti-angiogenic 
properties. Multiple late phase studies have shown Sunitinib to be superior to cytokine (INF- 
a) treatment in terms of Progression Free Survival (PFS) and response rate (Motzer, Hutson 
et al. 2007), however, this is not without side-effects; mainly neutro- and thrombocytopenia; 
these side-effects are numerous and unexpected, despite detailed knowledge of the 
anticipated targets (Motzer, Rini et al. 2006). Newer, rationally designed, TKI’s, such as 
Axitinib, are hoped to further reduce side effects by further receptor avidity (Rugo, Herbst et 
al. 2005). Recently axitinib was shown to increase PFS compared to Sorafenib (4.8 vs. 3.4 
months) after failure of Sunitinib first line treatment, the difference was almost doubled in 
patients who initially reeeived IFN-a treatment (Rini, Escudier et al. 2011). There are 
suggestions that the previous treatment with TKI’s primes tumour resistance to TKI’s utilised 
as line treatments.
Many studies have shown that activating mutations in the von Hippie Lindau (VHL) 
pathway occur at a high frequency in renal carcinoma, especially the clear cell variant 
(Clifford, Prowse et al. 1998). A downstream product of the VHL protein is VEGF (Maher, 
Neumann et al. 2011). A noted observation of many renal cell carcinoma (RCC) patients is 
the elevated serum VEGF level (George and Bukowski 2007). From this the anti-angiogenic 
treatment of RCC with Avastin (monoclonal anti-VEGF antibody) was investigated, showing 
inereased PFS compared to placebo treatment (Yang, Haworth et al. 2003).
Everolimus, an inhibitor of mammalian target of rapamycin (mTOR), is a treatment 
for late stage renal carcinoma. The activation of the mTOR pathway and assembly of the 
mTOR complex is one of the control nodes in the system of overall governance of protein 
synthesis. The mTOR pathway phosphorylates the eukaryotic initiation factor 4E binding 
protein (eIF4E-BP), inactivating it, leading to more, active eIF4E, which increases the 
translation of the hypoxia inducible factor (HIF) genes. In both normoxic and hypoxic 
cancerous conditions, this excess of HIF is not degraded by the proteasome, binding to 
hypoxia response elements of genes that will restore homeostasis and increases their 
transcription and translation, which is aided by the increased levels of eIF4E. Targeting neo- 
angiogenesis at one of the main signalling proteins, allows inhibition of multiple pathways by
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which this vital, to cancer evolution, process occurs (Kapoor and Figlin 2009). In clinical 
trials Everolimus showed enhanced PFS, after TKI treatment failure, compared to placebo 
control (Motzer, Escudier et al. 2008). It is noted that Everolimus induees only partial tumour 
regression at a very low rate (~1%), suggesting a more cytostatic than anti-tumour effect 
(Houghton 2010).
5.1.3 The growth factor axis in renal cancer
Renal cancer is normally a well vascularised tumour type. This is due to its frequent 
over-activation of well-defined growth faetor pathways, the most thoroughly studied, and 
common, mutations are c-Met, VEGF and PDGF.
VEGF-A is a mitogenic growth factor that can vary in weight from 121kDa to 
206kDa, due to alternative splicing and glycosylation patterns. It is released by cancer cells 
and can signal in both a paracrine and autocrine manner, depending on which of its receptors 
it binds to. Paracrine signalling to associated endothelial cells occurs through VEGFR2 (also 
known as Flk-lor KDR) and the accessory receptor, neuropilin 1. Upon VEGF binding the 
receptor associates with neuropilin land then dimerises (homodimer of heterodimers). 
VEGFRs then transphosphorylate critical tyrosine residues which then allows the activation 
of multiple survival, migration and proliferation pathways (Koch, Tugues et al. 2011). 
Phosphorylated VEGFR2 can activate Phospholipase C y (PEG y) (Xia, Aiello et al. 1996), 
Phosphatidyl inositol-3-kinase (PI-3-K) (Laramee, Chabot et al. 2007), Src leading to Foeal 
adhesion kinase (FAK) (Rousseau, Houle et al. 2000), p38 mitogen associated protein kinase 
(MAPK) (Gee, Milkiewicz et al. 2010) and cdc-42 (phosphatase assoeiated with cell cycle 
progression) (Lamalice, Houle et al. 2004).
Platelet derived growth factor (PDGF) is another mitogenic growth factor of 30kDa, 
consisting of two polypeptide chains linked by disulphide bridges. There are four isotypes 
that represent the polypeptide chains, A to D, A and B can form homo and heterodimers, 
whilst C and D can only form homodimers. The receptor exists as a and p isoforms, PDGF 
AA binds only to PDGFR a, whilst PDGF B containing dimers can bind both receptor 
isoforms. Like VEGF, PDGF bound to its receptor causes receptor dimerization, 
transphosphorylation of critical tyrosine residues that activate survival and migration 
pathways (Fredriksson, Li et al. 2004). PDGF AA secretion has been shown to increase with 
grade of clear cell renal cell carcinoma (CCRCC), as well as PDGFR aa presentations. The
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presence of high expression of PDGFR aa showed a statistieally significant shorter PFS, 
suggesting the blockade of autocrine and paracrine PDGF signalling is a viable treatment, in 
at least CCRCC (Sulzbacher, Bimer et al. 2003). Phosphorylated PDGFRs can activate the 
Ras/Raf/MEK/ERK (Grammer and Blenis 1997), PI-3-K/Akt (Escobedo, Keating et al. 1988) 
and PEC y/Ca^^ (Hasegawa-Sasaki, Lutz et al. 1988) or Calmodulin-dependent protein 
kinases (CAMKs)ZProtein Kinase C (PKC) , of which PKC eta is noted as upregulated in 
CCRCC (Brenner, Farber et al. 2003) and CAMKs have been shown to support a resistance 
to apoptosis (Fasanaro, Magenta et al. 2006).
Hepatocyte growth/scatter factor (HGF) and its receptor c-mct are mutated in 
hereditary cases of papillary RCC (PRCC). HGF is secreted, activated by cleavage, binds to 
c-met which dimerises and transphosphorylates critical tyrosine residues in the kinase and 
adapter intracellular domains, c-met signalling can have powerful signals for proliferations, 
transformation, survival and invasion (Organ and Tsao 2011). Activated c-met can signal 
through the Ras/RafMEK/ERK pathway via Son Of Sevenless (SOS, binds to the adapter 
domain via GRB2/SHC/SHP2) to Ras (Graziani, Gramaglia et al. 1993) or GABl (main 
scaffold protein binding the adapter domain) with SHP2 to ERK (Maroun, Naujokas et al. 
2003), STAT3 (Signal Transducer and Activator of Transcription, a powerful transcription 
factor) (Boccaccio, Ando et al. 1998), p38 to JNK (c-Jun N-terminal Kinase) (Rodrigues, 
Park et al. 1997), PI-3-K to Akt (Ponzetto, Bardelli et al. 1994) or Src to FAK (Ponzetto, 
Bardelli et al. 1994). Activations of c-met is not wholly dependent on homodimerisation, 
studies have shown other receptor tyrosine kinases (Lai, Abella et al. 2009), integrins 
(Trusolino, Bertotti et al. 2001) and intercellular adhesion molecules (Olaku, Matzke et al. 
2011) can induce phosphorylation of c-met’s adapter domain or strengthen existing aetive 
pathway’s signals, c-met is a proto-oncogene and activating mutations in the kinase domain 
are common in hereditary PRCC, in sporadic PRCC, trisomy of chromosome 7, 
amplification, duplication etc. are common (HGF and c-met are located on 7q, meaning that 
uncontrolled autocrine signalling can occur) (Fischer, Palmedo et al. 1998).
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5.2 AIM AND HYPOTHESIS
The aim of this body of work was to establish the effect of ZA on renal cancer cell 
lines, to define a dose of ZA that would be cytotoxic to those renal cancer lines and explore 
the mechanisms of that cytotoxicity. Ideally, I C 5 0  concentrations of ZA for renal cell lines 
would be much greater than that for endothelial cells. As such, it would infer that any effect 
caused by the low doses of ZA with which we would treat tumour models of renal cancer, 
would be due to an anti-angiogenic effect rather than any direct anti-tumour effects that is 
notable in many purported anti-angiogenic treatments. The hypothesis for this body of work 
is that, with carefully calculated doses, ZA will have an anti-angiogenic effect rather than a 
direct anti-tumour effect, to slow tumour growth in vivo.
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5.3 RESULTS
5.3.1 High concentrations of ZA over prolonged time periods causes reduced 
proliferation of renal cancer cells in vitro
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Figure 5.3.1.1 IC50 values for 3 renal cancer cell lines exposed to ZA for prolonged periods o f time, determined 
by MTS assay. Error bars indicate ±  SEM (Standard Error o f the Mean), n>3.
IC50 (pM)
Cell Line 24 hours 48 hours 72 hours 96 hours
Renca 354.4 (±29.32) 142.3 (±8.63) 84.95 (±11.98) 65.49 (±6.721)
769-P 739.3 (±158.2) 152.1 (±23.51) 61.12 (±10.48) 39.26 (±4.848)
MZRCC 1770 1109 (±48.43) 440 (±25.43) 330.2 (±45.57) 113.4 (±13.2)
Table 5.3.1.1 IC50 values for 3 renal cancer cell lines exposed to ZA for prolonged periods o f time ±  SEM 
(Standard Error o f the Mean).
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To affirm the work of (Pandha, Birchall et al. 2006) for 769-P and (Soltau, Zirrgiebel 
et al. 2008) for Renca, renal cancer cell lines were exposed to Zoledronate for prolonged 
periods to time to establish IC50 values (Figure 5.3.1.1). Pandha et al. established that after 72 
hours of exposure to ZA, the IC50 for 769-P renal adenocarcinoma was approximately 25pM, 
which is within a log category of the attained value in this set of experiments, so can be 
considered valid. Soltau et al. determined the IC50 of ZA in Renca cells after 72 hours was 94 
± 47pM, again the value attained in this set of experiments can be considered valid. This data 
shows that renal cancer cell lines are more resistant to the effects of ZA (most likely the 
inhibition of prénylation) than endothelial cells at these time points (see Figure 4.3.1.1), when 
measured by MTS. The data shows that these cell lines are at least 3 times less sensitive to 
the effects of ZA than HUVECs under similar conditions. To further investigate whether the 
tumour limiting effect of ZA, seen in animal models, is in any way associated with an anti­
tumour, rather than anti-angiogenic, effect, these cell lines were then subjected to apoptosis 
and caspase analysis.
5.3.2 Classifying ZA’s effect on renal cancer cell lines
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Figure 5.3.2.1 Renca cells treated for 48 hours with varying concentrations o f cisplatin. This experiment was to 
determine a suitable dose for use in further experiments as a positive control for apoptosis analysis, n=l.
Renca cells were plated at 5xl0^/well on a 96 well flat bottomed plate and treated 
with varying concentrations of cisplatin for 48 hours. This experiment was to determine a 
suitable dose that would induce apoptosis in Renca cells to use as a positive control in the 
apoptosis analysis. Using Calcusyn (Biosoft, Cambridgeshire), the I C 5 0  at these experimental 
conditions was 20.96pM, for convenience and surety that apoptosis would definitely be
147
induced, all cell lines that underwent apoptosis analysis would be treated with 50pM for 48 
hours and 25pM for 96 hours for cisplatin to serve as a positive control.
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Figure 5.3.2.2Apoptosis and Caspase assays o f Renca cells treated for 48 hours with ZA. Renca cells treated 
with ZA for 48 hours were analysed for levels o f apoptosis by flow cytometry via Aimexin V binding (top left 
and lower) and caspase-3 activation (top right). Treatment with up 4 times the IC50 o f ZA produced no 
significant changes in apoptosis compared to those treated with PBS. n = 3 and the error bars represent the 
SEM. a) p<0.0001 by 2way ANOVA with Bonferroni post-test, b) p<0.001 by 2way ANOVA with Bonferroni 
post-test, c) p<0.0001 2way ANOVA with Bonferroni post-test, d) p<0.05 by Iway ANOVA with Dunnett’s 
post-test, e) p<0.0001 by Iway ANOVA with Dunnett’s post-test, f) p<0.001 by Iway ANOVA with Dunnett’s 
post-test.
Renca cells exposed to ZA for 48 hours (Figure S.3.2.2) showed no statistically 
significant increase in levels of apoptosis detectable by either Annexin V binding to 
phosphatidylserine or Caspase-3 activation. This suggests that the I C 5 0  value obtained
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pertains to ZA’s cytostatic effects on these renal caneer cells rather than any direct 
cytotoxicity. The treatment with cisplatin showed a great decrease in viable cells and a 
reciprocal increase in early apoptosis. The laek of Caspase-3 activation is slightly perplexing, 
leading to two arguments; either the ‘apoptosis’ is caspase independent or that there were 
fewer cells analysed for their caspase level, hence the lower level. This line of investigation 
has established that Renca cells are very susceptible to apoptosis caused by cation chelation 
by EDTA, what is slightly odd however is that ZA, even at four times the concentration, 
cannot induce the same effects. The overall affinity of EDTA for positively charged ions (Na, 
K, Ca etc) and its concentration could account for the apoptosis induction that is evident by 
both caspase activation and Annexin V binding.
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5.3.2.3 Apoptosis and Caspase assays o f Renca cells treated for 96 hours with ZA. Renca cells treated with ZA 
for 96 hours were analysed for levels o f apoptosis by flow cytometry via Annexin V binding (top left and lower) 
and caspase-3 activation (top right). Treatment with even half the established IC50 concentration o f ZA induced 
a statistically significant response in the flow cytometry results (top left and lower), n = 3, error bars indicate 
SEM. Caspase-3 activation results seem to contradict this data (top right), n = 3, error bars indicate SEM. *** 
denotes p < 0.001 by Iway ANOVA with a Dunnett’s post test with PBS as control. All changes o f condition in 
flow cytometry (lower) compared to PBS are significant (p < 0.05 by 2way ANOVA with Bonferroni’s post­
test) apart from necrosis where there is no statistical difference was observed between treated and PBS treated 
cells.
Treating Renca cells for 96 hours (Figure 5.3.2.3) with the IC50 concentration of ZA 
causes a statistically significant decrease (-15.81% to -7.371%, 95% Confidence Intervals 
(Cl), p < 0.0001) in viable cells, an increase in early (0.6847% to 9.122%, 95% Cl, p < 0.05) 
and late apoptotic cells (2.761 to 11.2%, 95% Cl, p < 0.0001), compared to PBS treated cells 
(2way ANOVA with Bonferroni post-test). Increases in ZA concentration compound these 
effects, inducing further apoptosis. Once more, the use of EDTA in these experiments, meant 
to control for whether cation chelation is responsible, shows that Renca cells apoptose
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(Aimexin V binding) in response. Any concentration of ZA (down to 50% of the IC50 - 
32.75|xM) causes a statistically significant increase in apoptotic cells (Iway ANOVA with 
Dunnett’s post-test, p < 0.001). However, this increase in apoptotic cells measured by 
Aimexin V binding is not mirrored in the Caspase-3 activation. Analysis by Iway ANOVA 
shows a statistically significant decrease in Caspase-3 activation compared to PBS treated 
cells for all treatment types. This result would be confirmed by the addition of N- 
Benzyloxycarbonyl-Val-Ala-Asp(O-Me) fluoromethyl ketone, a peptide designed to 
inactivate proteases that attempt to hydrolyse its peptide bond, to the experiments to ensure 
that the apoptosis, measured by the presentation of phosphatidylserine, is definitely Caspase- 
independent.
151
GO-
GO-
<A
0)u
o
20-
m 1 0 0 -
CL
o
*' 5 0 -
rea
E O '  
o u 
0ro .50 - 
re
o
-100
^  P B S
ESH 1 0 0 Q M  E D T A  
B  3 . 1 2 5 0 M  Z A  
DID 6 . 2 5 0 M  Z A  
^  1 2 . 5 Q M  Z A  
^  2 5 0 V 1  Z A  
B  5 0 Q M  Z A  
^  1 0 0 Q M  Z A
™  1 0 0 0 M  E D T A  
E Ë 3  3 . 1 2 5 Q M  Z A  
B  6 . 2 5 0 M  Z A  
DID 1 2 . 5 Q M  Z A  
^  2 5 0 M  Z A  
^  5 0 Q M  Z A  
B  1 0 0 O M  Z A
80-1
6 0 -
0>o
o
20-
W 1 0 0 -  
0. 
o
■a
® 5 0 -re
o.
Eou0 0- O) 
c  re
^  rîi  rtl É E 3 TT
u
-5 0
^  P B S  
ESH 3 . 1 2 5 Q M  Z A  
B  6 . 2 5 0 M  Z A  
DID 1 2 . 5 0 M  Z A  
^  2 5 Q M  Z A  
^  5 0 Q M  Z A
3 . 1 2 5 Q M  Z A
E s a 6 . 2 5 Q M  Z A
B 1 2 . S O M  Z A
B 2 5 0 M  Z A
5 0 O M  Z A
See next page for figure legend.
152
Figure 5.3.2.4 Cell cycle analysis o f Renca cells treated with ZA. Renca cells treated for 48 hours (top) and 96 
hours (second from bottom) with sub-IC^o concentrations o f ZA to investigate alterations to the cell cycle in 
response to ZA exposure, n<3, error bars denote SEM. When expressed as raw data (top), 48 hours o f exposure 
to lOOpM EDTA, causes a statistically significant increase in cells in the sub-Go/Gi phase (a = p < 0.01 
analysed by 2way ANOVA with Bonferroni’s post-test with PBS as the control). When expressed as percentage 
change compared to PBS (second from top), further patterns emerge. Although analysis by Iway ANOVA, 
excluding lOOpM EDTA, showed no statistically significance between the means, post-test analysis showed a 
definite linear trend (b = p < 0.01) between ZA concentration and a decrease o f cells in Gq/G i phase, a similar 
result o f analysis o f the cells in S-phase (e = p < 0.05). ZA treatment o f Renca cells for 48 hours showed 
inereased levels o f cells with a sub-Go/Gi DNA content (d = Iway ANOVA with linear post-test, both p values 
were less than 0.05). 96 hours o f ZA exposure (second from bottom) causes a statistically significant decreases 
in the number o f cells in the Gq/G i phase o f the cell cycle (e = p < 0.05, f  = p < 0.001, both analysed by 2way 
ANOVA with Bonferroni’s post-test with PBS as the control). When the raw data is expressed as percentage 
change compared to PBS (bottom), further patterns emerge. Iway ANOVA analysis o f the change in the 
percentage o f cells in the Gi/Gq phase o f the cell cycle show a statistically significant decrease correlating with 
concentration o f ZA (g = p < 0.001 with linearity p < 0.0001). The increase in the change in the percentage o f  
cells in S-phase is also statistically significant in both its differences in means and linearity (h = p < 0.05 and p < 
0.01 respectively).
As previously demonstrated in Figure S.3.2.2 and Figure 5.3,2.3, Renca cells are 
particularly sensitive to cation chelation, with EDTA treatment inducing apoptosis with both 
the presentation of phosphatidylserine and caspase-3 activation. Cells that have a lower DNA 
content than that of the G q/ G i phase are judged to have undergone incorrect mitosis and as 
such are destined to apoptose within a short space of time. This data showing that EDTA 
induces an increase in cells with an abnormally low DNA content is consistent with the 
previous apoptosis data, the reason for its lack of representation in the percentage change 
compared to PBS is that PBS treated cells have low levels of cells in apoptosis approximately 
5% total by this analysis method (approximately 15% by Annexin V binding), and that the 
massive percentage change induced by EDTA treatment would dwarf all other bars on the 
upper right diagram. The means of the change of percentage of cells with a sub-Go/Gi 
content are statistically significant (p < 0.05) and are judged to behave in a linear manner (p < 
0.05, but only an r^=0.1285) compared to PBS, however, this change is small compared to 
that of EDTA, suggesting once more that Renca cells are sensitive to cation chelation to a 
significant degree. Although there is apparent decrease in the percentage of cells in G q/ G i 
phase, compared to PBS, the means are not different in a statistically significant manner (p = 
0.0825), however, linear trend analysis (p < 0.01) suggests that further increases in ZA 
concentration would prove to be significant. Also, the changes in the percentage of cells in
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the S-phase of the cell cycle, compared to PBS, are considered to be non-significant by Iway 
ANOVA, but linearity (p < 0.05) would also suggest that further increases in ZA 
concentration would compound effects. When Renca cells are treated for 96 hours with 
varying concentrations of ZA, the only significant difference you see in the raw data (by 
2way ANOVA with Bonferroni’s post-test with PBS as the control) is a decrease in the 
number of cells in the G q/ G i phase when treated with 25 or 50pM ZA (p < 0.05 and p < 0.001 
respectively). The expression of the data as percentage change compared to PBS provides a 
further insight, Iway ANOVA analysis shows that both the change in means with increasing 
ZA concentration in the percentage of cells in the G q/ G i phase (decreasing) and the 
percentage of cells in the S-phase (increasing) are significant (p < 0.001 and 0.05 
respectively) and demonstrate a linear relationship (p < 0.0001, r^=0.6137 and p < 0.01, 
r^=0.3483 respectively). In previous work. Figure 4.3.2.3, similar and higher concentrations 
of ZA were used to assess for apoptotic effect. The percentage of cells that have a below 
G q/ G i DNA content supposedly represents a proportion of cells that are moving towards 
apoptosis, however with the stringent gating employed for cell cycle analysis, you can expect 
the number of cells deemed to be ‘apoptotic’ to be much lower in cell cycle analysis. This 
data does show remarkable similarity to the apoptosis data and as such can be considered 
valid. Inspection of this data shows a decrease in the percentage of cells in G q/ G i phase, 
which is recouped with a reciprocal increase in the percentage of cells in either G]/M or S 
phase. Since the effect on the percentage of cells in the Gi/M phase, compared to PBS, is 
considered to be statistically insignificant, further analysis can be discarded, however, since 
the increase in S-phase is significant conclusions can be drawn. This stalling in the process of 
synthesis of new DNA means that ZA affects the replication machinery (i.e. depletion of a 
critical protein, by interruption of its biosynthesis) or the biosynthesis of the constituents of 
DNA, possibly in the biosynthesis of nucleotides since ZA can be judged to be similar to 
ATP (non-nitrogen containing bisphosphonates mimic ATP in the priming of tRNA’s with 
amino acids), preventing the phosphorylation of nucleosides. Finally, it should be noted that 
the concentrations required to achieve this perturbation of the cell cycle, in vitro, are 
remarkably high (and these effects may be artefactual) since in an in vivo setting, the highest 
achievable serum concentration is ~l-2pM  ZA.
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Figure 5.3.2.5 Apoptosis and Caspase assays o f 769-P cells treated for 48 hours with ZA.769-P cells treated 
with ZA for 48 hours were analysed for levels o f apoptosis by flow cytometry via Annexin V binding (top left 
and lower) and caspase-3 activation (top right). Although the percentage o f cells presenting phosphatidylserine 
increased, with increasing ZA concentration (upper left), only 50pM cisplatin for 48 hours provided a 
statistically significant increase by Iway ANOVA with Dunnett’s post-test (p < 0.001 — indicated by a, n=3, 
error bars denote SEM). Analysis o f Annexin V binding and 7-AAD uptake to determine apoptotic level shows 
that 50pM cisplatin and 608.4pM ZA caused a significant decrease in viable cells (d = p < 0.0001, e =  p < 
0.001) and a corresponding increase in late apoptotic cells (f  = p < 0.0001 and g = p < 0.05 for 50pM cisplatin 
and 608.4pM ZA respectively), n = 3, error bars denote SEM. Caspase-3 activation shows that increasing ZA 
concentration caused increase caspase-3 activation. To correct for differences in cell number being used in the 
assay (which cannot be controlled by plating dilution due to the length o f the assay), flow rate data from the 
flow cytometer was used to estimate cell number, which was then used to assess the fluorescence as Relative 
Fluorescent Units (RFUs)Zcell, which was then expressed as a percentage o f PBS. b = p < 0.05 and c = < 0.01 by 
Iway ANOVA with Dunnett’s post-test, n = 3, error bars denote SEM.
Treating 769-P, a clear cell renal cancer cell line, with the IC50 concentration of ZA 
(determined by MTS assay) does not illicit a similar response when judged by Annexin V 
binding to phosphatidylserine as a measure of apoptosis. However, as the concentration is
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increased, a significant decrease in viable cells is visible, as well as cells that are in late 
apoptosis. This result is mirrored consistently in the Caspase-3 activation data, once cell 
number has been corrected for. The statistically significant increase in Caspase-3 activation 
seen in 769-P cells treated for 48 hours with 304.2pM ZA, without a significant change in the 
Annexin V binding can be explained by the fact that Caspases are one of the main control 
nodes in the apoptosis cascade and as such are switched on early in apoptosis, whilst the 
presentation of phosphatidylserine occurs at a later stage.
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Figure 5.3.2.6 Apoptosis and Caspase assays o f 769-P cells treated for 96 hours with ZA. 769-P cells treated 
with ZA for 96 hours were analysed for levels o f apoptosis by flow cytometry via Annexin V binding (top left 
and lower) and caspase-3 activation (top right). Assessment o f apoptosis by flow cytometry (top left and lower) 
indicate that both 25pM cisplatin and 157.04pm ZA treatment o f 769-P cells induce an apoptotic response (a = 
p < 0.001 and b = p < 0.05 by Iway ANOVA with Dunnett’s post-test with PBS as control. c= p < 0.05 by Iway 
ANOVA with Dunnett’s post-test with EDTA as control, d = p < 0.0001, e = p < 0.001, f = p  < 0.01, g = p < 
0.0001 and h = p < 0.01 by 2way ANOVA with Bonferroni’s post-test with PBS as control.), n=3, error bars 
indicate SEM. Caspase-3 activation (upper right), however, showed that only 96 hours treatment o f 769-P’s with 
157.04pM ZA generated a statistically significant response, once corrected for cell number.
As was anticipated the treatment of 769-P cells with cisplatin for an extended time 
period induced a significant decrease in viable cells and, reeiproeally, an inerease in apoptotic 
cells. The treatment with 4 times the IC50 (determined by mitochondrial viability -  MTS 
assay) also induced apoptosis. Again, a probable hypothesis for this seemingly large gap 
between MTS determined IC50 and insensitivity at the molecular level may be that ZA causes 
the inactivation mitochondria without inducing apoptosis, a state which cells can existing in
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for protracted periods. A notable observation is that the cells seem to bypass early apoptosis 
and double stain for phosphatidylserine and DNA (95% Cl of difference 2.919% to 21.61% 
compared to PBS). Curiously, this late apoptosis is not end stage apoptosis, as there is little 
evidence of DNA fragmentation in the staining pattern. The activation of Caspase-3 mirrors 
the apoptosis data for cells treated with 4 times the I C 5 0 ,  but not for the cisplatin treated ones. 
Possibly, with such a high proportion of cells aheady in late apoptosis, caspases have already 
been thoroughly degraded and cease their function. Flow rate from the flow cytometry would 
suggest that at both 48 and 96 hours treatment with the respective I C 5 0  concentrations of ZA 
that there is an anti-proliferative effect in action, rather than direct cytotoxicity. It should 
however be noted that the flow rate gleaned from the FACS data is only a very rough 
estimate of cell number as the FACS picks up cell particles as well as whole cells.
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See next page for figure legend.
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Figure 53.2.1  Cell cycle analysis o f 769-P cells treated with ZA. The exposure o f 769-P cells to varying 
concentration o f ZA over a 48 (top) and 96 hour (second from bottom) time course alters the cell cycle. Data is 
expressed as both raw data, e.g. the percentage o f cells in each stage o f the cell cycle (top and second from 
bottom) and as a percentage change, compared to PBS (second from top and bottom), for both time points, n > 
3, error bars denote SEM. The only statistically significant alteration to the raw cell cycle data is an increase in 
the percentage o f cells in the sub-Gi phase after treatment with lOOpM ZA for 48 hours (top, 2way ANOVA  
with Bonferroni post-test, with PBS as control, a = p < 0.01). When this 48 hour cell cycle data is expressed as a 
percentage change (second from top), the decrease in both the levels o f cells in G^/M and S phase are significant 
(Iway ANOVA, b = p < 0.01 and c = p < 0.05), and the decrease is judged to correlate linearly with ZA 
concentration (b = p < 0.001 r^  = 0.4572 and c = p < 0.01 r^  = 0.3626). By 2way ANOVA with Bonferroni post­
test, with PBS as the control, there were no significant differences caused by the treatment o f ZA on 769-P cells 
for 96 hours (second from bottom and bottom), but there are some trends. When the data is expressed as the 
percentage change compared to PBS (bottom), these trends become significant. For all the stages o f  the cell 
cycle, the mean changes in the percentages o f cells did not vary in a statistically significant manner (analysed by 
Iway ANOVA). However, the results for Gq/Gi and S phases showed statistically significant linearity o f change 
(d = p < 0.05 r^  = 0.3136 and e = p < 0.01 r^  = 0.366 respectively). Although, when a two tailed unpaired 
Student’s t-test was performed on the changes in S-phase o f 3.125pM ZA and 50pM ZA (not shown), the result 
was statistically significant in its increase (p < 0.05).
The presence of a statistically significant increase in cells with a sub-Go/Gi DNA 
content (inferred to be apoptotic) after 48 hours of lOOfiM ZA treatment, is unexpected, as 
was demonstrated in Figure 5.3.2.5, concentrations this low do not generally cause 
statistically significant levels of cell death. However, the concentrations used in this 
experiment to investigate if ZA has any effect on the cell cycling of 769-P cells; do approach 
the MTS identified I C 5 0  concentration for 96 hours, so any conclusions must take this into 
account. Although there were no significant changes in any of the stages of the cell cycle (by 
2way ANOVA), there was linearity in the decrease in G q/ G i and the increase in S phases. 
Also when 3.125|iM was compared to 50pM ZA treated 769-P’s, by unpaired, two-tailed. 
Student’s t-test, there was a statistically significant difference. Once more, physiologically 
achievable concentrations of ZA seem not to have a large effect on the regular cell cycling of 
769-P at either 48 or 96 hours.
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Figure 5.3.2.8 Apoptosis and Caspase assays o f MZ RCC 1770 cells treated for 48 hours with ZA. MZ RCC 
1770 cells treated with ZA for 48 hours were analysed for apoptosis by flow cytometry (top left and bottom) and 
caspase activation (top right). Treatment o f MZ RCC 1770 cells with 50pM cisplatin, 220pM and 1760pM ZA 
all caused a statistically significant increase in apoptotic cells compared to PBS (Iway ANOVA with Dunnett’s 
post-test; a = p < 0.001, b = p < 0.05 and c = p < 0.05), n =2, error bars denote SEM. Cispatin treatment and 
1760pM ZA both caused significant decreases in viable cells, compared to PBS treatment (2way ANOVA with 
Bonferroni’s post-test; e = p < 0.0001 and f  = p < 0.01, respectively) with 50pM cisplatin causing cells to 
transition to late apoptosis (2way ANOVA with Bonferroni’s post-test, g = p < 0.0001), n =2, error bars denote 
SEM. Only 48 hours o f treating MZ RCC 1770 cells with 440pM (the IC50 value determined by MTS assay) 
caused a significant increase in relative Caspase-3 activation compared to PBS (Iway ANOVA with Dunnett’s 
post-test, d = p < 0.05), n =2, error bars denote SEM.
The exposure of MZ RCC 1770 cells to 48 hours of ZA treatment only resulted in a 
significant decrease in viable cells in those treated with four times the MTS assay determined 
IC50, when analysed by 2way ANOVA. However, when the total percentage of cells 
expression phosphatidylserine is calculated and then analysed by Iway ANOVA, both half 
the IC50 and four times the IC50 showed increases in apoptotic cells. It should be noted that
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when EDTA is used as the comparison in both the 1 and 2way ANOVAs, the only 
statistically significant difference is in the cisplatin treated cells. This can therefore be viewed 
that ZA has no significant cytotoxic effect, over cation chelation, at 48 hours. The levels of 
caspase-3 activation, once corrected for cell number, are only significantly elevated for the 
I C 5 0  concentration of ZA when compared to PBS. However, if  the analysis is repeated using 
EDTA as the control there is no statistical significant inerease in caspase-3 activity. This 
result may be due to the limited number of repeats (n=2) for this experiment, hopefully 
further repetition would decrease the scale of the error bars. Similarly, the flow rate data, 
either raw or expressed as percentages, showed that there was no significant difference 
between EDTA treated and ZA treated. The reason for such limited number of repeats is that 
the concentration of clinical grade ZA is ~3mM, with four times the I C 5 0  being approximated 
two thirds of this concentration, it meant that large volumes of ZA were used in these 
experiments and as such further repetition was inhibited by lack of resources and time 
constraints. It should also be noted that the dilution of media in the preparation of a 
concentration of ZA that is four times the I C 5 0 ,  could play a significant part in explaining 
these results.
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Figure 5.3.2. 9 Apoptosis and Caspase assays o f MZ RCC 1770 cells treated for 96 hours with ZA. MZ RCC 
1770 cells treated for 96 hours were analysed for apoptosis by flow cytometry (top left and bottom) and caspase- 
3 activation (top right). 25pM cisplatin, 226.8pM ZA and 453.6pM ZA all induced a significant decrease in 
viable cells (c = p < 0.0001) and a reciprocal increase in late apoptotic cells (d = p < 0.0001), analysed by 2way 
ANOVA with Bonferroni’s post-test comparing against PBS. Iway ANOVA with Dunnett’s post-test against 
PBS o f all cells presenting phosphatidylserine demonstrates similar results but with a lower level o f significance 
(a = p < 0.001), n = 2, error bars denote SEM. 96 hours treatment with 113.4pM EDTA induced a large 
induction o f caspase-3 activity (analysed by Iway ANOVA with Dunnett’s post-test comparing to PBS, b = p < 
0.01), once corrected for cell number, n = 2, error bars denote SEM.
Treating MZ RCC 1770 cells for 96 hours with ZA produces some rather interesting 
results. The assessment of apoptosis by presentation of phosphatidylserine shows great 
decreases in viable cells when treated with twice and four times the IC50 concentration, with a 
reciprocal increase in the numbers of cells in late apoptosis. Why these cells enter late 
apoptosis and seemingly bypass early apoptosis may be due to a myriad of explanations, one 
of which could be a narrow therapeutic index for this cell line. Strangely, the Caspase-3
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activation data does not mirror this finding, in fact, only EDTA treated cells showed a 
statistically significant increase in Caspase levels when corrected for cell number. The 
fluorescence detected is certainly from the Caspase cleaving the non-fluorescent substrate to 
the fluorescent product, due to the inhibition by the Caspase inhibition that was performed 
simultaneously. Similarly, flow rate data shows no statistically significant difference between 
EDTA treated cells and those treated with ZA. In an attempt to explain these facts, there are 
several hypotheses that may be correct. With regard to the flow rate data, it may be that 
cation chelation produces a cytostatic effect in this particular cell line. For the Caspase data it 
may that EDTA treated cells are only just entering a state of apoptosis at this point, so the 
Caspase levels would be highest, or possibly that due to a narrow therapeutic window, 
226.8pM and 453.6pM ZA has caused such significant cytotoxicity that there are insufficient 
cells, and therefore Caspase, to perform an accurate reading. The main interest is the conflict 
between the Caspase data and the binding of Annexin V in MZ RCC 1770, treated for 96 
hours with 113.4pM EDTA, to which a possible explanation could be that ZA inhibits the 
prénylation of proteins, shifting the cytostatic cation chelation effect into a fully cytotoxic 
effect.
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Figure 5.3.2.10 Cell cycle analysis o f MZ RCC 1770 cells treated with ZA. MZ RCC 1770 cells were exposed 
to increasing concentrations o f ZA for 48 (top and second from top) and 96 hours (second from bottom and 
bottom), the data was then either expressed as either the raw percentage o f cells (top and second from bottom) 
or as the percentage change compared to the cells treated with PBS (second from top and bottom). Due to time 
constraints the upper graphs represent n=l, however, the lower graphs represent n > 3 with the error bars 
denoting SEM. Discussion for the exposure o f MZ RCC 1770 cells to ZA, for 48 hours, will follow below. 
Analysis with 2way ANOVA with Bonferroni post-test, with PBS treated cells as the control showed 
statistically significant increases in the percentage o f cells in the Gq/Gi phase when treated with 25pM and 
50|iM ZA (a = p < 0.0001, b = p < 0.0001) and decrease in the percentage o f cells in the Gi/M phase (e = p < 
0.01). Analysis by Iway ANOVA of the raw data expressed as the percentage change compared to PBS yields 
further results, the increase in the levels o f Gq/Gi is statistically significant (d = p < 0.01) but it also increases in 
a linear fashion (p < 0.001, r^  = 0.7052). The decrease seen in G2/M levels is also statistically significant (e = p 
< 0.05) and linear (p < 0.01, r^  = 0.5284), similarly the decrease in S phase levels, which were not significant in 
the raw data, is statistically significant (f  = p < 0.01) and linear (p = 0.0001, r^  = 0.7683).
Only superficial conclusions can be drawn from the 1 data set of MZ RCC 1770 cells 
exposed to ZA for 48 hours, it would seem that like that of 96 hours both the percentage of 
cells in G2/M and S phase decrease. However, there is a great increase in the number of cells 
that are judged to be in sub-Go/Gi, much greater than that of 96 hours. One hypothesis for 
this sub-Go/Gi (see figure 5.3.2.11b) is genetic and mitotic instability, those most unstable 
have apoptosed in the following 48 hours and are eliminated from the stringent gating 
procedure. However, a large increase is also shown for EDTA (see figure 5.3.2.11b), but the 
sub-Go/Gi peak is not as defined as those for lOOpM ZA (figure 5.3.2.11c). What is peculiar 
is how close the sub-Gi/Go peak is (to the actual Gi/Go peak) and how well defined it is; this 
has led to debate as to whether it is actually sub-Gi/Go at all. Sub-Gi/Go is generally 
characterised by DNA fragmentation which would provide a large peak lower in the 
fluorescence, which is not seen in this case. It would appear that the exposure of MZ RCC 
1770 cells to ZA for 96 hours perturbs the cell cycle, leading to a dose responsive increase in 
cells in Go/Gi and decreases across all other phases. This strongly suggests that there is cause 
for cells to be held at the checkpoint before synthesis of DNA, this checkpoint’s purpose is to 
ensure there are sufficient resources and lack of DNA damage before initiation of a very 
depleting process. Apoptosis data from figure 5.3.2.9 suggests that there should be some 
apoptosis at these concentrations of ZA, but should be barely detectable above the PBS 
baseline, a result that is not categorically confirmed by the sub-Go/Gi fraction, but as 
previously mentioned, this fraction is not a representative of the spectrum of cells being 
analysed, due to tight gating procedures.
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Figure 5.3.2.11 Example o f MZ RCC 1770 histograms of DNA comem. Cell cycle analysis o f MZ RCC 1770 
after 48 hours (a = PBS treated, b = lOOpM EDTA, c = lOOpM ZA). Note the very little sub-Go/Gi fraction in 
(a), increased sub-Go/Gi fraction with spectrum of fragmentation in (b) and increased sub-Go/Gi fraction with 
defined sub-Go/Gi DNA content in (c).
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5.3.3 The effect of VEGF on the proliferation of renal cell lines
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Figure 5.3.3.1 The response o f Renca cells to VEGF. Renca cells were plated at lx l07m l on a 96 well plate and 
exposed to increasing concentrations of VEGF. Proliferation was measured by MTS assay every 24 hours (A- 
D), from 24 hours through to 96 hours. No significant difference, from the untreated cells, was noted at any 
concentration or time point. Error bars denote SEM and n=2.
Treatment of Renca cells (murine renal carcinoma) with recombinant murine VEGF- 
A, elicits no change in proliferation rate, compared to PBS treated controls. This suggests 
that, although for many types of renal tumour, the VEGF axis is important for vasculature, it 
does not stimulate the MAPK pathway in an autocrine manner. Recent reports have shown 
that VEGFRl is present in Rene a cells, and is phosphorylated when these eells are challenged 
with VEGF (Lee, Karl et al. 2010), this lack of increased proliferation could be due to the 
pathway either being already saturated with positive signals or that there is regulation of this
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pathway through some mechanism to dampen these signals, possibly due to a reduction in 
neuropilin-1 presence at the cell surface.
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Figure 5.3.3.2 The response of 769-P cells to VEGF. 769-P cells were plated at IxloVml on a 96 well plate and 
assessed by MTS proliferation assay for response to VEGF over 24 (A), 48 (B) and 96 (C) hours, error bars 
denote SEM and n=2.
As with Renea, 769-P (human clear cell renal carcinoma) cells do not increase their 
proliferation rate in response to recombinant human VEGF-A, possibly for the reasons 
mentioned previously. This lack of response to VEGF challenge allows us to assume that any 
response in tumour models that is different is directly due to the effect on endothelial cells. 
As was shown in Figure 4.3.3.5, concomitant treatment with recombinant VEGF increased 
the resistance of endothelial cells to ZA-induced inhibition of endothelial cell proliferation.
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5.3.4 The effect of the vascular disrupter, DMXAA, on Renca cells in vitro
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Figure 5.3.4.1 The exposure o f Renca cells to DMXAA over prolonged periods (24-96 hours) has an inhibitory 
effect on proliferation in vitro. ICso’s were calculated using Calcusyn (Biosoft, Cambridgeshire), to the degree 
of accuracy acceptable for tissue culture, error bars indicate SEM, n = 3.
5, 6-Dimethylxanthenone-4-acetic Acid (Vadimezan, DMXAA; Sigma-Aldrich, 
Dorset) is a tumour vasculature disrupting agent (Ching, Cao et al. 2002) whieh has been 
trialled in small cell lung caneer. DMXAA causes apoptosis of tumour associated endothelial 
cells, as well as increasing levels of immune system activating cytokines, espeeially, tumour 
necrosis factor a (Ching 2004, 906 REF). Its purpose here is to be used in vivo to compare 
ZA against. In order to establish a suitable dosing quantity, Renea cells were assayed for the 
eoneentration that would inhibit their proliferation in vitro, a dose less than this would only 
affect endothelial cells. The 96 hour mean IC50 is 0.02667mg/ml in lOOpl (2.667pg), 
suggesting that a 50pl dose at 0.25mg/ml (12.5pg) should mostly just effeet the endothelial 
cells in the tumour.
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5.3.5 Treatment of in ovo renal carcinoma tumour model with ZA
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Figure 5.3.5.1 Treatment of in ovo Renca tumours with ZA. Renca in ovo tumours were grouped on day 0 and 
treated once intra-tumourally with 50pl o f the following; PBS, 0.25mg/ml DMXAA, 50ng/ml recombinant 
murine VEGF, 50ng/ml rmVEGF and lOOpM ZA or lOOpM ZA. Animals were then terminated on day 3 results 
are of 3 independent experiments with n>4 for each group, error bars denote SEM.
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Figure 5.3.5.2 Relative tumour growth (compared to Day 0) o f  Figure 5.3.5.1. Renea in ovo  tumour 
growth curves as in Figure 5.3.5.1 but expressed as relative tumour growth.
The treatment of in ovo tumours with what has previously been determined to be a 
moderate anti-angiogenic therapy was proved to be difficult with the short time-course 
involved. The above graphs showing both actual and relative Renca tumour volume in ovo, 
show no significant difference between that of any of the treatments and that of PBS (by one­
way ANOVA, Dunnetf s post-test with PBS as the control). With this type of tumour, this is 
not unexpected, renal tumours are notorious for their well vascularised nature, suggesting that 
they secrete a great spectrum of angiogenic factors, suggesting that they would be difficult to 
treat, especially in a short time course. All tumours were collected at the end of each 
experiment, bisected, with half being preserved in RNA later and the other half eventually 
being paraffin blocked.
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5.3.6 Treatment of in vivo renal carcinoma tumour model with ZA
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Figure 5.3.6.1 Treatment o f in vivo Renca tumours with ZA. Renca in vivo tumours were grouped on day 0 and 
treated once intra-tumourally with 50pl o f the following; PBS, 0.25mg/ml DMXAA, 50ng/ml recombinant 
murine VEGF, 50ng/ml rmVEGF and lOOpM ZA or lOOpM ZA. Animals were terminated on day 3, results are 
of 2 independent experiments (figures 5.3.6.1A and 5.3.6.IB) with n=4 for each group, error bars denote SEM; 
figure 5.3.6.1C represents the mean o f the 2 independent experiments.
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Treatment Treatm ent
Treatment
Figure 5.3.6.2 Relative tumour growth o f  Figure 5 .3 .6 .I . Renca in vivo  tumour growth curves as in 
figure 4.3.6.1 but expressed as relative tumour growth. * denotes p < 0.05 analysed by Iw ay A N O V A  
with D un netf s post-test with PBS as control. A s in figure 5.3.5.2, figures 5 .3 .6 .2A  and B represent 
two independent experiments w hilst figure 5.3.6.2C  represents the mean.
This murine experiment is a direct mirror of the in ovo experiment performed 
previously, only different in the number of repeats performed. Like in ovo there was only a 3 
day time course from the grouping of tumour bearing animals into treatment groups to the 
termination of the experiment. In this ease there was no significant difference between any of 
the treatments and the control group (one way ANOVA with Dunnetf s post-test with PBS as 
the control condition) when expressed as direct tumour volume. However, when the data was 
expressed as relative to initial tumour volume, there was significance in the decrease 
observed in the DMXAA treatment group compared to PBS (p < 0.05 by one way ANOVA 
with Dunnetf s post-test with PBS as the control condition). Like in ovo, these animals were 
dosed with 50pl intra-tumourally once on day 0. It was disappointing that no significant
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difference was seen with ZA; however, this was not unexpected with the previous in ovo and 
in vitro data. A hypothesis for the efficacy of DMXAA in this in vivo flank model, rather than 
in ovo, could be thus; since tumour cells are engrafted into the chicken embryo at a very early 
stage in development, the vessel architecture that develops is not as representative of human 
disease, in that it is rather stable and distinctly less friable. However, with the murine flank 
model, tumour cells are embedded in adult animals, they release angiogenic growth factors, 
which degrade the basement membrane and mobilise endothelial cells from the existing 
vascular bed to allow perfusion of the tumour. These blood vessels are stimulated with 
repeated, prolonged and high dose angiogenic growth factors, making the overall architecture 
very unstable. This difference may be the reason why DMXAA, a vascular disrupter, 
produces a significant decrease in tumour volume in this short time course experiment. VEGF 
was included as a treatment group in this experiment to act as a positive control, a treatment 
that would increase tumour size. The result that there was no significant difference (either in 
actual nor relative tumour volume) between VEGF and PBS is an unexpected outcome. The 
situation may be that Renca tumours already secrete a large quantity of VEGF and stimulate 
ECs to enable vascularisation and tumour growth, as such, it may not be possible to further 
raise this level (artificially), hence no response. Further work to quantify the plasma 
concentrations of VEGF in Renca bearing BALB/C mice compared to control mice would 
provide a definitive conclusion to this work.
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Figure 5.3.6.3 Prolonged treatment of in vivo Renca tumours. Renca in vivo tumours were grouped on day 0 and 
treated three times per week, intra-tumourally with SOpl o f the following; PBS, 0.25mg/ml DMXAA, 50ng/ml 
recombinant murine VEGF, 50ng/ml rmVEGF and lOOpM ZA or lOOpM ZA. Animals were terminated on day 
22 or when the tumour exceeded 15mm in any dimension, results are of 2 independent experiments (figures 
5.3.6.3A and 5.3.6.3B) with n>8 for each group, error bars denote SEM; figure 5.3.6.1C represents the mean of 
the 2 independent experiments.
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Figure 5.3.6.4 Relative tumour growth of Figure 5.3.6.3. Renca in vivo tumour growth curves as in figure
5.3.6.3 but expressed as relative tumour growth. Figures 5.3.6.2A and B represent two independent experiments 
whilst figure 5.3.6.2C represents the mean.
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These experiments were designed to discover ZA’s capability as an anti-angiogenic 
treatment in an established murine flank tumour model of renal carcinoma. With prolonged 
treatment (three times per week) this dose of ZA, nor any of the other treatments, did not 
reduce tumours nor slow their growth in a significant manner. However, in one experiment it 
was noted that some animals dosed with VEGF or VEGF and ZA, demonstrated better 
tumour control than their otherwise treated counterparts. The hypothesis for this is that this 
experiment was performed in BALB/C mice, which are immune-competent and were treated 
with high doses of recombinant murine VEGF, produced in E. coli. It is possible that the 
differential glycosylation or that the high dose lead to the processing of the rmVEGF and the 
generation of an auto-antibody against the peptide. A recombinant, humanised anti-VEGF 
monoclonal antibody against VEGF is aheady in clinical use (Avastin, Bevacizumab) and as 
such, the auto-antibody helped to restrict the angiogenesis and suppress tumour growth in 
approximately three animals. To this end, terminal blood was drawn from these animals and 
could be subjected to a VEGF-baited ELISA to determine the levels of anti-VEGF antibodies 
and compare them against untreated controls. It has been suggested that some of the largest 
tumour volumes belong to the anti-vaseular treatments (ZA and DMXAA), though this is 
true, these maximal volumes represent singular animals which so not accurately represent the 
mean tumour growth and were culled immediately after measurement.
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Figure 5.3.6.5 Survival curves of Renca in vivo tumour growth of Figure 5.3.6.3. Figure 5.3.6.5A corresponds to 
figure 5.3.6.3A  and figure 5.3.6.5B corresponds to figure 5.3.6.3B, error bars denote SEM, n>8 for each group.
No significant difference in survival between treated and untreated was observed, 
however this was probably due to insufficient numbers of animals for this type of analysis.
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5.4 DISCUSSION
This body of work establishes I C 5 0  concentrations for three renal cancer cell lines. As 
was hoped, these values were higher than that of a cell line of an endothelial nature at all 
time-points investigated. Using three methods, at two time-points, we attempted to elucidate 
the mechanism by which ZA causes inhibition of growth. Unfortunately, there does not 
appear to be a singular mechanism by which ZA affects these cell lines. The in vitro I C 5 0  
concentration of the vascular disrupter, DMXAA was also established for Renca cells. It was 
also shown that renal cell lines do not increase their proliferation in response to VEGF 
treatment. The in ovo and in vivo experiments showed that ZA did not affect tumour growth 
in either of the models, nor did it improve survival time. It would appear that DMXAA 
treatment slows the growth of this tumour model, but only in a short time scale.
The cytotoxic effect of ZA on multiple renal cell lines has been established in 
previous reports as well as this chapter. In order of most resistant to most sensitive to ZA- 
induced reduced proliferation is as follows; MZ RCC 1770, Renca then 769-P. The IC50 for 
769-P established here is approximately twice that previously reported (Pandha, Birchall et 
al. 2006). However, this difference could be accounted for by the difference in seeding rate (2 
vs. IxlO^^/ml). The IC50 concentration for Renca demonstrated is within the error of 
previously reported experiments (Soltau, Zirrgiebel et al. 2008). This lends credence to this 
result as Soltau et a l utilised a completely different readout for proliferation, 
Bromodeoxyuridine (BrdU) incorporation -  DNA synthesis, suggesting ZA does effectively 
inhibit the proliferation of Renca cells in vitro at these coneentrations. No previous reports 
have been published as to the effect ZA has on the proliferation of MZ RCC 1770 cells, but 
with the low levels of variation between repeat assays, confidence in this results is not 
unfounded. Pandha et a l treated 769-P cells for 72 hours with lOOpM ZA and then used a 
FACS version of the Terminal deoxynucleotidyl transferase dUTP nick-end labelling 
(TUNEL) assay to determine levels of DNA fragmentation and infer levels of apoptosis. At 
72 hours, lOOpM ZA (approximately four times their measured IC50 concentration) caused 
74.6 ±20.74% (±SD) of cells to apoptose compared to 1.5 ±0.2% (±SD) for untreated cells. 
Unfortunately, our results, based on the binding of Annexin V, do not match these results. At 
48 hours, by our results, lOOpM ZA would only induce apoptosis in approximately 1.5% of 
cells. At 96 hours, lOOpM ZA would only induce apoptosis in 3% of cells. This conflict 
between studies is rather perplexing. DNA fragmentation is judged to be one of the final 
stages in apoptosis, whilst Annexin binding is one of the earliest. One possible explanation as
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to the difference between studies is that Pandha et a l used serum-free media for 
experimentation, whilst we utilised serum reduced (2%). This lack of serum signals (pro­
proliferation etc.) could prime 769-P cells for apoptosis much more strongly than when these 
signals are present at a low concentrations. Our use of the Caspase-3 assay also helps to allay 
possible fears that this set of experiments are fundamentally different, higher levels of ZA do 
induce Caspase cascade activation, one of the hallmarks of apoptosis. Without previous 
reports to confirm the data of Renca and MZ RCC 1770, the validity of the data can only be 
judged by the variation and experimental error of the data. Generally, Renca cells are 
susceptible to cation chelation induced apoptosis at 48 hours (demonstrated by both Annexin 
V binding and caspase-3 activation) and at 96 hours (demonstrated by Annexin V binding, 
but not by caspase-3 activation). The lack of activation of caspase-3 for all the treatments of 
Renca cells at 96 hours suggests one of the following scenarios: that there were insufficient 
cells in these assays to correctly demonstrate caspase-3 levels, cell number was greatly 
different from PBS to other treatments or that cation chelation switches from Caspase- 
dependent to Caspase-independent in the space of 48 hours. Of the 3 scenarios, given the laek 
of a critical step in the caspase-3 activation assay (a cell count before commencement), the 
second is most likely, further work incorporating a cell count before the lysis step would 
confirm or refute these findings. The results for MZ RCC 1770 was acceptable, however, 
there were some possible inadequacies in data acquisition. The calculated 48 hour I C 5 0  
(440pM) was high meaning that when we used four times the I C 5 0  concentration to further 
investigate, this reached above half the concentration of the supplied ZA (~3mM). This high 
concentration require large volumes of ZA to be used in each experiment, as such due to a 
lacking supply, this experiment was only performed twice. The Annexin V binding data is 
reproducible; however, the caspase-3 activation data for 440pM ZA is not significantly 
different firom that of 440pM EDTA, suggesting the possibility that this caspase-3 activation 
may be cation chelation induced. The findings for 96 hours are slightly contradictory, the 
caspase-3 activation for 113.4pM EDTA is much greater than that of the corresponding ZA 
concentration, but this is not reflected in the Annexin V binding data. It would appear that 
MZ RCC 1770 cells spend little time in early apoptosis (Annexin V positive, DNA negative) 
and move straight to late apoptosis (Annexin V and DNA positive), under increased 
concentrations of ZA, more cells are deemed to be late apoptotic. Once again it may be that 
this increased level of Annexin V binding is due to high levels of cation chelation, as such, 
further investigations, using corresponding concentrations should be performed to confirm 
the validity of these results. Further work should include repeats of MZ RCC 1770 treated
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with ZA: Annexin V binding and Caspase assays, as well as cell cycle analysis. It should be 
noted that any repetition of the Caspase assay should now include a step for cell counting 
before lysing the cells, with the assay protocol stating that the optimum cell number is 
approximately 1x10^ cells. To further investigate ZA’s effects on renal cancer cell lines, more 
renal cell lines could be used.
The effect of ZA on the cell cycle of renal carcinoma cells must also be investigated 
as it may shed light on whether ZA has any cytostatic effect. Renca cells show decreased 
Go/Gi levels in response to ZA; however, this cannot be purely attributed to ZA as EDTA is 
noted to have the same effect at 48 hours. The difference between ZA and EDTA at 48 hours 
is that EDTA induces a great increase in the sub-Go/Gi fraction indicating apoptosis, a result 
that is corroborated by the caspase-3 activation data. Interestingly, the accumulation of cells 
in the S-phase at 96 hours, although not significant in the raw data, is when it is expressed as 
percentage change compared to PBS. 769-P cells showed an increase in sub-Go/Gi cells at 48 
hours, although not significant compared to EDTA, and a general decrease in S and Gi/M 
phases, possibly suggesting incorrect cytokinesis being the result of ZA treatment. However 
at 96 hours, this sub-Go/Gi increase has been resolved (possibly due to gating eliminating the 
partly deteriorated cells) and an increase in S-phase is evident. MZ RCC 1770 showed large 
percentages of cells in sub-Go/Gi, however, so did EDTA at 48 hours, suggesting this is 
purely a chelation effect. At 96 hours there are interesting changes in the cell cycle, a Go/Gi 
stall, cells do not enter S-phase and those aheady at that point continue to cycle. Overall this 
cell cycle data could be improved by further repetition (especially MZ RCC 1770 at 48 
hours) and the inclusion of an EDTA comparator (96 hours, all cell lines, an oversight on my 
part due to the experiments being performed 18 months previous, at which point I still lacked 
an appreciation of the effect chelation can have). Finally it should be noted that the 
concentration of ZA used in these experiments are significantly less than the MTS identified 
I C 5 0  (with the exception of 769-P at 96 hours), so any effect that ZA has at these 
concentrations would only be compounded at higher concentrations, approaching the I C 5 0 .
Recent reports (Lee, Karl et al. 2010) suggest that the differential activation of 
VEGFRl and VEGFR2 control the metastasis location in renal and colonic carcinoma (Renca 
and CT26 cells respectively). These results showed no increase in proliferation (at 12 hours), 
in a serum starved environment, in response to VEGF. The extended time course, shown here 
categorically shows no increase in proliferation, even in the presence of high concentrations 
of VEGF (up to 50ng/ml). This experiment was to demonstrate that in the animal (multiple
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tissue types and systems involved in tumour growth) models that will be used, that any 
increase in tumour size will be due to increased blood supply and not direct, pro-proliferation 
signals to the tumour cells.
Recent trials of DMXAA as a combination treatment with paclitaxel and carboplatin 
as a first line treatment for stage Illb/IV non-small cell lung cancer failed (Lara, Douillard et 
al. 2011); this doesn’t detract from its in vitro and in vivo pre-clinical efficacy. DMXAA’s 
use here, at the dose estimated, will hopefully be mostly anti-angiogenic, but there may well 
be some direct anti-tumour effects. One notable issue is that it has been shown that DMXAA, 
as a vascular disrupting agent, produces a short term effect (approximately four hours), we 
hope to counteract this using a multiple dosing schedule similar to that of ZA to maximise 
effect.
Previous reports have established that the Cmax of ZA (Chen, Berenson et al. 2002) is 
approximately l-3pM in patients, which corresponds to an effective in vitro dose of 100- 
300nM, which ZA achieves as its primary purpose as osteoclast inhibitor (Evans and 
Braidman 1994). Results shown in this chapter demonstrate that renal carcinoma cells are at 
least three times less sensitive to ZA induced cell death than endothelial cells. This data 
shows that at these concentrations, divalent cation chelation cannot be excluded as the main 
inducer of apoptosis. Although clinically relevant doses of ZA have little effect, higher, 
though not especially cytotoxic, concentrations begin to have an effect on the cell cycle and 
may contribute to a cytostatic effect. No response to VEGF stimulation, in terms of 
proliferation, suggests that these cells will be ideal in animal models to determine whether 
ZA has a pronounced anti-angiogenic effect, without any anti-tumour effects. Establishment 
of DMXAA dosages suitable for in vivo experiments will allow us to compare ZA’s modest 
in vitro anti-angiogenic capability with a compound specially designed to affect the 
vasculature of tumours and so judge ZA’s pre-clinical anti-angiogenic effects.
Multiple reports have purported ZA to have anti-angiogenic properties with doses not 
achievable clinically; there are few reports which demonstrate these responses at doses 
achievable in humans. Our attempts to model and treat human tumourigenesis (utilising 
multiple models) with ZA were unsuccessful in generating any difference from the PBS 
control in terms of both tumour volume and survival time. The direct comparison between in 
ovo and in vivo ZA treatment on a short time course demonstrated the validity of the in ovo 
model. The dose of ZA used (50|il at lOOpM or ~65pg/kg, assuming a 25g animal, well
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within the no observable adverse effect level for multiple dosing and since administration 
was intra-tumoural, the bio-availability should be close to 100%) should have the desired 
effect on endothelial cells, without inducing cytotoxicity in the tumour cells, based on in vitro 
results. Also, this dose of ZA is very representative of the dose which is clinically possible 
(~60(j,g/kg). In order to establish anti-angiogenic properties, mean vessel density staining 
should have been performed, however attaining a functioning antibody proved difficult. 
Antibodies that would detect both chicken and mouse CD31, CDS 1/61 and VE-cadherin (all 
from Abeam, Cambridge) were trialled and resulted with the following; no binding, no 
binding and non-specific binding respectively (data not shown). Although dual species 
antibodies would be ideal, it would be possible to use species specific markers to assess 
tumour vascularisation. As was established previously, Renca cells do not undergo changes in 
proliferation when stimulated with VEGF. However, in the tumour models no significant 
increase in tumour growth was observed when injected with VEGF, this suggests that the 
endothelial cells were maximally stimulated with this growth factor previous to its 
introduction. Increasing the treatment frequency and prolonging the time course of the 
experiment did show any significant difference between PBS and any of the treatment 
groups, in terms of both tumour volume and survival. A recent report using orthotopic Renca 
tumours demonstrated that DMXAA could induce tumour necrosis, but did not affect tumour 
volume compared to controls (Ellis, Shah et al. 2012). However, the dose used in this 
experiment is approximately 1/50^  ^ compared to that used by Ellis et a l, as well as the 
difference in delivery (intra-tumoural versus intra-peritoneal) and dosing schedule (3 times 
per week versus once per week). Our dose levels were based on in vitro data, which will 
hopefully be validated once the immunohistochemistry is performed. Further work using the 
terminal plasma extracted from the mice will help to determine the level of immune system 
activation and whether any anti-VEGF antibodies were produced and whether that was 
responsible for the prolonged survival of mice treated with VEGF. Further work should 
include; the identification and use of an endothelial-specific marker for 
immunohistochemistry for staining of in ovo and in vivo tumours, as well as classical H&E 
staining and staining for cell proliferation or death (PCNA or Caspase). It would also be 
advantageous to perform a VEGF baited enzyme linked immunosorbent assay (ELISA) to 
test for auto-anti-VEGF antibodies. Finally, investigation of the genes identified by 
microarray analysis, as important in tumour formation, at the RT-qPCR level to see if there is 
any alterations to further validate the comparison of in ovo to in vivo.
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Chapter 6 
Final Discussion
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6.1 FINAL DISCUSSION
In one form or another, the chorioallantoic membrane assay has been used for many 
years to study embryology, evolutionary biology, cancer and used, industrially, in vaccine 
production. The method presented in this body of work for a variation of the CAM assay is a 
product of a great deal of refinement, which produces reproducible tumour growth. To date, 
many tumour types have been attempted in ovo (Appendix 1), this report is the first instance 
of Renca growth in ovo. The other cell lines used in this report have been previously 
described and the histology presented here is similar. Few reports discuss engraftment 
success or the growth rates of engrafted tumour cells, the results presented here help to 
further establish this variation of the CAM assay as a suitable tumour model. Although 
previously described (Khanal, Oh et al. 2011; Kim, Hur et al. 2011), only a recent publication 
showed HT-29 in ovo histology (Thapa, Kang et al. 2012) which seems to agree with the 
histology presented here. LoVo has also been previously used (Yang, Lin et al. 2005), but 
again, only recent publications (Durupt, Koppers-Lalic et al. 2012) demonstrate the 
histological architecture, which was replicated in the results presented here. PC-3 cells grown 
in ovo have been well documented in multiple reports (see Appendix 1), histology of these 
tumours presented here is similar to that of the literature (Kunzi-Rapp, Genze et al. 2001), 
except, we managed to develop macro tumours. LnCAP has also been documented as 
growing in ovo (see Appendix 1) and the histology presented in the literature (Kunzi-Rapp, 
Genze et al. 2001) matches that which was observed here. Again, the generation of macro 
LnCAP tumours in this body of work, strengthens the argument for the CAM assay’s use as a 
tumour model and opens up opportunities for intra-tumoural treatment. The use of 
luminescence to measure tumour growth and the cell viability is well utilised in vivo, but 
there is little to no mention of it in ovo within the literature. The work presented here proves 
that the CAM assay is robust enough to support this method of tumour assessment. GFP has 
been used for in ovo fluorescence (Lugassy, Kleinman et al. 2004), the insertion of the gene, 
here, using an oncolytic herpes virus construct, had high background at the time of 
measurement. It would appear that engraftment of cells with this gene aheady present, would 
be the most effective approach. Viral therapy of cancer is still an avenue of treatment that is 
under intensive research. Reovirus has been trialled in a wide spectrum of cancers, but has 
not been assessed as an in ovo treatment. Although basic in its experimental design, the 
exposure of LoVo in ovo tumours to Reovirus, combined with the complex architecture that 
LoVo in ovo tumours develop, suggests that this model has promise in viral testing. The
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cultivation of tumour cells in tissue culture is a great environmental change from the tissue 
these cells originated from. Their survival implies a great number of genetic changes for 
survival in an environment vastly different from that of the body. This is the reason why 
murine models are considered the gold standard of cancer models, there is less environmental 
pressure on gene expression, so they are likely to behave more like the original cancer. From 
this, we hoped to examine the gene expression changes which occur in a tumour cell’s 
adaptation to the chorioallantoic membrane growth environment. Few microarray analyses 
have been performed in conjunction with the CAM assay and none with this experimental 
design. As was expected, there were a great number of genes which were differentially 
expressed in each cancer cell line’s adaptation to the CAM assay as a growth environment. 
Identification and validation of genes with similar expression profiles, across multiple 
cancerous cell lines, of varying origin will allow the elucidation of a genetic profile that may 
have implications in tumour development. With no similar experimental design in the 
literature, comparisons are rarely valid. Only one report mentions both the CAM assay and 
IGFBP3 (Oh, Kim et al. 2006), however, the CAM assay that was utilised did not involve 
tumour cells. Other IGFBP genes; 2 (Azar, Azar et al. 2011) and 7 (Chen, Yoo et al. 2011; 
Pen, Durocher et al. 2011), have been associated with the CAM assay. Azar et al. showed 
that IGFBP2 increases neo-vascularisation in neuroblastoma cells by upregulation of VEGF. 
Conversely, Pen et al. showed that IGFBP7 improved neo-vascular stability and possibly 
acted as a tumour suppressor in neuroblastoma. A finding that was supported by similar 
activity in hepato-cellular carcinoma, reported by Chen et a l. Overall, this would suggest that 
the IGF axis plays an important part in the development of in ovo tumours. No reports in the 
literature suggest a link between SENP6 and the CAM assay. Further work should establish 
whether the decreased levels observed in ovo contribute to tumour growth. The inability to 
validate NCOA3 by qRT-PCR was disappointing as NC0A3 is a transcription factor that is 
heavily involved in cancer and would have made an ideal candidate gene for further 
investigation. This negative result was, however, not entirely unexpected. As discussed 
previously, some microarray results are purely artefactual, hence the requirement for 
validation with another method of assessing mRNA levels. The growth of head and neck 
cancer biopsies has already been demonstrated in the literature (Gronau, Thess et al. 2006; 
Hoppenheit, Huttenberger et al. 2006), whose results we sought to emulate. The lack of 
success may just be a function of the limited number of tumour samples (Gronau et al. 
utilised 30 patient samples). This lack of success in results, though disappointing, does not
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detract from the success of developing a suitable method for the disaggregation of patient 
tumour tissue.
Comparison between the results of endothelial cells treated with ZA in the literature 
and the results presented here is difficult due to different endothelial cell origin, treatment 
protocol and assay selection. Comparison can be found in Table 6.1.1
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Zoledronate’s effect on cancer cells, both in vitro and in vivo, is still under 
intense scrutiny. Whether ZA has anti-angiogenic capabilities in a Renca tumour 
model was investigated by Soltau et a l The in vivo experiments performed by Soltau 
et a l suggest a dosing schedule of 200pg ZA/kg of mouse per day (since day 1 of 
tumour implantation), elicits an anti-angiogenic response. Assuming a 70kg human 
(with a frilly functional renal system), the maximal dose for anti-bone resorption is 
~65pg/kg per month, a large difference in drug administed compared to the pre- 
clinical model. The treatment schedule utilised here (3 X 65pg/kg doses per week, 
once tumours are detectable by palpation) is not as aggressive as Soltau et a l, but is 
still more than a clinical dose. This bridge between pre-clinical and clinical would 
suggest that clinically achievable doses of ZA have little to no anti-angiogenic effect 
in this model of renal carcinoma. Previous in vitro work on ZA’s effects on 769-P 
cells failed to establish a definitive 48 hour I C 5 0 ,  which this study also provides. 
Pandha et a l assessed ZA’s apoptotic effect on 769-P cells by TUNEL assay and 
found an increase over the untreated control, the experiments presented here, 
incorporating a chelator control, only showed apoptosis at 96 hours, with 4 times the 
I C 5 0  dose.
This body of work has refined an existing model for tumour neo-angiogenesis, 
supplied work that suggests ZA may be a treatment which may possess anti- 
angiogenic properties and then called that efficacy into question in a pre-clinical 
model. The efficacy of ZA as an anti-angiogenic treatment at clinically relevant 
concentrations and dosing schedules requires fiirther elucidation. There may be 
realistic possibilities of fiirther exploiting the anti-tumour potential of ZA through its 
effects on angiogenesis, as well as its direct anti-tumour effects and improvement of 
cancer associated bone disease.
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6.2 Further Work
Further work for Chapter 3:
• Attempt inoculations of further renal and colorectal cell lines in the CAM 
assay
• Transfect a suitable cell line with GFP and/or luciferase and assess tumour 
level by fluorescence or luminescence
• Retest the ability of Reovirus to infect Renca cells
• Investigate Reovirus treatment of LoVo in ovo after inoculation with an anti- 
Reoviral antibody
• Assess cell viability in LoVo in ovo tumours treated with Reovirus, 
specifically IHC for PCNA or Caspase
• A microarray of in vitro LoVo cells, in vitro LoVo cells treated with Reovirus, 
in ovo LoVo tumours and in ovo LoVo tumours treated with Reovirus, may 
shed some light into the transcriptomic changes that occur with Reovirus 
infection
• Further cell lines should be analysed by microarray to further refine the model 
of genes whose regulation is altered in the in ovo environment
• Further cell lines to be assess for transcriptome changes in response to the in 
ovo growing environment
• Validation by qRT-PCR of more genes identified by microarray analyses 
across all tumour lines
• Track identified genes at the protein level by Western blot.
• Additional head and neck cancer biopsies, biopsies of other cancer types and 
possible treatment of successful tumours
Further work for Chapter 4:
• Further replication of HUVECs treated with ZA and assessed by Annexin V, 
caspase activation and cell cycle analysis
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• Repeat HUVECs treated with endostatin in vitro in basal media without 
heparin
• Repeat HUVECs treated with thalidomide in vitro after activation by 
CYP2C19
• Investigate the role of surface ATP synthase -  treatment with blocking 
antibody followed by ZA treatment
Further work for Chapter 5:
• Possibly using another chelator control e.g. EOT A in further experiments
• Repeat caspase activation assay experiments, incorporating a cell count before 
the lysis step
• Treat Renca cells with Z-VAD FMK (a caspase inhibitor) followed by ZA and 
assess Annexin and caspase levels to determine if ZA treated Renca cells 
apoptose independent of caspase
• Repetition of MZ RCC 1770 treated with ZA assessed by caspase assay, 
Annexin V and cell cycle analysis at 48 and 96 hours
• Repetition of all cell cycle analysis at 96 hours to include a chelator control
• Using a VEGF baited ELISA to detect murine auto-anti-VEGF antibodies
• H&E staining of tumour sections and specific staining for a marker of 
angiogenesis to assess ZA treated Renca tumours by mean vessel density
• qRT-PCR analysis of genes identified by the CAM microarray in Renca in 
vivo tumours to compare to the in ovo situation
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APPENDIX 1
Cancer Cell line Reference
Bladder UMUC2 (Shimada, Nakamura et al. 2009)
KU7 (Shimada, Nakamura et al. 2007; Shimada, Nakamura et al. 2009)
MGH
(Chin, Lau et al. 2007; Saw, Olivo et al. 2007; Chin, Heng et al. 2008; 
Chin, Thong et al. 2009)
UMUC6 (Shimada, Nakamura et al. 2007)
UMUC14 (Shimada, Nakamura et al. 2007)
Breast MCF-7
(Kim, Choi et al. 2009; Park, Park et al. 2009; Chien, O'Kelly et al. 
2011; Huwiler, Bourquin et al. 2011; Thapa, Lee et al. 2011)
TAMR-MCF-7 (Kim, Choi et al. 2009; Oh, Kim et al. 2010; Thapa, Lee et al. 2011)
MDA-MB-435 (Zhang, Yang et al. 2008; Bottos, Destro et al. 2009)
MCF-7/ADR (Kim, Cho et al. 2008)
MDA-MB-468 (Lester, Jo et al. 2007)
MDA-MB-231 (Baum, Hlushchuk et al. 2007; Chen, Chiou et al. 2007)
Cervical HeLa (Furumai, Uchida et al. 2010; Xiao, Fan et al. 2010)
MS751 (Zhai, Bommer et al. 2010)
GIN 612 (Zhai, Bommer et al. 2010)
Ca Ski (Zang, Sim et al. 2007)
Colorectal HCT116 (Kim, Hur et al. 2011)
HT-29 (Khanal, Oh et al. 2011; Kim, Hur et al. 2011 )
SW620 (Subauste, Kupriyanova et al. 2009; Ho, Wu et al. 2010)
SW480
(Demir, Dimmler et al. 2009; Demir, Naschberger et al. 2009; Subauste, 
Kupriyanova et al. 2009; Kmdija, Schmid et al. 2010)
HRT-18 (Kern, Untergasser et al. 2009)
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LS147T (Mulder, Castermans et al. 2009)
Colo-699N (Pastorino, Di Paolo et al. 2008)
LoVo (Yang, Lin et al. 2005; Durupt, Koppers-Lalic et al. 2012)
Fibrosarcoma HT-1080
(Connor, Subbaram et al. 2005; Deryugina, Zijlstra et al. 2005; Gu, 
Bailey et al. 2005; Madsen, Deryugina et al. 2006; Zijlstra, Seandel et 
al. 2006; Zijlstra, Lewis et al. 2008; Blouse, Botkjaer et al. 2009; Fortin, 
Wei et al. 2011; Fortin, Wei et al. 2011)
SSKII (Ismail 2008)
Gastric Biopsy (Osiac, Saftoiu et al. 2011)
Glioma U87-MG
(Pisati, Belicchi et al. 2007; Lin, Jan et al. 2008; Auf, Jabouille et al. 
2010; Jacoby, Dyskin et al. 2010; Durupt, Koppers-Lalic et al. 2012)
GI-LI-N (Pagnan, Di Paolo et al. 2009; Pastorino, Loi et al. 2010)
ACBT (De Magalhaes, Liaw et al. 2010)
LN229 (Brown, Staniszewska et al. 2008; Tallen, Farhangi et al. 2009)
U373 (Kem, Untergasser et al. 2009)
c6 (Parthymou, Lampropoulou et al. 2008; Sahin, Vercamer et al. 2009)
Biopsy (Balciuniene, Tamasauskas et al. 2009)
HTLA-230 (Pastorino, Loi et al. 2010)
D54-MG (Jacoby, Dyskin et al. 2010)
U118 (Durapt, Koppers-Lalic et al. 2012)
HNC SGT (Park, Moon et al. 2010)
biopsy (Gronau, Thess et al. 2006; Hoppenheit, Huttenberger et al. 2006)
CLS-354 (Hoppenheit, Huttenberger et al. 2006)
SCC-4 (Yang, Yang et al. 2008)
227
Hepatic HEp3(-GFP)
(Zijlstra, Lewis et al. 2008; Zhang, Schulte et al. 2010; Chang, Pieretti- 
Vanmarcke et al. 2011; Palmer, Lewis et al. 2011)
HEPG2 (Dai, Wang et al. 2007; Komi, Sogabe et al. 2010)
H epa-lclc7 (Buchler, Reber et al. 2009)
HCC biopsy (Ribatti, Belloni et al. 2008)
Leukemia Jurkat (Ganor, Grinberg et al. 2009)
K562 (Taizi, Deutsch et al. 2006; Zhou, Wang et al. 2007)
Lung H1299 (Mousa, Yalcin et al. 2012)
NCI-H446 (Wan, Chai et al. 2011)
A549 (Zhao, Miao et al. 2005)
NCI-H460 (Chin, Heng et al. 2007)
NCI-H526 (Chin, Heng et al. 2007)
H460 (Oh, Kwon et al. 2010)
H358 (Clarhaut, Gemmill et al. 2009)
TW12 (Durupt, Koppers-Lalic et al. 2012)
MZ2-MEL43 (Durupt, Koppers-Lalic et al. 2012)
Melanoma SK-Mel-28 (Jacoby, Dyskin et al. 2010)
MeWo (Zang, Sim et al. 2007)
B16
(Lugassy, Vemon et al. 2006; Hu, Roth et al. 2008; Kem, Untergasser 
et al. 2009; Mitchell, Pobre et al. 2010)
C8161
(Lugassy, Vemon et al. 2006; Lugassy, Kleinman et al. 2007; Lugassy, 
Torres-Munoz et al. 2009)
A375 (Estrada, Dong et al. 2009)
A2058 (Estrada, Dong et al. 2009)
MV3 (Brown, Staniszewska et al. 2008)
T-Hep3 (Estrada, Dong et al. 2009)
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Uveal lines (Berube, Deschambeault et al. 2005)
MEL2A (Durupt, Koppers-Lalic et al. 2012)
MelJuSo (Durupt, Koppers-Lalic et al. 2012)
Multiple
Myeloma
RPMI8226 (Chen, Shi et al. 2010)
Neuroblastoma HTLA-230 (Marimpietri, Nico et al. 2005; Brignole, Marimpietri et al. 2006)
UKF-NB-3 (Michaelis, Klassert et al. 2009)
SH-SY5Y (Pastorino, Brignole et al. 2006; Volland, Kugler et al. 2009)
Biopsy
(Marimpietri, Nico et al. 2005; Brignole, Marimpietri et al. 2006; 
Marimpietri, Brignole et al. 2007)
AON (Ribatti, Nico et al. 2006)
IMR-32 (Mangieri, Nico et al. 2009)
NB7 (Wrasidlo, Mielgo et al. 2008)
NB7C8 (Wrasidlo, Mielgo et al. 2008)
GI-LI-N (Pastorino, Di Paolo et al. 2008)
SK-N-AS (Hecht, Schulte et al. 2005)
SK-N-SHEP (Azar, Azar et al. 2011)
Osteosarcoma MNNG (Balke, Neumann et al. 2010)
U 20S (Balke, Neumann et al. 2010)
SAGS (Balke, Neumann et al. 2010)
Ovarian NuTu-19 (Mondon, Zeisser-Labouebe et al. 2011)
IGROV-1 (Chang, Pieretti-Vanmarcke et al. 2011)
0VCAR3
(Xia, Meng et al. 2006; Fang, Zhou et al. 2007; Xia, Meng et al. 2007; 
Pastorino, Di Paolo et al. 2008; Luo, Rankin et al. 2009)
229
A2780-1A9 (Manenti, Riccardi et al. 2005)
Pancreatic Panel
(Schneiderhan, Diaz et al. 2007; Beilke, Oswald et al. 2010; Jacoby, 
Dyskin et al. 2010)
Bxpc3 (Laklai, Laval et al. 2009)
MiaPaCa-2 (Buchler, Reber et al. 2009; Schneiderhan, Scheler et al. 2009)
PancTul (Vogler, Walczak et al. 2008; Vogler, Walczak et al. 2009)
PDAC (Dumartin, Quemener et al. 2010)
ASPC-1 (Buchler, Reber et al. 2009)
Capan-1 (Buchler, Reber et al. 2009)
Capan-2 (Buchler, Reber et al. 2009)
Prostate DU-145
(Konishi, Shimada et al. 2008; Shimada, Nakamura et al. 2008; Liu, Li 
et al. 2011)
PC-3
(Syrovets, Gschwend et al. 2005; Khodavirdi, Song et al. 2006; Fang, 
Ding et al. 2007; Fang, Zhou et al. 2007; Kuefer, Genze et al. 2007; 
Shimada, Nakamura et al. 2008; Matsumura, Shimada et al. 2009; 
Shimada, Nakamura et al. 2009; Estrada, Syrovets et al. 2010; Jacoby, 
Dyskin et al. 2010; Morad, Schmidt et al. 2011; Steinmetz, Ablack et al. 
2011; Wittig-Blaich, Kacprzyk et al. 2011)
LNCAP
(Khodavirdi, Song et al. 2006; Kuefer, Genze et al. 2007; Estrada, 
Syrovets et al. 2010)
C4-2 (Schütz, Schrader et al. 2011)
Renal HEK-293 (Beilke, Oswald et al. 2010)
Thryoid FTC-236 (Yalcin, Bharali et al. 2010)
h-MTC (Yalcin, Dyskin et al. 2010)
Appendix 1 A selection o f tumourigenic cell types which have been implanted in the CAM model over 
the last 6 years.
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APPENDIX 2
Treatment Description Reference
YCG063 Reactive oxygen species inhibitor (Kim, Park et al. 2011)
(8R)-3p,8-Dihydroxypolypoda- 
13E,17E,21-triene
Plant derivative (Morad, Schmidt et al. 2011)
15 -hy droxypurpurin-7-lactone 
dimethyl ester pdt
PDT (Lim, Nowak-Sliwinska et al. 
2010)
2,2-diphenyl-1-picryl hydrazine Flavone VEGFR2 antagonist (Rajesh, Harshala et al. 2010)
2-acetylfuro-1,4-nap thoquinone PDT (Kuete, Wabo et al. 2011)
4-Hydroxylonchocarpin Flavone inhibitor o f angiogenesis (Kuete, Ngameni et al. 2011)
6,8-Diprenyleriodictyol Flavone inhibitor o f angiogenesis (Kuete, Ngameni et al. 2011)
6-Prenylapigenin Flavone inhibitor o f angiogenesis (Kuete, Ngameni et al. 2011)
Acidic mucopolysaccharide from 
Holothuria leucospilota
Plant derivative (Zhang, Lu et al. 2009)
Acyclic retinoid (Komi, Sogabe et al. 2010)
ALKl-Fc Antibody (Mitchell, Pobre et al. 2010)
allyl isothiocyanate Plant derivative (Kumar, D'Souza et al. 2009)
Angiotensin-(l-7) Endogenous inhibitor of 
angiogenesis
(Soto-Pantoja, Menon et al. 
2009)
anti alpha6 integrin Antibody (Primo, Seano et al. 2010)
anti-gamma tubulin Antibody (Fortin, Wei et al. 2011)
anti-pNRXN Antibody (Bottos, Destro et al. 2009)
anti-SEMA3F Antibody (Clarhaut, Gemmill et al. 2009)
anti-UPAR AB Antibody (Buchler, Reber et al. 2009)
Beta-35 Transferrin derived peptide (Liang, Butterfield et al. 2011)
Beta-elemene (Chen, Lu et al. 2011)
beta-hydroxyisovalerylshikonin Plant derivative (Komi, Suzuki et al. 2009)
boron dipyrromethene derivatives for 
PDT
PDT (Lim, Thivierge et al. 2010)
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BTB domain o f promyelocytic 
leukemia zinc finger protein
Protein (Rho, Choi et al. 2010)
Cameroonian spices Plant derivatives (Kuete, Krusche et al. 2011)
cancer-associated LI cell adhesion 
molecule
Protein (Friedli, Fischer et al. 2009)
cardiotoxin III Snake venom (Chen, Yang et al. 2009)
CC-5079 Tubulin inhibitor (Vu, Miller et al. 2010)
celastrol Antioxidant (Zhou and Huang 2009)
cisplatin Chemotherapeutic (Pastorino, Loi et al. 2010)
compounds from Brazilian green 
propolis
Plant derivative (Hattori, Okuda et al. 2011)
Cowpea mosaic virus nanoparticles vimentin (Steinmetz, Ablack et al. 2011)
Cucurbitacin E Plant derivative (Dong, Lu et al. 2010)
CXCL4Ll/PF-4var47-70 Protein (Vandercappellen, Liekens et 
al. 2010)
Danshensu Far eastern medicine (Zhang, Chen et al. 2010)
Decursin and decursinol Far eastern medicine (Jung, Lee et al. 2009; Son, 
Kim et al. 2009)
dexamethasone Chemotherapeutic (Xia, Meng et al. 2007)
dibromotyrosine analogues Sponge derivative (Sallam, Ramasahayam et al. 
2010)
diphtheria toxin (Zhang, Schulte et al. 2010)
erlotinib TKI (Nowak-Sliwinska, Weiss et 
al. 2012)
extracellular protein kinase A Protein (Szkudlarek, Bosio et al. 2009)
Ferulic acid Antioxidant (Lin, Chiu et al. 2010)
galectin-1 Protein (Thijssen, Barkan et al. 2010)
Gancaonin Q Flavone angiogenesis inhibitor (Kuete, Ngameni et al. 2011)
GRP-78 Protein chaperone (Kem, Untergasser et al. 2009)
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GXl + TNF a Peptide and TNF-a (Chen, Cao et al. 2009)
Gynura segetum Plant derivative (Seow, Beh et al. 2011)
HangAmDan Far eastern medicine (Bang, Kim et al. 2011)
Hedyotis Diffusa Willd extract Far eastern medicine (Lin, Wei et al. 2011)
hexahydrocannabinol analogs (Thapa, Lee et al. 2011)
hexenyl ester o f 5-aminolevulinic acid 
PDT
PDT (Park, Moon et al. 2010)
julibroside J8 Plant derivative (Hua, Feng et al. 2009)
Kaempferol Flavinoid (Luo, Rankin et al. 2009)
Kisspeptin-10 Protein (Cho, Yi et al. 2009)
low molecular weight polysaccharide 
isolated from Agaricus blazei
Mushroom derived (Niu, Liu et al. 2009)
LY294002 AKT inhibitor (Fang, Ding et al. 2007; Liu, Li 
et al. 2011)
Macrophage inhibitory cytokine-1 Protein (Huh, Chung et al. 2010)
measles viruses (Ong, Trejo et al. 2009)
methyl jasmonate Plant derivative (Pereira Lopes, Barbosa et al. 
2010)
Monascus-fermented rice extract Plant derivative (Ho, Wu et al. 2010)
MPEG-hexPLA micelles (Mondon, Zeisser-Labouebe et 
al. 2011)
Mullerian Far eastern medicine (Chang, Pieretti-Vanmarcke et 
al. 2011)
MVL-PLA2 Snake venom protein (Bazaa, Pasquier et al. 2010)
Non-peptidic thrombospondin-1 Protein (Colombo, Margosio et al. 
2010)
novel peptide from human 
apolipoprotein(a)
Protein (Yi, Cho et al. 2009)
NSITC Cathepsin L inhibitor (Rebbaa, Chu et al. 2009)
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orosomucoid Protein (Irmak, Oliveira-Ferrer et al. 
2009)
Oyster Polypeptide Protein (Wang, Liu et al. 2009)
Paeonol oxime Chemotherapy (Lee, Kim et al. 2010)
Paeonol Chemotherapy (Kim, Lee et al. 2009)
PEGylated SN38 Chemotherapy (Pastorino, Loi et al. 2010; 
Sapra, Kraft et al. 2011)
pentraxin-3 Protein (Leali, Alessi et al. 2011)
(Fortin, Wei et al. 2011)
Phenyl 4-(2-Oxoimidazolidin-l- 
yl)benzenesulfonates
Combretastatin A-4 mimics (Fortin, Wei et al. 2011)
Phospholipase A2 from venom Snake venom protein (Kessentini-Zouari, Jebali et al. 
2010)
p-HPEA-EDA activates AMP-activated protein 
kinase
(Khanal, Oh et al. 2011)
Physalis angulata Plant derivative (Hseu, Wu et al. 2011)
Plumbagin Flavinoid (Lai, Liu et al. 2012)
poly-L-lysine dendrimer (Al-Jamal, Al-Jamal et al. 
2010)
polysaccharides from Antrodia 
cinnamomea
Fungal derivative (Yang, Zhou et al. 2009)
quercetin Far eastern medicine (Oh, Kim et al. 2010)
rhVEGI-192 VEGF inhibitor (Chen, Wu et al. 2010)
roscovitine (seliciclib) Cdk inhib (cdkS) (Liebl, Krystof et al. 2011)
Secreted frizzle-related protein 2 Protein (Courtwright, Siamakpour- 
Reihani et al. 2009)
Small molecule XIAP inhibitors Chemotherapy (Vogler, Walczak et al. 2009)
Soluble epithin/PRSS14 Protein (Kim, Lee et al. 2010)
sorafenib TKl (N0 wak-Sliwinska, Weiss et
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al. 2012)
SIP lyase Protein (Huwiler, Bourquin et al. 
2011)
Spliceostatin A Protein (Furumai, Uchida et al. 2010)
SR16388 Steroid derivative (Chao, Amin et al. 2011)
substituted-1,3,4-oxadiazole 
derivatives
(Kumar, D'Souza et al. 2009)
sunitinib TKI (Nowak-Sliwinska, Weiss et 
al. 2012)
Syndecan-1 Protein (Shimada, Nakamura et al. 
2009)
Tetraidothyroacetic acid (tetrac) and 
tetrac nanoparticles
Chemotherapy (Yalcin, Bharali et al. 2010)
tetrathiomolybdate Chemotherapy (Joimel, Gest et al. 2010)
Thrombospondin-1 Protein (Laklai, Laval et al. 2009)
Tirucallic acids (Estrada, Syrovets et al. 2010)
TM601, a synthetic chlorotoxin 
peptide
Scorpion venom derivative (Jacoby, Dyskin et al. 2010)
Toona sinensis Plant derivative (Hseu, Wu et al. 2011)
TRAIL TNF-related apoptosis inducing 
ligand
(Oh, Kwon et al. 2010)
Trifolium pratense L Plant derivative (Krenn and Paper 2009)
Tumstatin45-132-TNFalpha Protein chimera (Yan, Xu et al. 2010)
turmeric Plant derivative (Pantazis, Varman et al. 2010)
U0126 Erk inhibitor (Liu, Li etal. 2011)
Vanillin Plant derivative (Lirdprapamongkol, Kramb et 
al. 2009)
VEGF121/gelonin chimera Protein chimera (Mohamedali, Ran et al. 2011)
VEGF165-PE38 Protein/venom chimera (Hu, Ji etal. 2010)
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VEGI-armed oncolytic adenovirus (Xiao, Fan et al. 2010)
viral nanoparticles (Steinmetz, Ablack et al. 2011)
visudyne PDT (Nowak-Sliwinska, van 
Beijnum et al. 2010)
WEPPG (Chinese plant extracts) Far eastern medicine (Kim, Kim et al. 2011)
Xanthone VI Flavinoid (Kuete, Wabo et al. 2011)
Appendix Table 2 A selection o f treatments used in the CAM assay either as variation 1 or 3. PDT = 
Photodynamic therapy, TKI = Tyrosine kinase inhibitor
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